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Abstract

MATRIX METALLOPROTEINASE EXPRESSION IN MODELS OF PARKINSON’S
DISEASE
By Justin Adam McClain, B.A.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Helen L. Fillmore, Ph.D.
Associate Professor, Department of Neurosurgery

Parkinson’s disease (PD) is a devastating neurodegenerative disorder characterized
by progressive loss of dopaminergic neurons located in the substantia nigra. Accumulating
evidence indicates that microglia-driven neuroinflammation contributes significantly to
chronic neurodegeneration in PD. The matrix metalloproteinases (MMPs) play an
important role in several neuroinflammatory paradigms; however, their relationship to
dopaminergic neurodegeneration in PD remains relatively unexplored. To address this, the
temporal relationship between MMP-2, MMP-3, MMP-9, and MMP-13 expression and
dopaminergic neurodegeneration was compared in the 6-hydroxydopamine (6-OHDA) and
xii

lipopolysaccharide (LPS) models of PD. In dopaminergic SH-SY5Y cells, 6-OHDA
treatment significantly increased MMP-13 mRNA expression; however, examination of 6OHDA-lesioned rats demonstrated that MMP-13 protein expression does not change over
the neurodegenerative time course, indicating that MMP-13 likely is not a major factor in
neurotoxin-mediated neurodegeneration. MMP-3 and MMP-9 were not detected in either
6-OHDA model, but an increase in proMMP-2 expression was detected in nigral tissue
samples 5 days post-surgery. This holds potential significance; however, active MMP-2
was not detected at any time point, suggesting that MMP-2-mediated proteolysis is not
involved in 6-OHDA-induced neurodegeneration. In contrast to the 6-OHDA models, LPS
triggered dramatic increases in MMP-2 and MMP-3 expression and activation that
correlated with the neurodegenerative phase of this model. A significant increase in
proMMP-9 was associated with this model, while no change in proMMP-13 was detected.
In addition to MMP characterization, connective tissue growth factor (CTGF/CCN2), a
protein that is transcriptionally and post-translationally regulated by MMPs was examined.
In the LPS model, CTGF/CCN2 expression increased 5-fold and a protein fragment
potentially representing cleaved CTGF/CCN2 was detected. The changes in CTGF/CCN2
occurred during peak increases in MMP-2 and MMP-3 activity. These experiments
illustrate a strong temporal relationship between increased MMP expression and activation,
elevated CTGF/CCN2 expression, and inflammation-induced dopaminergic
neurodegeneration. There are clear differences between the 6-OHDA and LPS models that
could hold significance for the pathogenesis of PD. Future studies aimed at interrupting
MMP and CTGF function in the LPS model are required to further establish their role in
xiii

inflammation-induced neurodegeneration and to assess their potential as a therapeutic
target for the development of novel neuroprotective therapies for PD.

xiv

CHAPTER 1
Introduction to Parkinson’s Disease

1.1 The Importance of Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease
following Alzheimer’s disease. In 2005, total PD prevalence among the world’s 10 most
populous nations exceeded 4 million, with this number expected to double by 2030 as the
population ages (53). PD is a chronic syndrome that results in severe disability. As a
result, the economic burden of PD is staggering. In 2002, the total cost of PD reached an
estimated $23 billion in the United States, which is projected to exceed $50 billion by
2040 (92).
PD is characterized by the progressive loss of dopaminergic (DA) neurons in the
substantia nigra pars compacta (SNc). The substantia nigra belongs to a group of
extrapyramidal structures, the basal ganglia, which modulates motor activity through
communication with supplemental and premotor cortex that control the initiation and
proper sequence of movements (135, 159). Major basal ganglia structures include the
striatum (caudate and putamen), globus pallidus, subthalamic nucleus, and substantia
nigra, which is divided functionally and anatomically into the pars compacta and pars
reticulata. DA neurons in the SNc project to the striatum where they release dopamine, a
neurotransmitter that modulates two critical pathways connecting the striatum to the
1

globus pallidus (Figure 1.1A). In the direct pathway, dopamine promotes excitation of
GABAergic striatal neurons that project to GABAergic neurons located in the internal
segment of the globus pallidus, resulting in decreased GABAergic outflow to its targets
in the thalamus. In the indirect pathway, dopamine decreases excitability of GABAergic
striatal neurons that project to the external segment of the globus pallidus, whose neurons
enhance inhibition of the subthalamic nucleus. This decreases subthalamic excitatory
output (glutamatergic) to the internal segment of the globus pallidus, causing a decrease
in GABAergic outflow to the thalamus. In both pathways, the overall effect of dopamine
is to lessen tonic inhibition exerted by the internal segment of the globus pallidus on the
ventral anterior nucleus of the thalamus, allowing information to flow to the
supplemental and premotor cortex.
In PD, degeneration of DA neurons in the SNc results in the loss of dopamine
influence in the striatum (Figure 1.1B). A failure of excitatory thalamic output to the
supplemental motor and premotor cortex ensues, interfering with basal ganglia control
over movement and leading to the manifestation of the cardinal symptoms of PD: resting
tremor, bradykinesia, and rigidity (135). These symptoms are controllable in the early
stages of PD using dopamine replacement therapies, such as Levodopa and dopamine
agonists; however, as the disease progresses, their effectiveness dwindles and debilitating
dyskinesias can result (115, 195). Other symptoms of PD, such as freezing episodes and
autonomic dysfunction, fail to respond to dopamine replacement therapies altogether
(165). The failure of dopamine replacement therapies to arrest PD progression
underscores the need to develop new treatment strategies that target the underlying cause
2
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FIGURE 1.1: Schematic of Basal Ganglia Circuitry
A) Normal circuitry of the basal ganglia emphasizing the central modulatory role of the
SNc on striatal output to the globus pallidus. Dopamine influence over both the direct
and indirect pathways decreases the tonic inhibition exerted by the internal segment of
the globus pallidus over the ventral anterior nucleus of the thalamus. B) In PD,
degeneration of DA neurons located in the SNc causes an imbalance (depicted by arrow
thickness) within the basal ganglia which strengthen tonic inhibition on the thalamus.
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of DA neurodegeneration. This will require a better understanding of the disease
mechanisms that contribute to the pathological features of PD.

1.2 Early History of Parkinson’s Disease
In 1817, James Parkinson published his “Essay on the Shaking Palsy,” in hopes of
generating interest among the scientific community for a disease he realized “had escaped
particular notice” (166). Earlier descriptions of Parkinsonian symptoms existed,
particularly regarding the tremor. These disorders were collectively referred to as
shaking palsy, but Parkinson believed the symptoms he observed in six case studies
represented a specific syndrome he termed paralysis agitans. He described in detail the
resting tremor, flexed-forward posture, and festinating gate and provided compelling
arguments that this disorder differed from other forms of shaking palsy.
Parkinson’s work was well received by the medical community, but the next
major advances did not occur until the 1880s with the French physician Jean-Martin
Charcot (75). He coined Parkinson’s disease and further characterized tremor by noting
frequency, size of oscillations, and when tremor occurred. Through these careful
measurements Charcot succeeded in distinguishing the Parkinsonian tremor from tremor
associated with multiple sclerosis and other neurological disorders (74). Charcot’s
biggest contributions were made with the detailed description of bradykinesia and
rigidity. Parkinson likely mistook these features for paralysis; however, Charcot proved
that PD patients did not suffer from paralysis, but rather they were very slow in their
execution of movements. Charcot also noted that not all PD sufferers presented with the
4

same symptoms. Some were dominated by tremor, while others presented with rigidity
and bradykinesia as the predominant features.
In response to these early descriptions, a considerable amount of effort was
invested to uncover the underlying pathology responsible for PD. In 1910, Fritz Lewy
described insoluble inclusion bodies present in the dorsal motor nucleus, nucleus basalis
of Meynert, and substantia innominata in pathological specimens from PD patients (65).
Nine years later, Konstantin Tretiakoff examined the SNc in 54 brains, 6 of which came
from PD patients (120). He discovered that in every PD case, there was a severe loss of
pigmented neurons in the SNc, suggesting that the loss of these cells somehow
contributed to PD. In addition, he described the presence of Lewy Bodies in surviving
pigmented neurons, which would later be recognized as the second pathological hallmark
of PD.

1.3 The Importance of Dopamine
The next major leap culminated in the early 1960s with the discovery of the
importance of dopamine and development of the first rational therapy for PD.
Catecholaminergic biosynthesis pathways (Figure 1.2) were uncovered in the late 1930s
and methods were developed to detect these chemicals in isolated tissue preparations
(75). At first, dopamine was thought to function solely as the precursor to
norepinephrine; however, measurements in brain tissue demonstrated that dopamine was
found primarily in the caudate and putamen, suggesting that dopamine was functionally
important in the striatum (9, 28, 194). Norepinephrine was present in the striatum in only
5
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FIGURE 1.2: Catecholaminergic Neurotransmitter Biosynthesis
Tyrosine serves as the precursor to all catecholamines. Tyrosine hydroxylase (TH)
catalyzes the rate limiting step in catecholamine biosynthesis, adding a hydroxyl group
onto the aromatic ring of tyrosine to form L-dihydroxyphenylalanine (L-Dopa). Water
forms as a byproduct and tetrahydrobiopterin (BH4) serves as a co-factor for this reaction.
Aromatic L-amino acid decarboxylase (AAAD) converts L-Dopa to dopamine, releasing
CO2. If dopamine β-hydroxylase (DβH) is present within the neuron, dopamine will be
converted to norepinephrine. Epinephrine is generated from norepinephrine in a reaction
catalyzed by phenylethanolamine N-methyl transferase (PNMT). Other abbreviation:
BH2=dihydrobiopterin, Asc=ascorbic acid, DHAsc=dehydroascorbic acid, SAMe=Sadenosyl methionine, SAH=homocysteine.
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trace amounts. Given that PD was thought to involve the extrapyramidal system, Herbert
Ehrlinger and Oleh Hornykiewicz (1960) compared dopamine and norepinephrine levels
from various brain regions in neurologically normal, PD, and Huntington’s disease
patients (58). They found marked reductions in dopamine in striatal samples from all PD
cases, while no changes were observed in samples from Huntington’s disease patients.
This was the first demonstration that dopamine was centrally involved in PD
pathogenesis. At the time, it was known that extensive loss of striatal neurons was
involved in Huntington’s disease, which indicated that the striatum was not the source of
dopamine (58). These studies formed the basis for the development of dopamine
replacement therapies.
L-Dopa, the precursor to dopamine, was a likely candidate for the first attempt at
dopamine replacement therapy because it readily crosses the blood-brain barrier (BBB),
whereas, dopamine cannot. Birkmeyer and Hornykiewicz (1962) were the first to employ
L-Dopa in PD patients and their description of its incredible effects were as follows:
“The effect of a single i.v. administration of L-DOPA was, in short, a complete
abolition or substantial relief of akinesia. Bedridden patients who were unable to
sit up, patients who could not stand up from a sitting position, and patients who,
when standing, could not start walking, performed all these activities after LDOPA with ease. They walked around with normal associated movements and
they even could run and jump. The voiceless, aphonic speech, blurred by palilalia
and unclear articulation, became forceful and clear again as in a normal person.
For short periods of time the patients were able to perform motor activities which
could not be prompted to any comparable degree by any other known drug” (12).
These observations revolutionized the PD field and several drugs have since been
developed that extend L-Dopa’s beneficial effects. Unfortunately, as the disease
progresses, L-Dopa loses its effectiveness and in many cases its prolonged use leads to
7

the development of disabling dyskinesias (115). However, L-Dopa is still the most
effective treatment known for PD (165).
Hornykiewicz suspected that the source of striatal dopamine somehow involved
the SNc (89). He measured SNc dopamine in PD patients and found that there was a
dopamine deficiency similar in magnitude to what had been described earlier in the
striatum. Using this information, Poirer and Sourkes were able to show evidence that
stereotaxic lesions placed into the SNc resulted in severe loss of striatal dopamine (170).
Subsequent studies would later confirm the existence of a dopaminergic nigrostriatal tract
(147).

1.4 Pathological Features of the Substantia Nigra in Parkinson’s Disease
Three major features are associated with SNc pathology in PD: depigmentation
due to degeneration of neuromelanin-containing DA neurons, widespread Lewy body
pathology within surviving DA neurons, and chronic neuroinflammation characterized by
microgliosis (99, 120). Extreme depigmentation of the SNc can be detected without
magnification. In addition, much of the remaining melanin is extracellular or engulfed by
activated microglia (46, 138). Lewy bodies are eosinophilic, insoluble inclusion bodies
that contain a dense core surrounded by lower density material (55). Identification of αsynuclein, an abundant pre-synaptic protein of still unknown function, as the principle
protein component within these structures was a major breakthrough in PD research (179,
211). As described below, α-synuclein gene duplication, point mutation, and overexpression have all been linked to PD (195). Along with DA degeneration and formation
8

of Lewy Bodies, a significant inflammatory reaction is present characterized by
microglial activation (138). Early immunohistochemistry studies revealed that activated
microglia surround degenerating DA neurons, leading to the hypothesis that microglia
participate in neurodegeneration associated with PD. Studies described in chapter 2
provide compelling evidence that microglial-derived proinflammatory cytokines, nitric
oxide, and reactive oxygen species (ROS) contribute significantly to DA neurotoxicity in
PD (14).

1.5 Environmental Risk Factors for Parkinson’s Disease
The first direct evidence for an environmental factor that could directly cause PD
came from drug users who were accidentally exposed extreme levels of 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP). These individuals believed they were
injecting themselves with synthetic heroin; however, the drug was improperly
synthesized and contained high levels of MPTP, a contaminating byproduct of synthesis
(116). They quickly developed severe L-dopa-responsive Parkinsonism and autopsy
revealed significant loss of DA neurons and decreased striatal dopamine content and TH
expression (48, 116).
Elucidation of the mechanism of MPTP-induced DA neurodegeneration provided
strong support for the involvement of environmental factors in PD. Neurotoxicity
exhibited by MPTP requires its conversion to MPP+ by monoamine oxidase B within
astrocytes (117). MPP+ is selectively recognized by dopamine reuptake transporters
located on DA neurons, leading to transport into the neuronal cytoplasm. Once inside the
9

neuron, MPP+ accumulates within mitochondria via an energy-dependent mechanism,
where it potently inhibits NADH dehydrogenase (complex I), (176). Complex I
inhibition interferes with mitochondrial electron transport chain function, resulting in
increased superoxide production and oxidative stress (175). It is this oxidative stress
coupled to decreased mitochondrial ATP production that is believed to trigger neuronal
death. Selective DA neurotoxicity exhibited by MPTP raised the possibility that other
complex I inhibitors or related structural compounds found in the environment may
increase PD risk. For example, the complex I inhibitor rotenone is the active substance in
many insecticides used in the agricultural industry and paraquat, which is structurally
similar to MPTP, is present in herbicides. Although human exposure to these compounds
has not been conclusively demonstrated to lead to PD, administration of rotenone or
paraquat to rodents results in Parkinson-like pathology and symptoms (11, 24).
In addition to pesticide exposure, several additional environmental risk factors
have been suggested to increase PD susceptibility. These include chronic exposure to
heavy metals, air pollution, well water and milk consumption, and high caloric intake
(34, 141). Certain occupations have also been linked to PD, such as farming, carpentry,
cleaning, and welding. While all of these factors are suggested to increase PD risk, none
have been shown to directly cause PD (34).

1.6 Genetic Risk Factors for Parkinson’s Disease
Gene mutations in α-synuclein, parkin, DJ-1, PTEN-induced putative kinase-1
(PINK1), and leucine-rich repeat kinase-2 (LRRK2) have all been linked to inheritable
10

forms of PD. Study of these gene mutations has provided valuable information regarding
the mechanisms leading to DA neurodegeneration. However, familial forms of PD
account for less than 10% of all PD cases, the remaining arising in sporadic or idiopathic
form (221). Sporadic PD is thought to result from a complex combination of
environmental and genetic factors that increase disease susceptibility.
Several point mutations in the α-synuclein gene have been identified in familial
PD that result in single amino acid substitutions, including Ala53Thr, Ala30Pro, and
Glu47Lys (112, 171, 244). These point mutations are inherited in an autosomal dominant
pattern. In addition to point mutations, α-synuclein gene duplications and triplications
have been described, resulting in over-expression of this protein in individuals carrying
the mutation (157, 205). The precise function of α-synuclein remains to be elucidated,
but it is localized to presynaptic terminals, suggesting that it may be important in synaptic
transmission (179). α-Synuclein is the principle component of insoluble filament
deposits in Lewy Bodies associated with sporadic PD, further indicating that this protein
is intimately involved in PD pathogenesis (210, 211).
Parkin deletion mutations have been identified in families exhibiting autosomal
recessive inheritance of PD (110). The mutation is characterized by the complete loss of
exon 4, resulting in complete loss of function. Parkin mutations are the most common
form of early onset familial PD, representing approximately 50% of these cases (195).
Although severe loss of nigral DA neurons occurs, PD patients harboring parkin
mutations do not display typical Lewy Body pathology associated with sporadic PD and
those with α-synuclein mutations (110). In addition, the role of activated microglia and
11

neuroinflammation is not known. The parkin gene encodes an E3 ubiquitin ligase
required for the proper ubiquitination of proteins destined for clearance by proteosome
machinery (247). Since the parkin mutation results in loss of function, DA toxicity is
believed to be caused by accumulation of undigested proteins. In sporadic PD, nitrated
and S-nitrosylated parkin has been detected, which interferes with its E3 ligase function
and promotes accumulation of its target proteins in cell culture models (40).
Early onset PD can also be traced to autosomal recessive mutations in the gene
encoding DJ-1. Two mutations have been identified: one involves a gene deletion that
completely knocks out DJ-1 function and the second is a point mutation that causes DJ-1
to accumulate in mitochondria (19). DJ-1 is a ubiquitously expressed protein with
unknown function; however, under conditions of oxidative stress it directly interacts with
α-synuclein to inhibit fibril formation (251). This function of DJ-1 was only expressed
when the protein was oxidized, suggesting that under conditions of oxidative stress, DJ-1
may perform important neuroprotective functions. In support of this, cortical neurons
isolated from DJ-1-/- mice displayed increased susceptibility to oxidative stress induced
damage, while neurons engineered to overexpress DJ-1 were resistant to oxidative
damage (103). The presence of Lewy body and neuroinflammation pathology has not yet
been associated with DJ-1 mutations.
Similar to parkin and DJ-1 mutations, point mutations or deletions of the PINK1
gene have been associated with early onset PD (195). A point mutation has been
described in the PINK-1 kinase domain, while the deletion mutation results in truncated
PINK1 that is missing its last 145 amino acids (226). PINK1 is a ubiquitously expressed
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serine-threonine kinase that localizes to mitochondria. Target proteins for PINK1
phosphorylation have not yet been identified (195). Transfection of SH-SY5Y cells with
mutant PINK1 resulted in increased mitochondrial dysfunction that was followed by
apoptosis when stressed with a proteosome inhibitor (226). In contrast, overexpression of
PINK1 in SH-SY5Y cells protected them from the toxic effects of the inhibitor. The
presence of neuroinflammation and Lewy Body pathology has not been examined in PD
patients harboring this mutation.
LRRK2 mutations have been associated with a large proportion of autosomal
dominant inherited PD with 19 pathogenic mutations described to date (140, 252).
LRRK2 is a large, highly conserved protein expressed in neurons, astrocytes, and
microglia, as well as most other tissues (140). PD patients harboring LRRK2 mutations
display pathology typical of sporadic PD including loss of nigral DA neurons and
widespread Lewy Body pathology (252); however, the presence of microglia-driven
neuroinflammation in these cases has not been examined. In fact, LRRK2 has been
shown to accumulate within Lewy Bodies associated with sporadic PD and other similar
protein deposits present in various other neurodegenerative diseases (140). Expression
appears to be cytoplasmic in addition to association with the mitochondrial outer
membrane, and at least 3 of the LRRK2 point mutations are believed to impart a gain-offunction in the protein’s kinase domain (195). The association of LRRK2 and PINK1
with familial PD indicates that regulation of protein phosphorylation may be critical in
sporadic PD.
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1.7 Complexities of Parkinson’s Disease: More than Dopaminergic
Neurodegeneration
Since the discovery of the importance of the nigrostriatal track in motor
symptoms of PD, most research has focused solely on this system; however, many PD
symptoms are not motor in nature, suggesting that brain structures in addition to the basal
ganglia are involved in PD. Sensory dysfunction occurs in most PD patients,
characterized by hyposmia, pain hypersensitivity, and abnormal sensations (169).
Evidence suggests that hyposmia precedes onset of cardinal motor symptoms and
considerable research is exploring the use of olfactory tests as an early diagnostic tool for
PD (54). Constipation, urogenital dysfunction, and orthostatic hypotension indicate that
the autonomic nervous system is involved in PD. Additional non-motor symptoms
common in PD patients include sleep disorders, mood disorders, dementia, and psychosis
(169).
The cause of non-motor symptoms in PD is unknown, but a neuropathological
staging hypothesis was recently developed in an attempt to explain their origin. This
hypothesis was based on rigorous analysis of Lewy Body pathology in PD patients,
which revealed dozens of regions in the central and peripheral nervous systems that
contain α-synuclein filled Lewy Bodies (21, 22). The order of Lewy Body appearance in
these structures has been divided into 6 stages, with 1 being the earliest stage of disease
and 6 being end stage. The hypothesis posits that in stage 1, Lewy Body pathology
begins in the anterior olfactory nucleus, mitral and tufted cells in the olfactory bulb, and
preganglionic parasympathetic neurons originating in the dorsal motor nucleus of the
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vagus nerve that project to postganglionic neurons innervating that enteric nervous
system (21). Lewy Body pathology then is predicted to travel from the dorsal motor
nucleus of the vagus throughout specific nuclei in the brainstem, including the SNc, and
then towards various cortical brain regions involved in sensory perception, movement,
and mood. This staging hypothesis potentially explains many of the clinical non-motor
features of PD. It is interesting to note that in PD patients, activated microglia have been
described in many of the same regions associated with Lewy Body pathology (70).
Proponents of this hypothesis contend that early appearance Lewy body pathology in the
enteric nervous system and olfactory bulb support the idea of environmental causes of
PD, since neurons in these regions come into close proximity to external environmental
substances (21).

1.8 Current Treatments for Parkinson’s Disease
Current drug treatments for PD focus on replenishing the brain’s lost dopamine
supply. Initially, dopamine replacement therapies alleviate motor symptoms associated
with PD; however, these therapies fail to arrest chronic neurodegeneration, resulting in
the eventual return of motor difficulties combined with additional debilitating drug side
effects. The common theme among current PD therapies is that there is an initial period
of great therapeutic effect followed by a slow decline in effectiveness due to continued
disease progression. The surgical technique of deep brain stimulation was developed for
PD in order to manipulate the basal ganglia circuitry in an attempt to restore proper
signaling. This therapeutic approach holds great promise, but also has its shortcomings.
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Novel therapies must address the issue of neuroprotection, which can only occur once the
underlying causes of progressive neurodegeneration are uncovered. Current therapeutic
options for PD are briefly described below along with potential future neuroprotective
strategies.
The dramatic initial observations following the first attempts using L-Dopa in PD
patients provided the framework for rational drug design aimed at restoring lost brain
dopamine. L-Dopa is still regarded as the best available PD treatment option for three
main reasons: 1) it markedly reduces morbidity and mortality in PD patients; 2)
compared to other available dopamine replacement therapies, L-Dopa has the greatest
therapeutic effect on debilitating motor symptoms; and 3) all PD patients (autopsy
confirmed) are responsive to L-Dopa therapy (165, 178). Its effects are due to its ability
to efficiently cross the BBB where it reacts with aromatic amino acid decarboxylase to
form dopamine. L-Dopa therapy allows patients to maintain high quality of life for an
average of 5 years. At this point, L-Dopa’s effectiveness slowly declines and higher
doses are needed to provide symptomatic relief. This often leads to L-Dopa-induced side
effects including dyskinesias and sudden on-off periods; therefore, drug development has
focused on delaying the need for high-dose L-Dopa treatment (165). This has resulted in
discovery of several drugs that can prolong or enhance the effect of L-Dopa so that high
dose therapy can be delayed as long as possible.
There are three classes of drugs approved for PD that extend the therapeutic effect
of L-Dopa. Typically, L-Dopa therapy is combined with carbidopa, a peripheral
decarboxylase inhibitor, which maximizes L-Dopa transport into the brain by delaying its
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conversion to dopamine until it has crossed the BBB. Formation of dopamine in the
periphery is undesirable because it cannot cross the BBB and high peripheral dopamine
can cause nausea and hypotension (178). In addition to carbidopa, peripheral catechol Omethyltransferase (COMT) inhibitors and monoamine oxidase-B inhibitors (MAO-B) can
be included in the drug regimen (165). Peripheral COMT renders L-Dopa inert by
degrading circulating L-Dopa into 3-O-methyldopa before it enters the brain. Like
carbidopa, COMP inhibitors extend the L-Dopa plasma half-life, resulting in increased
delivery to the brain. Studies have also indicated that COMT inhibitors can reduce LDopa-associated side effects (165). Blockade of MAO-B retards dopamine catabolism by
preventing its conversion to 3,4-dihyroxyphenylacetic acid (178). These drugs extend the
half-life of dopamine, thus lowering the dose of L-Dopa needed for symptom alleviation.
Dopamine agonists represent an alternative approach to L-Dopa therapy in PD.
These drugs mimic the effect of dopamine in the brain by binding to D1 and D2 receptors
expressed on striatal neurons. Clinical trials comparing various dopamine agonists to
standard L-Dopa therapy demonstrate that a significant reduction in drug-induced
dyskinesias can be attained with dopamine agonists (98). Unfortunately, dopamine
agonists are not as effective as L-Dopa in alleviating the motor symptoms associated with
PD, and they often cause visual hallucinations, increased somnolence, and generalized
edema. Despite these shortcomings, dopamine agonist therapy may be best to treat early
symptomatic PD. Advocates of this therapeutic strategy believe that treatment with
dopamine agonists delays the eventual need for L-Dopa therapy (115).
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In addition to dopamine replacement therapies, anticholinergic drugs and
amantadine are occasionally used early in the symptomatic phase of PD. Anticholinergic
drugs have beneficial effects on resting tremor, but do not affect rigidity or bradykinesia
(165). Amantadine is an antiviral medication shown to relieve rigidity and bradykinesia,
but its use is confined mainly to early disease stages due to neuropsychiatric side effects
(98, 165).
Surgical treatment options can also be considered in the course of PD treatment,
although these are usually delayed until the patient progresses to the point at which
dopamine replacement therapies are no longer effective. Deep brain stimulation (DBS) is
the most common surgical option for PD patients. This technique implants a thin-wire
electrode into the brain, which is connected to a pacemaker-like, battery-driven
neurostimulator implanted beneath the skin, usually near the clavicle (165). The
neurostimulator sends high frequency electrical signals through the electrode aimed to
overcome deficits in basal ganglia output to the thalamus caused by DA denervation of
the striatum. DBS was developed to replace dated surgical techniques that lesioned or
removed parts of the basal ganglia that sought to reduce inhibitory influence of the globus
pallidus over the thalamus. High frequency stimulation simulates these lesions without
damaging the tissue (165). The subthalamic nucleus is the most common DBS target in
PD. This procedure improves rigidity, tremor, bradykinesia, postural instability, and gait
(81, 219). The mechanism by which subthalamic DBS results in symptom improvement
is not known. Based on the current understanding of basal ganglia circuitry, loss of
dopamine should cause subthalamic overactivation (Figure 1.1B), leading to increased
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tonic inhibition over the thalamus. Bilateral high frequency DBS reduces subthalamic
activity, which would be expected to decrease activity in the internal segment of the
globus pallidus, resulting in a reduction of thalamic inhibition. Instead, subthalamic DBS
reinforces tonic inhibition of the thalamus (228).
Subthalamic DBS provides patients with remarkable motor symptom
improvement, but does not relieve non-motor complications associated with PD, which
continue to worsen over time. In addition, early improvements in gait, posture, and
bradykinesia erode within 3-5 years of surgery although improvements in tremor and
rigidity last for at least 5 years (81). An emerging issue with subthalamic DBS is
increased memory deficits after prolonged DBS (85). Other important concerns include
complications from surgery and periodic battery replacement, which requires subsequent
surgery after initial neurostimulator placement (165). These issues limit DBS therapy to
later stages of disease progression.

1.9 Cell Replacement Therapies
An alternative to drug-based dopamine replacement is the use of cell-based
strategies to replace degenerated DA neurons. Successful DA cell replacement therapies
require that the transplanted cells terminally differentiate into DA neurons that release
appropriate quantities of dopamine when needed (114). In addition, these cells must
integrate into the striatal circuitry by establishing new synapses with proper post-synaptic
targets (224). Based on successful demonstration of therapeutic benefit in animal
models, transplantation of fetal mesencephalic tissue was attempted in humans with
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varied success. Grafted fetal tissue survived and new DA neurons integrated into the
striatal circuitry; however, severe dyskinesias appeared in 15% of the patients and
surviving grafted DA neurons displayed Lewy Body pathology at autopsy, leading to the
conclusion that this is not an effective approach (163, 224). The lack of therapeutic
benefit has been attributed to the low population of DA neurons present in fetal grafts.
DA neurons make up only 5-10% of the total graft population, emphasizing the need to
develop techniques to obtain pure DA cells for transplantation (163). Embryonic, neural,
and adult stem cells from various tissues have been proposed as potential sources for DA
neurons. These sources have great therapeutic potential; however, they are not ready for
clinical trial. Large populations of DA neurons can be obtained from differentiated
embryonic stem cells in culture; however, when transplanted into animal models, these
neurons lose some DA characteristics, indicating that the cells are not stably
differentiated, and a large proportion of animals develop tumors (114, 163). Methods to
obtain DA neuronal population large enough for transplantation from neuronal and adult
stem cells are still under development (114, 224).
Additional cell-based approaches are being considered. Instead of replacing lost
DA neurons, transplanted cells could be used to deliver a continuous source of dopamine
or therapeutic drug, such as a neuroprotective trophic factor. For example, clinical trials
are currently underway in which the therapeutic benefit of retinal pigment cell
transplantation into the striatum is being considered. These cells naturally secrete LDopa, along with many other potentially therapeutic growth factors (163).
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1.10 Towards Neuroprotective Therapies
Several targets have been identified for the development of neuroprotective
therapies. Many drugs have been shown to protect DA neurons in response to neurotoxic
insults in cell culture and animal models, but translating these results to PD has proven
difficult (164, 196). However, knowledge gained from animal models of PD has led to
clinical trials to test for potential neuroprotective properties of coenzyme Q10 (CoQ10),
glial cell-line derived neurotrophic factor (GDNF), and MAO-B inhibitors. MAO-B
inhibitors are used to block the breakdown of dopamine into 3,4-dihyroxyphenylacetic
acid and hydrogen peroxide; therefore, these drugs have anti-oxidant properties in
addition to prolonging dopamine half-life. PD patients placed on MAO-B inhibitors at
the time of diagnosis show delayed need for dopamine replacement therapies. This
would seem to suggest a neuroprotective effect; however, the delay could be due to the
symptomatic benefit of prolonged dopamine half-life (164). CoQ10 is a mitochondrial
protein with potent antioxidant properties due to its role in movement of electrons
between complexes in the electron transport chain. Animal studies with CoQ10 have
been promising, but initial clinical trials have failed to show significant diseasemodifying effects indicative of slowed progression or neuroprotection (196). Perhaps the
most well-studied neuroprotective drug to date has been GDNF. This neurotrophic factor
clearly has neuroprotective properties in many PD models. Unfortunately, these effects
were not seen in PD patients, and clinical trials were discontinued due to the lack of
neuroprotection and the appearance of severe side effects (98, 196). Based on evidence
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that oxidative stress contributes to DA neurodegeneration, drugs that reduce the oxidative
load on DA neurons may hold promise as neuroprotective therapies.
Development of effective neuroprotective strategies to treat PD will require a
better understanding of the underlying mechanisms that result in DA neurodegeneration.
Neuroprotective therapies tested to date focused on disease mechanisms believed to be
intrinsic to DA neurons, such as mitochondrial and dopamine-generated oxidative stress.
In light of recent developments cataloging the vast pathology beyond the DA neuron in
PD, such approaches may never succeed. A better approach may be to focus on the
common characteristics seen in regions affected in PD. To date, this includes microgliadriven neuroinflammation and α-synuclein pathology. Understanding how these
common disease mechanisms contribute to neurodegeneration in PD should result in
better design of neuroprotective therapies.
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CHAPTER 2
Neuroinflammation, Matrix Metalloproteinases, and Downstream
Targets in Dopaminergic Neurodegeneration

2.1 The Role of Neuroinflammation in Parkinson’s Disease
In addition to DA neurodegeneration and Lewy Body formation, microgliosis
represents a major pathological characteristic of PD (99). As the resident innate immune
component of the central nervous system, microglia continuously sample the extracellular
environment with their highly ramified processes, monitoring tissue for damage and other
pathophysiological events (218). In addition, microglia provide important trophic
support for normal neuronal function (15). In response to tissue injury, microglia
undergo a series of functional changes culminating into an activated microglial response.
Microglial activation is characterized by rapid population expansion, proinflammatory
factor release, and morphological transformation from a highly ramified state to an
amoeboid state (113). Fully activated microglia are capable macrophages which engulf
and eliminate cellular debris, while secreting ROS, nitric oxide, and numerous
proinflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin1β (IL-1β) (14, 16, 113). The microglial response can be graded. For example, microglia
can respond to injury or disease by releasing proinflammatory factors without attaining
phagocyte status (218).
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The importance of microglia and neuroinflammation in PD was first suggested
following immunohistochemistry studies on postmortem samples obtained from PD
patients. The authors found that activated microglia clustered around areas of active DA
neurodegeneration (138). Subsequent PET imaging studies using the [11C](R)-PK11195
ligand confirmed that widespread microglial activation was present PD patients at
varying disease stages, indicating that the microglial response is chronic (70). PK11195
is a ligand that specifically binds to peripheral benzodiazepine binding sites, which are
selectively increased in activated microglia (233). In addition to the presence of activated
microglia, several studies demonstrate that the SNc in PD patients is kept in a state of
inflammation. For example, TNF-α and IL-1β are elevated in nigral tissue samples
collected from PD patients compared to age-matched controls (17, 145). Enhanced
markers of oxidative stress including protein oxidation, lipid peroxidation, and DNA
oxidation have been demonstrated in these patients (80). The SNc is also under
nitrosative stress as indicated by high levels of nitrated and S-nitrosylated proteins (40).
Since proinflammatory cytokines, oxidative stress, and nitrosative stress are components
of the activated microglial response, activated microglia likely play a major role in PD
pathogenesis.
The function of activated microglia in PD and other neurodegenerative diseases
has been the subject of intense debate. It is not known if activated microglia are clearing
debris left behind by dying neurons or if they contribute directly to neurodegeneration.
This seems to be dependent on the area of the brain affected; however, accumulating
evidence strongly suggests that activated microglia contribute significantly to DA
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neurodegeneration. First, injection of lipopolysaccharide (LPS), a potent activator of
microglia, systemically or directly into the rodent SNc specifically caused DA neuronal
death, demonstrating that microglia-driven neuroinflammation can initiate DA
neurodegeneration (32, 68, 173). Second, injection of TNF-α and IL-1β together into the
rat medial forebrain bundle reduced the number of DA neurons in the SNc, indicating
that these microglia-derived proinflammatory cytokines contribute directly to
neurodegeneration (30). Third, activated microglia appear to be involved in neurotoxininduced DA neurodegeneration, since all neurotoxin models of PD are accompanied by
activated microglial responses (232). Fourth, inhibition of microglial activation with
anti-inflammatory drugs, such as cyclooxygenase inhibitors or minocycline, confers
significant neuroprotection against MPTP and 6-hydroxydopamine (6-OHDA) neurotoxic
insults (62).
It is important to note that DA neurons are more susceptible to inflammation than
other neuronal types. Injection of LPS into the SNc results in loss of DA neurons, but
nigral GABAergic and serotonergic neurons are spared (84). Moreover, injection of
identical quantities of LPS into the SNc, hippocampus, and cortex revealed that
neurodegeneration only occurred in the SNc (104). Three characteristics of the SNc and
DA neurons explain this increased sensitivity to inflammation. First, the SNc has the
highest concentration of microglia in the central nervous system (104). This high
microglial density likely means that more microglia are activated for a given stimulus
than other parts of the brain resulting in greater production of proinflammatory cytokines,
ROS, and nitric oxide. Second, constant low levels of dopamine auto-oxidation place DA
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neurons under enhanced oxidative stress even under normal conditions (130). Third,
heavy metal accumulation, particularly iron, within the SNc is postulated to further
enhance oxidative stress by driving hydroxyl radical formation from hydrogen peroxide
by the Fenton reaction (8).
The presence of chronically activated microglia and the high susceptibility of DA
neurons to microglial-derived inflammatory factors indicate that microglia are important
components of neurodegeneration in PD. The driving force behind microglia activation
is unknown but is hypothesized to arise from an initial insult to DA neurons that results in
the release of microglial activating factors (16, 80, 153). The idea that factors released
from degenerating neurons, which trigger inflammatory reactions is not new.
O’Callaghan and colleagues demonstrated that MPTP-induced striatal astrogliosis was
dependent on DA terminal degeneration (180). Treatment with the dopamine transporter
inhibitor, nomifensine, completely blocked the glial response to MPTP, indicating that
the astroglial response depended on neurodegeneration (160). Recent studies have
identified several potential microglial activating factors originating from degenerating
DA neurons. In primary culture studies, extracellular neuromelanin, α-synuclein, and
matrix metalloproteinase-3 (MMP-3) have each been shown to activate microglia (106,
108, 234, 246). In addition, when neuromelanin is injected into the SNc it induces DA
neurodegeneration that is accompanied by microglial activation (245). In mixed
mesencephalic cultures, MMP-3, released by DA neurons after MPP+ treatment, was
required for TNF-α and ROS production when added to microglia (106, 108).
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Importantly, MPP+-induced DA neurodegeneration requires microglial activation, which
can be blocked with α-synuclein antibodies or by genetic knockout of MMP-3 (106, 246).
The ability of mediators released from stressed DA neurons to activate microglia
has important implications for PD. Upon neurotoxic insult, DA neurons release several
factors as they degenerate which can activate microglia. DA neurons are very sensitive
to the products of microglia activation: proinflammatory cytokines, ROS, and nitric
oxide. This combination presents the possibility for a self-sustaining neurotoxic cycle
(Figure 2.1). Importantly, both neurotoxic and inflammatory agents could act as
initiators of this cycle, implying that DA neurodegeneration can be triggered through
different primary insults (14, 16). Mechanisms such as this could explain the
progressive, chronic nature of neurodegeneration associated with PD. Breaking
communication between degenerating DA neurons and resting microglia could halt
neuroinflammation in PD and protect DA neurons from microglia-mediated
neurodegeneration.

2.2 The Role of Neuroinflammation in Animal Models of Parkinson’s Disease
Neuroinflammation, described by the presence of morphologically activated
microglia, occurs in every neurotoxin PD animal model described to date (232). The role
of neuroinflammation in the LPS and 6-OHDA rodent models (those used in chapters 3
and 4) are described below.
LPS Model of DA Neurodegeneration. Mechanisms involved in
neuroinflammation-induced DA neurodegeneration can be directly examined using LPS.
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FIGURE 2.1: Self-sustaining Neurotoxic Cycle in DA Neurodegeneration
Evidence suggests that microglial activation following a neurotoxic insult is triggered by
the release of microglial-activating factors from degenerating DA neurons. Factors
identified to date include MMP-3, α-synuclein (SYN) and neuromelanin (NM). Since
DA neurons are sensitive to several proinflammatory factors produced by activated
microglia, including cytokines, ROS, and nitric oxide (NO), a self-sustaining neurotoxic
cycle may be responsible for chronic DA neurodegeneration associated with PD.
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LPS-mediated DA neurodegeneration is completely dependent on microglia, since DA
neurons are protected from LPS in neuronal-enriched primary cultures (23). Subsequent
development of in vivo models established that direct intranigral infusion of LPS in rats
results in cell death of nigral DA neurons that was accompanied by robust microglial
activation (32). In addition to activation of microglia, a strong, long-lasting astrocyte
response is initiated, although the role of astrocytes in DA neurotoxicity is not known
(95). This lesion is highly specific for DA neurons: striatal and nigral GABA and
serotonin levels remain steady, and LPS injection into the cerebral cortex or hippocampus
fails to induce neurodegeneration (84, 104). The reason for this selectivity is likely to be
due to the large density of microglia in the SNc compared to other brain regions and the
enhanced susceptibility of DA neurons to oxidative stress and proinflammatory cytokines
(104). DA neurotoxicity produced by LPS depends on production of ROS by NADPH
oxidase present in microglia. Ablation of functional NADPH oxidase blocks LPSinduced microglial activation and renders DA neurons resistant to LPS neurotoxicity
(172). The LPS model demonstrates that microglial-driven neuroinflammation is capable
of acting as the initial neurodegenerative stimulus in the self-sustaining neurotoxic cycle
hypothesized to drive progressive loss of DA neurons in PD (14).
The most commonly used LPS model employs intranigral injection of 2-10µg.
This results in an acute, powerful inflammatory response that causes 70-80% loss of DA
neuronal cell bodies in the SNc by 48 hours (96). Degeneration of DA terminals lags
behind with no loss at 48 hours and complete loss by day 30. Due to this anterograde
degeneration, striatal dopamine levels remain steady at early time points and behavioral
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deficits do not manifest until 3-4 weeks post-surgery (95, 96, 250). Although this model
induces neurodegeneration through inflammatory mechanisms, rapid loss of DA neurons
prevents the development of chronic self-sustaining neurotoxicity (Figure 2.2B). The
loss of DA neurons is permanent, but does not progressively worsen at least between
days 2 and 30 (96).
6-OHDA and Neuroinflammation. 6-OHDA selectively lesions DA neurons
when introduced into the nigrostriatal pathway. The lesion can be achieved by
stereotaxic injection of 6-OHDA into the SNc, medial forebrain bundle, or striatum and is
usually done unilaterally, so that the contralateral side can serve as an internal control
(52). Similar to MPP+, 6-OHDA gains entrance to DA neurons through dopamine
transporters, due to its structural similarity to dopamine. Once taken up by the neuron, 6OHDA quickly degrades resulting in ROS production that leads to apoptotic cell death.
Injection of 6-OHDA into the medial forebrain bundle or SNc causes rapid and complete
loss of nigral DA neurons, while striatal 6-OHDA injection can induce dose-dependent
loss of DA neurons in a retrograde direction that is slower and completed within 4 weeks.
Astrogliosis and microglial activation in 6-OHDA rat models have been reported by
several investigators (41, 182, 215). Intranigral injection of 6-OHDA caused a
significant increase in astroglial GFAP expression in the striatum (204, 214). This occurs
despite the inability of 6-OHDA to enhance GFAP expression when directly added to
astrocytes, indicating that 6-OHDA’s effects on GFAP must be dependent on DA
neurodegeneration (214). Intrastriatal injection of 6-OHDA results in morphological
activation of microglia at time points consistent with active DA neurodegeneration (41).
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FIGURE 2.2: Role of Neuroinflammation in LPS and 6-OHDA Models of PD
A) Intranigral LPS causes rapid microglial activation and DA neurodegeneration. In this
model, chronic cyclical DA neurodegeneration fails to develop due to the acute action of
LPS. Too few DA neurons survive the initial insult to sustain microglial activation. B)
Intrastriatal 6-OHDA induces DA neurodegeneration that results in rapid activation of
microglia. At least in the first 12 days post-surgery, loss of DA neurons is due
completely to the neurotoxic action of 6-OHDA; therefore, cyclical DA
neurodegeneration does not take place prior to this time.
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These experiments add more support for the idea that stressed DA neurons release factors
that promote neuroinflammation.
There is strong evidence that neuroinflammation accompanies 6-OHDA
neurotoxicity; however, it appears that significant 6-OHDA-mediated DA
neurodegeneration still occurs when microglia activation is blocked by cyclooxygenase
inhibitors (193). Rats were treated daily with oral administration of celecoxib (Celebrex)
starting just prior to surgery. At day 12, vehicle and celecoxib-treated rats both displayed
40% loss of nigral DA neurons, indicating that neurodegeneration prior to this time point
was solely due to 6-OHDA toxicity. However, progressive DA neurodegeneration
occurring between days 12 and 21 was significantly blocked by celecoxib, suggesting
that neurodegeneration triggered by 6-OHDA progresses in 2 phases: the first driven by
6-OHDA toxicity, the second involving microglia-induced neurotoxicity. This first phase
provides a window in which to study neurotoxin-induced neurodegeneration in the
absence of microglia-mediated neurotoxicity. In this phase, active neurodegeneration has
commenced and microglia have activated, but the microglia do not yet contribute to
neurodegeneration (Figure 2.2A).

2.3 Matrix Metalloproteinases
MMPs are a family of 22 zinc-dependent endopeptidases that degrade
components of the extracellular matrix (ECM). By cleaving ECM substrates, MMPs
stimulate matrix turnover and remodeling associated with wound healing, embryonic
development, and bone growth. In addition, ECM barriers are removed, promoting cell
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migration, angiogenesis, and extension of axonal growth cones (152). MMPs also
regulate the bioavailability of important signaling molecules by causing the release of
growth factors and cytokines sequestered in the ECM or attached to plasma membranes,
permitting them to mediate cell signaling pathways (136).
MMP domains and inserts. MMPs have been divided into five categories based
on substrate specificity and structural properties (Table 2.1). Generally, the MMPs
contain at least an N-terminal signal peptide followed by a prodomain, catalytic domain,
hinge region, and a C-terminal hemopexin-like domain (227) (Figure 2.3A). Known
exceptions include the matrilysins, which lack the hinge insert and hemopexin-like
domain, and MMP-23, which has a unique cysteine array and C-terminal IgG-like
domain in place of the hemopexin-like domain and is a type II membrane protein (167).
The signal peptide directs MMP translation to the rough endoplasmic reticulum. Here,
MMPs enter the secretory pathway and are ultimately expressed on the plasma membrane
or secreted into the ECM. The function of the prodomain is to maintain MMP latency.
The highly conserved PRCG(V/N)PD cysteine switch is located near the C-terminal end
of the prodomain. The cysteine within this sequence forms a critical bond with an
essential Zn2+ ion located in the active site of the catalytic domain (Figure 2.3B).
Disruption of the cysteine switch by proteolytic or non-proteolytic mechanisms results in
prodomain removal and activation (150). The catalytic domain holds the MMP
proteolytic machinery and contains the essential Zn2+ ion, which is anchored to 3
histidine residues within the conserved peptide sequence HEXGHX(L/M)G(L/M)XH
located at the active site (150). The hemopexin-like domain is a propeller structure
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Table 2.1: Mammalian Matrix Metalloproteinases
Type
Collagenase

MMP Designation
MMP-1
MMP-8
MMP-13

Common Name
Collagenase-1
Collagenase-2
Collagenase-3

Gelatinase

MMP-2
MMP-9

Gelatinase-A
Gelatinase-B

Stromelysin

MMP-3
MMP-10
MMP-11
MMP-19

Stromelysin-1
Stromelysin-2
Stromelysin-3
Stromelysin-4

Matrilysin

MMP-7
MMP-26

Matrilysin
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Mammalian MMP Domains and Structural Inserts
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FIGURE 2.3: Basic MMP Biology
A) The general domain arrangement for all mammalian MMPs is diagramed. B)
Schematic representation of the cysteine switch mechanism that controls activation of
latent MMPs. A single zinc ion is held in place at the active site by 3 highly conserved
histidine residues. MMP latency is maintained by the highly conserved cysteine located
in the prodomain with occupies the fourth coordination site of zinc, preventing water
from entering the active site. Proteolytic removal of the prodomain exposed the active
site so that it can interact with target substrates and allows water to interact with zinc,
which is required before hydrolysis can occur.
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involved in substrate recognition and in recognition of MMPs by the tissue inhibitor of
metalloproteinases (TIMPs).
In addition to the common domains, several MMPs have other functionally
important domains and peptide inserts. The MT-MMPs are tethered to the plasma
membrane by a single-pass type I transmembrane domain or by GPI anchors and localize
MMP activity to the pericellular environment. The gelatinases contain three fibronectin
inserts within their catalytic domain which assist in gelatin recognition (235). MMP-9
also contains an extended hinge region that resembles the α2 chain of type V collagen
(236). MMP-11, -23, -28, and the six MT-MMPs contain a furin cleavage site between
the prodomain and catalytic domain that is involved in intracellular MMP activation
(174).
Regulation of MMPs. The regulation of MMPs is complex and occurs at several
levels. Inflammatory cytokines, including TNF-α and IL-1β, along with several growth
factors trigger intracellular signaling cascades that result in MMP transcriptional
activation. For example, the MAP kinase cascades stimulated by IL-1β and TNF-α result
in activation of AP-1 transcription factors, which bind to several MMP promoters (51).
Pathways that activate NF-κB and Ets transcription factors are also involved in
upregulating transcription of MMPs. Conversely, transcription of several MMPs is
suppressed by glucocorticoids, retinoic acid, and anti-inflammatory cytokines such as
TGF-β1 and IFN-β (152). TGF-β1 and IFN-β stimulate activation of the SMAD and
STAT transcription factor families, respectively, which bind to and inhibit transcription
of MMPs containing the appropriate DNA binding sites (51). Cell-cell or cell-matrix
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interactions mediated by adhesion molecules and integrins can also lead to transcriptional
regulation of MMPs (152).
MMP prodomain removal is required for expression of MMP proteolytic function
and presents an important point of regulation. Activation can occur due to a proteolytic
event near the N-terminus of the prodomain. This causes a conformation change that
disrupts the cysteine switch and results in autocatalysis that removes the remainder of the
prodomain (151). Serine proteases (including plasmin, urokinase and tissue plasminogen
activator, and furin) and MMPs are the major proteases involved in proteolytic activation
of MMPs. ROS and reactive nitrogen species present in large quantities during
inflammation also can modify the cysteine switch to induce activation (66, 78, 162).
Activation of proMMP-2 appears unique among the MMPs in which the binding of
TIMP-2 to proMMP-2 is required for proMMP-2 activation by membrane-type MMPs
(150). Each of these MMP activation mechanisms are themselves tightly regulated and
MMP activation cannot occur unless their activators are present. Therefore,
transcriptional upregulation of MMPs does not translate into an increase in MMP activity
unless activation mechanisms are already in place.
Once activated, several mechanisms exist to suppress the proteolytic activity of
MMPs. The TIMPs are a family of 4 proteins that serve as the major endogenous
inhibitors of MMPs, binding to MMPs in a 1:1 ratio (152). Because of this ratio, MMPs
must outnumber TIMPs in order for MMP-mediated proteolysis to occur. TIMPs have
varying affinities for the MMPs and each MMP is inhibited by at least one TIMP. α2Macroglobulin is another endogenous inhibitor that suppresses activated MMPs.
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Receptor-mediated endocytosis can also limit MMP activity. MMP-13 has been shown
to bind to a specific cell surface receptor that results in MMP-13 internalization (7).
Tight MMP regulation is essential. Deregulation of MMP proteolytic activity can
have disastrous consequences and is commonly associated with chronic inflammatory
diseases outside the central nervous system, such as rheumatoid arthritis and
atherosclerosis where excessive ECM degradation contributes significantly to disease
pathology (3, 156). Moreover, increasing evidence suggests that MMPs have important
roles in neuroinflammation associated with neurodegenerative diseases including
Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and PD (107, 242).

2.4 The Role of Matrix Metalloproteinases in Parkinson’s Disease
Accumulating evidence suggests that MMPs may be important contributors to PD
pathogenesis. Analysis of nigral tissue collected post-mortem demonstrates that dramatic
upregulation of MMP-1 and MMP-9 occurs in a subset of PD patients (127). In MPTPtreated mice, MMP-2 and MMP-9 expression and activation significantly increased
during the neurodegenerative phase of this model (128). Importantly, pretreatment with
the broad-spectrum hydroxamate-based MMP inhibitor, Ro-28-2653, partially protected
nigral DA neurons and striatal dopamine depletion induced by MPTP-mediated
neurotoxicity (128). In this study, MMP-9 expression was localized to neurons and
microglia, suggesting that neuroinflammation contributed to the observed changes in
MMP-9 expression.
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Additional evidence signifying the potential importance of MMPs in PD stems
from studies on MMP-3. Initial experiments by Kim and colleagues demonstrated that
conditioned media from serum-starved PC12 cells induced activation of BV-2 microglia
cells (108). The PC12 cell line is commonly used as an in vitro tool to study
catecholaminergic neuronal biology. Subsequent experiments with these cell lines
revealed that the key activator of microglia present in PC12 conditioned media was
MMP-3, indicating that MMP-3 can serve as a microglial activating factor (108). Further
investigation showed that MMP-3-mediated activation of BV-2 microglia was dependent
on ERK and NF-κB activation. In a separate study, treatment of primary murine mixed
mesencephalic cultures with MPTP caused increased production of MMP-3 within
degenerating DA neurons (106). Addition of activated MMP-3 to primary microglia
cultures resulted in production of TNF-α and stimulated NADPH oxidase-dependent
ROS generation, both important markers for microglial activation. Genetic ablation of
MMP-3 completely spared DA neurons from MPTP toxicity and prevented activation of
microglia. These finding were extended with in vivo observations which showed that
MMP-3-/- mice exhibit remarkable resistance to MPTP toxicity and display an absence of
neuroinflammation (106). Based on these results, in vivo MMP-3 expression should have
been induced following MPTP administration in wild-type mice; however, despite
attempts with multiple antibodies, MMP-3 protein was not detected at any point (106).
In addition to acting as a potential microglial activating factor, MMP-3 may
support activation of microglia through other mechanisms. LPS-stimulated nitric oxide
and TNF-α in microglia can be blocked with N-isobutyl-N-(4-methoxyphenylsulfonyl)39

glycylhydroxamic acid (NNGH), a broad-spectrum MMP inhibitor with preference
towards MMP-3 (237). Dose-dependent inhibition of ERK, p38 MAP kinase, JNK, NFκB, and AP-1 activation were all shown to be involved in the NNGH effect. These
studies suggest that maximum activation of microglia by LPS requires MMP-3 activity.
Additional studies are needed to confirm these observations because NNGH may have
off-target effects that have not been described. NNGH is a hydroxamate MMP inhibitor,
which are notorious for inhibiting multiple MMPs and other metalloproteinase proteins.
To my knowledge, NNGH inhibition towards other MMPs has not been measured (129).
In addition to supporting microglial activation, MMP-3 may perform novel
intracellular functions that promote DA neurodegeneration as described by Choi and
colleagues (37). They were intrigued by the observation that MMP-3 released by DA
neurons stressed by MPTP, serum starvation, or tetrahydrobiopterin (BH4) was already in
the activate state (37, 106, 108). This suggested that activation occurred within the cell,
implying that MMP-3 could have novel intracellular functions. In support of this, both
pro and active MMP-3 were detected in cell lysates after treatment with BH4, and
inhibition of MMP-3 through pharmacological or siRNA methods partially protected the
cells from BH4 neurotoxicity (37). These studies suggest that MMP-3 contributes to DA
neurodegeneration by direct action on the DA neuron and through initiation of
neuroinflammation.
Further evidence from PD animal models indirectly supports an important role for
MMPs in DA neurodegeneration. In other models that involve neuroinflammation,
MMP-2, MMP-3, and MMP-9 disrupt the BBB by targeting the ECM in the basal lamina
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and proteins that form tight junctions (47, 148, 184, 185). BBB disruption occurs in both
the 6-OHDA and MPTP animal models of PD. Importantly, leakage of the BBB in both
models was found to be limited to areas of microglia activation and active DA
neurodegeneration (31, 248). Although it is not known if the BBB is compromised in PD
patients, emerging data indicates that the peripheral immune system plays a significant
role in PD neurodegeneration (146). In PD, T-cells show an increased ability to infiltrate
the brain parenchyma, suggestive of BBB dysfunction.

2.5 Relationship between α-Synuclein and Matrix Metalloproteinase-mediated
Dopaminergic Neurodegeneration
Along with MMP-3, α-synuclein has been identified as a potential microglial
activating factor. α-Synuclein is the major protein component of Lewy Bodies and is
believed to be an important contributor to DA neurodegeneration (195). This is based on
the discovery of genetic mutations and duplications in the α-synuclein gene associated
with familial PD and the propensity for overexpression of α-synuclein in sporadic PD.
The physiological function of α-synuclein remains to be elucidated, but overexpression in
transgenic mice and in cell culture models has demonstrated that it can be neurotoxic
(130, 195, 217). Several recent studies show that α-synuclein toxicity may be partly
dependent on its ability to directly activate microglia. Addition of α-synuclein to primary
microglia caused activation of NADPH oxidase and induced iNOS expression along with
increased prostaglandin, IL-1β, IL-6, and TNF-α production (216, 246). Moreover,
addition of α-synuclein to mixed mesencephalic cultures resulted in DA neurotoxicity
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that was completely microglia-dependent (246). Experiments with transgenic mice that
overexpress human α-synuclein specifically in DA neurons showed significant activation
of microglia prior to detectable cell loss (216, 220). These studies implicate α-synuclein
as a microglial activating factor and point to microglia-mediated neurotoxicity as an
important mechanism by which α-synuclein triggers DA neurodegeneration. In addition,
activation of microglia may be an early event in the neurodegeneration cascade, since
activated microglia are present prior to measurable DA neuron loss (216).
An important point to address regarding α-synuclein’s role as a microglial
activating factor is that it must be released from DA neurons. α-Synuclein is typically
regarded as an intracellular protein, since it does not contain the obligatory N-terminal
signal peptide that would send it through the secretory pathway. However, studies
analyzing cerebrospinal fluid from PD patients and age-matched controls have detected
this protein in abundance (20, 59). α-Synuclein secretion from healthy cells has been
demonstrated in several cell lines, including MN9D DA cells (59, 216). The mechanism
of α-synuclein secretion may be related to its ability to associate with membranes.
Although α-synuclein has no signal peptide, it does contain 2 di-acidic motifs near its Cterminus that has been predicted to act as an alternative signal to gain entry into the
endoplasmic reticulum and secretory pathway (59). Surprisingly, studies of cerebrospinal
fluid show that the amount of α-synuclein present does not differ between idiopathic PD
and control samples (20). If extracellular α-synuclein activates microglia, then why is
widespread microglial activation absent in neurologically normal individuals? The
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ability of α-synuclein to activate microglia seems to depend on its conformation, which
could be strongly influenced by MMP-mediated proteolysis.
In its native state, α-synuclein remains in a soluble, random coil conformation
with no defined tertiary or quaternary structure. Several post-translational modifications,
including phosphorylation, nitration, and oxidation, cause α-synuclein to reorganize into
β-sheet conformations that are vulnerable to oligomerization, fibril assembly, and
eventual insoluble aggregate formation (179). A dynamic equilibrium exists between the
random-coil and β-sheet conformations that favor the native conformation under
physiological conditions (131). However, appropriate α-synuclein point mutations, posttranslational modifications (phosphorylation, nitration, and oxidation), or interactions
with other proteins or heavy metals shifts equilibrium towards the β-sheet conformation
and subsequent fibril formation and aggregation (130). Aggregated α-synuclein is the
predominant form deposited in Lewy Bodies (195, 210, 211). In addition, analysis of
cerebrospinal fluid samples demonstrate that α-synuclein aggregates are the most
prominent form in PD patients, whereas, the soluble, random coil conformation
predominates in age-matched controls (60). In terms of neurotoxicity, α-synuclein
oligomers appear most important, since they exhibit greater neurotoxicity than monomers
or large insoluble fibril aggregates (130, 217).
Emerging evidence strongly indicates that MMP-mediated proteolysis may
negatively affect α-synuclein conformation status. Sung and colleagues (217)
overexpressed α-synuclein in dopaminergic SK-N-BE cells. Upon treatment of these
cells with the nitric oxide donor sodium nitroprusside, MMP-dependent cleavage of α43

synuclein was observed. Upon further examination, MMP-1, MMP-2, MMP-3, and
MMP-14 were all capable of degrading α-synuclein, with MMP-3 being most efficient.
Importantly, the authors demonstrated that MMP-3-digested α-synuclein increased αsynuclein oligomer and aggregate formation, which significantly enhanced α-synuclein
neurotoxicity. Recently, the ability of α-synuclein fragments to induce aggregate
formation was tested for MMP-1, MMP-3, trypsin, and proteinase-K (121). In agreement
with the previous study, partial α-synuclein digestion with MMP-1 and MMP-3 resulted
in increased aggregate formation. Trypsin and proteinase-K-digested α-synuclein failed
to enhance aggregation, suggesting that proteolysis-mediated α-synuclein aggregation is
MMP specific. Although not yet tested experimentally, MMP-directed digestion could
enhance activation of microglia by α-synuclein, since aggregated α-synuclein effectively
induces microglial ROS and prostaglandin production (246). The roles of other MMP
targets in DA neurodegeneration have not been studied.

2.6 Connective Tissue Growth Factor in Inflammation and Neurodegeneration
Connective tissue growth factor (CTGF/CCN2) is a 38kDa cysteine-rich matrix
associated protein involved in the signaling modification of other growth factors and
molecules associated with the ECM. Depending on cell type, upstream signaling
pathways, and the presence or absence of certain growth factors, CTGF/CCN2 can
influence cell proliferation, differentiation, survival, apoptosis, migration, chemotaxis,
neoplastic transformation, and adhesion (39, 49, 241). All CCN proteins contain four
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FIGURE 2.4: CTGF/CCN2 Motifs
CTGF/CCN2 contains four functional motifs. The insulin growth factor-like binding
protein motif (IGFBP) and von Willebrand factor motif (VWF-C/CT) is separated from
the thrombospondin-1 and C-terminal motifs by the hinge region. The hinge region is
susceptible to proteolytic cleavage by several MMPs. Cleavage of CTGF/CCN2 by
MMPs results in 2 fragments of approximate equal molecular weight (20-22kDa).
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motifs: insulin-like growth factor binding protein, von Willebrand factor,
thrombospondin-homology, and heparin-binding cysteine knot (Figure 2.4).
CTGF/CCN2 is upregulated in both fibrotic and peripheral inflammatory diseases
where it is thought to stimulate ECM accumulation and reorganization (118, 190). Little
is known about CTGF/CCN2 function in the central nervous system, although it is
expressed primarily by distinct neuronal populations. For instance, CTGF/CCN2
expression has been localized to neurons in the deep and intermediate regions of the
olfactory bulb and pyramidal neurons in layers III, V, and VII of the cerebral cortex (87,
111, 225). In addition to neurons, ependymal cells lining the ventricles and central canal
show strong CTGF/CCN2 expression. Its expression in astrocytes is debatable: Kondo et
al, (111) found strong CTGF/CCN2 protein labeling of astrocytes throughout cortical and
spinal white matter, but Heuer et al, (87) failed to localize CTGF/CCN2 mRNA to
astrocytes. Microglia and oligodendrocytes do not normally express CTGF/CCN2.
Despite the expression of CTGF/CCN2 in a variety of cells and locations in the central
nervous system, its physiological significance is unknown, although emerging evidence
indicates that CTGF/CCN2 may be important in the injured brain. For example, in
ischemic and traumatic brain injury, CTGF/CCN2 accumulates in reactive astrocytes
found around glial scars, suggesting that CTGF/CCN2 may be involved in scar formation
(197, 198). Importantly, this increase in expression begins by day 1 following injury and
persists for several months post-injury. In mice, kainic acid-induced lesion of the
hippocampus resulted in upregulated CTGF/CCN2 expression in both neurons and
reactive astrocytes (86). CTGF/CCN2 may also be involved in neurodegeneration. In
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patients with amyotrophic lateral sclerosis, CTGF/CCN2 is over-expressed in reactive
astrocytes and surviving motor neurons of the spinal cord, but not in activated microglia
(212). In addition, increased CTGF/CCN2 expression has been described in Alzheimer’s
disease, concentrated around β-amyloid deposits in reactive astrocytes and degenerating
axons (225). When CTGF/CCN2 was added directly to neuronal cell cultures, it induced
γ-secretase activity through an Akt-dependent mechanism that resulted in increased
release of amyloidogenic Aβ peptide, suggesting that CTGF/CCN2 contributes to plaque
pathology (249). To my knowledge, the role of CTGF/CCN2 in DA neurodegeneration
and PD has yet to be examined.
Data is emerging linking CTGF/CCN2 biology with that of MMPs. For example,
the hinge region located between the Von Willebrand factor and thrombospondinhomology motifs can be cleaved by MMP-1, -2, -3, -7 and -13 (83). In each case, MMPmediated cleavage of CTGF/CCN2 results in the generation of two CTGF/CCN2
fragments that are 20-23kDa in size. These fragments have been shown to have different
effects on biologic activities (6). It appears that N-terminal fragments mediate
differentiation whereas the C-terminal fragments control signaling leading to cell
proliferation (77). MMP-3 may also regulate CTGF/CCN2 function at the transcriptional
level. MMP-3 contains 6 nuclear localization signals and has been identified in the
nucleus of cultured chondrocytes and hepatocytes (57, 206). Intranuclear MMP-3 has
been shown to enhance CTGF/CCN2 transcription though direct interaction with the
CTGF/CCN2 promoter (57). MMP-3 DNA binding to the CTGF/CCN2 promoter was
confirmed with EMSA and ChiP assays. Overexpression of MMP-3 increased
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CTGF/CCN2 expression, while pharmacological MMP inhibition repressed transcription
of the CTGF/CCN2 gene. Importantly, exogenously added recombinant proMMP-3
could be internalized and transported to the nucleus. In addition to direct regulation of
CTGF/CCN2 transcription, recent evidence indicates that active intracellular MMP-3
participates in DA neuronal cell death and hepatocyte apoptosis (37, 206).
It is unclear whether proteolytic cleavage and/or transcriptional regulation of
CTGF/CCN2 by MMPs is important in vivo. However, it is interesting to note that these
two proteins are often found in the similar structures in various pathologies. For
example, MMP-3 is over-expressed in complicated atherosclerotic plaques, β-amyloid
plaques, and arthritic joints (1, 123, 243). In separate studies, CTGF/CCN2 was found to
be over-expressed in these same structures (42, 133, 225). Together with direct in vitro
evidence showing MMP-mediated regulation of CTGF/CCN2 and data demonstrating
expression of these proteins in similar structures, CTGF/CCN2 may mediate some
downstream effects of MMP-3-mediated neurodegenerative processes.

2.7 Project Hypotheses and Specific Aims
This project further explores the role of MMPs in PD using three different PD
models. The goal is to compare the temporal MMP response in neurotoxin and
inflammatory models to determine if MMPs could be involved in DA neurodegeneration
caused in either case. In addition, the effect of DA neurodegeneration on CTGF/CCN2, a
potential downstream MMP target is examined. Aside from MMP-3, the role of other
MMPs in DA neurodegeneration is relatively unexplored and the potential involvement
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of CTGF/CCN2 in DA neurodegeneration has never been examined. It was hypothesized
that MMPs could be involved in DA neurodegeneration through two mechanisms (Figure
2.2). First, MMPs may initiate microglial-driven neuroinflammation following
neurotoxic insult to the nigrostriatal tract. This is supported by MMP-3 studies which
demonstrate that MMP-3 is released by degenerating DA neurons in response to MPTP
and is capable of stimulating TNF-α and superoxide production in primary microglia
cultures (106, 108). Second, MMPs could function in the neuroinflammatory reaction
that directly contributes to DA neurodegeneration. This is supported by data implicating
microglia and astrocytes as sources of various MMPs in other neuroinflammatory
reactions (47, 184, 185).

Hypothesis 1: MMPs are involved in 6-OHDA-induced DA neurodegeneration.

Specific Aim 1a: Examine the effect of 6-OHDA on DA SH-SY5Y cell viability and
temporal MMP expression.
SH-SY5Y cells are an immortalized neuroblastoma cell line that exhibit
catecholaminergic properties such as TH and dopamine transporter expression and
stimulated release of dopamine and norepinephrine. Due to these properties, SH-SY5Y
cells are commonly used to study mechanisms of cell death induced by DA-specific
neurotoxins such as 6-OHDA. Techniques for specific isolation and maintenance of DA
neurons in primary culture do not exist. In contrast, SH-SY5Y cells are easily grown in
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culture and provide a homogenous population of DA-like cells, making them ideal to
study the effect of 6-OHDA on MMP expression.

Specific Aim 1b: Measure the effect of 6-OHDA on temporal nigral and striatal MMP
expression in hemiparkinsonian rats.
The purpose of this study is to confirm findings described in specific aim 1a using
an in vivo 6-OHDA model. When injected into the striatum, 6-OHDA causes
degeneration of DA neurons due to specific uptake through dopamine transporters and
subsequent oxidative stress. The neurodegeneration is accompanied by activation of
microglia and astrogliosis, suggesting that factors released from degenerating DA
neurons induce neuroinflammation (41, 204). Changes in MMP expression will be
measured at time points consistent with active neurodegeneration.

Hypothesis 2: MMPs and CTGF/CCN2 are involved in LPS-induced DA
neurodegeneration.

Specific Aim 2a: Correlate changes in MMP and CTGF/CCN2 protein expression with
DA neurodegeneration in LPS-induced Parkinsonism.
MMP expression is associated with microglia and astrocytes in response to
neuroinflammation that occurs in stroke, multiple sclerosis, and Alzheimer’s disease (47,
184, 185). In addition, CTGF/CCN2, a proteolytic and transcriptional target for MMPs,
may be involved in neuroinflammation present around amyloid-β plaques and active
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areas of spinal cord neurodegeneration associated with Alzheimer’s disease and
amyotrophic lateral sclerosis, respectively (212, 225). The effect of a direct
neuroinflammatory stimulus on MMP and CTGF/CCN2 expression in a PD model has
yet to be examined. The LPS model of PD will be used to examine these proteins. When
injected into the SNc, LPS induces robust microglial activation followed by specific
degeneration of DA neurons (32, 84).

Specific Aim 2b: Measure the effect of LPS on MMP and CTGF/CCN2 expression in
BV-2 microglia.
LPS acts by directly binding to toll-like receptor-4 (TLR4) and the MAC-1
receptor complex present on the surface of microglia (168). Therefore, changes in MMP
and CTGF/CCN2 expression may occur within microglia. To examine this possibility,
MMP and CTGF/CCN2 expression was measured after LPS treatment in BV-2 cells.
The BV-2 cell line is an immortalized murine microglia cell line used to study the
molecular biology of microglial activation.

Successful completion of these specific aims will provide important information
regarding the role of MMPs and CTGF/CCN2 in the self-sustaining neurotoxic cycle
hypothesized to drive chronic DA neurodegeneration in PD. In addition, the MMP
response to both neurotoxin and inflammation-induced neurodegeneration will be
elucidated.
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CHAPTER 3
The Effect of 6-Hydroxydopamine on Matrix Metalloproteinase
Expression in SH-SY5Y Cells and Hemi-parkinsonian Rats

3.1 Introduction
PD is the second most common neurodegenerative disorder, currently affecting
more than 4 million individuals throughout the world’s 10 most populous nations (53).
The cardinal motor symptoms of PD, including resting tremor, rigidity, and bradykinesia,
result from striatal dopamine depletion caused by progressive degeneration of
nigrostriatal DA neurons (135). Its greatest risk factor is age with both genetic and
environmental factors contributing to disease onset (34, 195). To date, no cure exists for
PD and current treatments target disease symptoms while having no effect on the
underlying pathological mechanisms that drive disease progression. A better
understanding of PD pathogenesis is required for the development of neuroprotective
therapeutic strategies aimed at slowing or even arresting disease progression.
Accumulating evidence suggests that MMPs play an important role in PD
pathogenesis. MMPs are zinc-dependent endopeptidases that degrade components of the
ECM, shed important cell signaling regulators from plasma membranes, and release
growth factors and cytokines sequestered within the ECM (33, 136, 152). With a wide
range of targets, MMPs can exert control over many important physiological processes
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including wound healing, bone growth, cell migration, and angiogenesis (152); however,
excessive proteolytic activity can contribute to a variety of disease processes, such as
plaque disruption in advanced stages of atherosclerosis, cartilage destruction associated
with rheumatoid arthritis, and BBB leakage characteristic of multiple sclerosis and
reperfusion injury following stroke (3, 156, 184). In a postmortem PD study, increased
MMP-1 and MMP-9 expression was detected in SNc samples in a subset of patients
(127). In addition, MMP-9 expression was increased in striatal and nigral tissue samples
following MPTP-induced DA neurodegeneration in mice (128). In this same model,
transient increases in striatal MMP-2 expression were detected (128). Importantly, MMP
inhibition with the broad spectrum MMP inhibitor Ro-282653 protected DA neurons
from MPTP-mediated neurotoxicity (128), suggesting that MMPs may be an attractive
therapeutic target in PD.
In this chapter, two models will be used to study the MMP response to the DA
neurotoxin 6-OHDA: the in vitro human SH-SY5Y cell model and the in vivo
hemiparkinsonian rat model. SH-SY5Y cells are a human neuroblastoma cell line that
express TH and DAT, synthesize dopamine, and display sensitivity to DA-specific
neurotoxins, including 6-OHDA (36, 189, 213). Due to these properties, SH-SY5Y cells
are commonly used to study events associated with DA neurodegeneration. Moreover,
changes in MMP expression in response to DA neurotoxicity have yet to be studied in a
human DA neuronal model.
Hemi-parkinsonian rats will be generated with a triple intrastriatal injection of 6OHDA. Like dopamine, 6-OHDA cannot cross the BBB and must be injected directly
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into the brain (10). Typically, 6-OHDA is injected unilaterally to create a hemiparkinsonian lesion in which the nigrostriatal tract ipsilateral to the injection site is
lesioned, while the contralateral side remains intact, serving as an internal control when
examining protein expression. Intrastriatal injection of 6-OHDA triggers retrograde
degeneration of DA terminals (Figure 3.1). The protocol used in these studies generates a
lesion which leaves the ventral tegmental DA neurons intact, while nigral DA neuronal
loss approaches 60% and striatal dopamine depletion reaches 70% (109). This relatively
mild lesion models the extent of nigrostriatal damage present during the early
symptomatic phase of PD (109).
Three key observations suggest that MMPs may play an important role in DA
neurodegeneration in response to 6-OHDA injection. First, two other DA-specific
neurotoxins, MPTP and BH4, induce MMP-3 expression in dying DA neurons in vitro
(37, 108). MPTP-induced MMP-3 expression was critical for generation of the activated
microglial response in mixed-mesencephalic cultures, supporting that MMP-3 could
serve as a microglial activating factor (106). Data from BH4-induced MMP-3 expression
suggested that MMP-3 could contribute to DA neurodegeneration through novel
intracellular mechanisms (37). These studies suggest that MMP release may be an
important characteristic of DA neurons once exposed to neurotoxic insults. Second,
injection of 6-OHDA anywhere along the nigrostriatal tract results in focal disruption of
the BBB concentrated around areas of active neurodegeneration both in the striatum and
SNc, indicating that BBB dysfunction may contribute to nigrostriatal degeneration (31,
43). MMPs are well known for their ability to disrupt the BBB in models of stroke.
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FIGURE 3.1: Unilateral 6-OHDA Model of Parkinson’s Disease
Unilateral intrastriatal 6-OHDA causes selective DA degeneration that proceeds in a
retrograde fashion with severe dopamine depletion in the injected striatum completed
prior to cell soma degeneration in the SNc. The contralateral nigrostriatal tract remains
intact.
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They contribute to BBB leakage through degradation of the ECM forming the basal
lamina and cleavage of tight junction proteins located between capillary endothelial cells
(27, 188, 240). Astrocyte-derived MMP-2, pericyte-derived MMP-3, and neutrophilderived MMP-9 all coordinate BBB disruption in response to reperfusion injury
following cerebral ischemia (27, 183). Third, several immunohistochemical studies have
identified activated microglia in the SNc and striatum following 6-OHDA administration
(31, 41, 193, 215). Activated microglia have been recognized as important sources for
MMP-3 in vascular dementia and rodent models of stroke (79, 187, 208). In addition,
primary microglia cultures release large amounts of MMP-9 upon LPS-induced activation
(237).
The goals for experiments executed in this chapter were as follows: 1) determine
the 6-OHDA dose-response relationship and time-dependent effect on SH-SY5Y cell
viability; 2) examine the temporal effect of 6-OHDA on MMP mRNA expression in SHSY5Y cells in order to identify MMPs released by stressed SH-SY5Y that could mediate
6-OHDA neurotoxicity; 3) characterize the 6-OHDA neurodegenerative response in vivo
by elucidating the time course for striatal and nigral TH depletion; (4) measure the
temporal protein expression and activation profile of striatal and nigral MMP-2, -3, -9,
and -13; and (5) correlate changes in MMP expression and activation with DA
neurodegeneration assessed by depletion of TH protein expression. These experiments
will identify other MMPs that could serve as candidate microglial activating factors and
will determine if a direct nigrostriatal tract neurotoxic insult entails upregulation and
activation of MMPs.
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3.2 Materials and Methods
Materials. Human SH-SY5Y neuroblastoma cells were purchased from ATCC
(Manassas, VA). Ketamine (100mg/mL), xylazine (100mg/mL), and buprenorphine
(0.3mg/mL) were obtained from the central pharmacy at Main Hospital, Medical College
of Virginia campus. Pentobarbitol was supplied in a Euthasol formulation (390mg/mL)
by the Department of Animal Resources, Virginia Commonwealth University.
DMEM/F-12, Penicillin/streptomycin, phosphate-buffered saline (PBS), 0.25% trypsinEDTA, 0.4% trypan blue, TRIzol reagent, 4-12% polyacrylamide 10 and 15-well Bis-Tris
gels, 0.45µm nitrocellulose membranes, sample reducing agent, LDS sample buffer, MES
running buffer, antioxidant solution, and western blot transfer buffer were acquired from
Invitrogen Corp. (Carlsbad, CA). Millex sterile syringe filters, mouse anti-rat TH (Cat#
MAB318), goat anti-mouse MMP-13 (Cat# AB8120), and rabbit anti-human cyclophilinA (Cat# 07-313) were procured from Millipore (Billerica, MA). Culture flasks and
plates, chloroform, 2-propanol, sterile drapes, No. 3 scalpel blades, bone wax, 4-0
chromic gut sutures, 10% povidone/iodine solution, alcohol prep pads, coronal small
rodent brain matrix, cutting mat, brain matrix razor blades, sodium dodecyl sulfate
(SDS), NaCl, Tween-20, deoxycholic acid, Tris-HCl, and bovine serum albumin (fraction
V) were purchased from Fisher Scientific (Pittsburgh, PA). 6-hydroxydopamine-HCl
(Cat # H4371-100MG), L-ascorbic acid, diethyl pyrocarbonate (DEPC), and NP-40 were
obtained from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was secured
from Gemini Bio-products (West Sacramento, CA). Goat anti-mouse MMP-2 (Cat#
AF1488) and goat anti-mouse MMP-9 (Cat# AF909) were obtained from R&D Systems,
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Inc. (Minneapolis, MN). Goat anti-human MMP-3 (Cat# ab18898) and full length
recombinant mouse MMP-9 were purchased from Abcam, Inc. (Cambridge, MA). Goat
anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP were purchased from Rockland
Immunochemicals, Inc. (Gilbertsville, PA). Bovine anti-goat IgG-HRP (Cat# sc-2350)
was procured from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). SuperSignal West
Dura extended duration HRP substrate solution was obtained from Pierce (Rockford, IL).
Enhanced Chemiluminescence HRP substrate solution was purchased from GE
Healthcare (United Kingdom). Protease inhibitor cocktail was purchased from
Calbiochem (San Diego, CA). Absolute ethanol was purchased from AAPER Alcohol
and Chemical Company (Shelbyville, KY). RQ1 Dnase kit was purchased from Promega
Corp. (Madison, WI). Universal human reference RNA was obtained from Stratagene
(Cedar Creek, TX). Non-fat dry milk was bought from The Kroger Co. (Cincinnati, OH).
Methanol was purchased from Colonial Scientific, Inc. (Richmond, VA).
SH-SY5Y Cell Culture. Human SH-SY5Y neuroblastoma cells were maintained
in DMEM/F-12 supplemented with 10% FBS, 100U/mL penicillin, and 100µg/mL
streptomycin. Cells were passed regularly as needed and spent media was refreshed
twice weekly. Only cells from passages 7-11 were used for cell viability and real-time
PCR experiments. For cell viability measurements, cells were plated at a density of
20,000 cells/cm2 in T25 flasks. For Real-time PCR experiments, cells were plated at a
density of 30,000 cells/cm2 in T25 flasks to increase RNA yield. Prior to 6-OHDA
treatment, serum was reduced to 5% FBS for 24 hours, then to 2% FBS for 24 hours, and
finally to 0.5% FBS for 24 hours.
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6-OHDA Treatment. All 6-OHDA preparations were made immediately prior to
use. 6-OHDA was dissolved in 2mg/mL ascorbic acid prepared in PBS to make a 10mM
stock solution. This solution was sterilized by passage through a syringe filter containing
0.45µm diameter pores. Ascorbic acid is included in the vehicle solution in order to
minimize oxidative degradation of 6-OHDA prior to addition to cell cultures. To
formulate treatment media, sterile 6-OHDA stock solutions were diluted to 15, 30, 45, 60,
75, or 90µM directly in DMEM/F-12 containing 0.5% FBS. Vehicle media contained the
appropriate volume of 2mg/mL ascorbic acid.
Trypan Blue Exclusion Cell Viability Assay. Treatment media was aspirated
and saved. Cultures were washed twice with PBS and washes were combined with saved
treatment media so that all detached cells were collected. Remaining attached cells were
incubated in 1.5mL 0.25% trypsin-EDTA for 5-15 minutes at 37°C and then were made
into a single cell suspension by passing them through a 1mL pipet tip 50 times. The
trypsin reaction was stopped with 2mL 10% FBS in DMEM/F-12. Cells were combined
with saved treatment media and were centrifuged for 6 minutes at 1000 rpm. Supernatant
was discarded and cell pellet was resuspended in 300µL serum free DMEM/F-12. Cell
suspension aliquots (100µl) were combined 1:1 with 0.4% trypan blue. After 3 minutes,
unstained viable cells were counted in both chambers of a brightline hemocytometer with
improved Neubauer ruling (Hausser Scientific, Horsham, PA). The total number of
viable, dye excluding cells in each culture was calculated with the following equation:
Total viable cells = (a/b)*cd
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where ‘a’ is equal to the number of viable cells per mm2, ‘b’ is equal to the total volume
of the counted area (10-4cm3), ‘c’ is equal to the dilution factor (2), and ‘d’ is equal to the
total volume of cell suspension.
RNA Extraction and Quantitative Real-Time RT-PCR. SH-SY5Y RNA was
extracted with TRIzol reagent following the manufacturer’s instructions. Briefly, cells
grown and treated in T25 flasks were incubated in 1mL TRIzol reagent for 5 minutes to
lyse the cells. Cells were scraped and the homogenate was transferred to a 1.5mL
microcentrifuge tube. Chloroform (200µL) was added and samples were mixed
vigorously for 15 seconds and then were incubated at room temperature for 2.5 minutes.
Samples were centrifuged at 12,000 x g for 15 minutes at 4°C. The aqueous phase was
saved and RNA was precipitated with the addition of 500µL 2-propanol and subsequent
incubation at room temperature for 10 minutes. RNA was pelleted by centrifugation at
12,000 x g for 15 minutes at 4°C. Supernatant was discarded and RNA pellet was gently
washed with 75% ethanol and centrifuged at 7,500 x g for 5 minutes at 4°C. Supernatant
was discarded; pellet was dried, resuspended in DEPC-treated nanopure water, and
heated to 57°C for 10 minutes to ensure complete dissolution. RNA concentration and
purity was determined by measuring A260/A280 on the Ultrospec 2000 UV/visible
spectrophotometer (GE Healthcare, UK). RNA samples were treated with RQ1 Dnase.
Dnase reactions were carried out at 37°C for 30 minutes. Reaction was terminated with
addition of RQ1 Dnase stop solution and subsequent heating to 65°C for 10 minutes.
Dnase-treated RNA samples were sent to the Nucleic Acid Core Facility at Virginia
Commonwealth University for quantitative real-time PCR measurements. TaqMan
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primer and probe sequences were designed by this core facility for MMP-2, -3, -7, -9, 13, -14, -15, and -24. Measurements were made using the ABI Prism 7900 Sequence
Detection System (Applied Biosystems, Carlsbad, California). Cyclophilin-A expression
was used as the endogenous control, while total human reference RNA was used as the
positive control for MMP expression and to construct standard curves used to quantify
MMP expression.
Surgical Procedures. Twenty-three adult male Sprague-Dawley rats (250-350g)
were housed individually in an AAALAC accredited (#00036), USDA registered (#52-R007), and PHS approved (#A-3281-01) animal facility. Room temperature and humidity
were kept constant, a 12-hour light/dark cycle was maintained, and food and water were
available ad libitum. Rats were monitored by qualified animal technicians throughout the
studies and were examined daily after surgery to check for weight loss, lethargy,
periorbital crusting or bleeding, and gait. If deficits were observed, appropriate measures
were taken to alleviate pain and suffering. All experiments were carried out in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University.
Immediately prior to intrastriatal injection of 6-OHDA, rats were anesthetized
with ketamine/xylazine (100mg/kg/10mg/kg, i.p.). Hair was removed from the scalp and
the surgical area was cleaned with alternating povidone/iodine antiseptic and alcohol
washes. After the rat was draped and mounted onto the rodent stereotaxic frame (Kopf
Instruments, Tujunga, CA), a single incision was made through the skin along the
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rostrocaudal length of the scalp using a No.10 scalpel blade attached to a No. 3 handle.
Three injections were made into the DA terminal region of the right striatum along its
rostrocaudal axis using the following coordinates in relation to Bregma (in mm): AP
+1.0, ML -3.0, DV -5.0; AP -0.1, ML -3.7, DV -5.0; and AP -1.2, ML -4.5, DV -5.0
(109). At each site, a burr hole was drilled and 10µg of 6-OHDA (2µl of 5µg/µl) or
ascorbic acid (2µl of 2mg/mL) was delivered with a 10µl Hamilton syringe fitted with a
26-guage needle. The needle was held in place for 5 minutes prior to injection. Flow
rate (1µl/min) was kept constant with a motorized syringe pump (BASi, West Lafayette,
IN). Five minutes after the conclusion of the injection, the needle was slowly removed to
prevent fluid backflow through the needle track (quarter turn per 10 seconds). Burr holes
were filled with bone wax and the wound was sutured closed. Body temperature was
maintained at 37°C throughout the duration of the surgery with a homeothermic blanket
(Harvard Instruments, Holliston, MA) and post-operative pain was managed with
buprenorphine (0.02mg/kg) injected in 12 hour intervals during the first 48 hours postsurgery. Rats were kept under a heat lamp until recovered from anesthesia. Based on
previous studies, it is expected that the lesion will result in a 60-70% loss of nigral DA
neurons after 3 weeks (109).
Protein Extraction. Rats were euthanized with pentobarbital (150mg/kg, i.p.)
followed by rapid decapitation 1, 5, 10, and 21 days post-surgery. Brains were rapidly
removed and placed ventral-side up in a rat brain matrix. Two 2mm thick coronal tissue
blocks were cut through the striatum and a single 2mm coronal tissue block was cut
through the midbrain using brain matrix razor blades (Figure 3.2). Tissue blocks were
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transferred to the cutting mat, which was kept cold with an ice pack. Ventral midbrain or
striatum was dissected, cut through the midline to separate ipsilateral and contralateral
tissue, and immediately placed in 1.5mL microcentrifuge tube containing 100µl (300µl
for striatum) ice-cold protein extraction buffer (50mM Tris-HCl pH 7.2, 150mM NaCl,
1% sodium deoxycholate, 1% NP-40, 0.5% SDS) with an added protease inhibitor
cocktail. Tissue chunks were homogenized with microcentrifuge tube pestles and
homogenates were centrifuged at 14,000 x g for 30 minutes at 4°C. Supernatants were
saved and stored at -80°C until use.
Western Blot. Sample protein concentrations were determined with the DC
protein assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin
solutions to construct the standard curve. LDS sample buffer and sample reducing agent
were added to samples (40µg for MMP blots, 5µg for TH blots). Samples were heated to
70°C for 10 minutes, loaded on 4-12% polyacrylamide Bis-Tris gels, separated by SDSPAGE (50 minutes at 200V), and transferred to nitrocellulose membranes (2 hours at
30V). All western blots used for MMP-13 detection were run under non-reducing
conditions (all procedures are identical to reducing conditions except that reducing agent
was omitted from the sample preparation and antioxidant was not added to the running
buffer). Membranes were blocked for 1 hour in 5% non-fat dry milk prepared in trisbuffered saline containing 0.05% Tween-20 (TBST). Membranes were incubated in TH,
MMP-2, MMP-3, MMP-9, or MMP-13 primary antibody overnight at 4°C. Membranes
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Striatum

Striatum

Substantia Nigra
FIGURE 3.2: Methods for Obtaining Striatal and Ventral Midbrain Tissue Samples
Two striatal tissue blocks were cut, each 2mm thick (top and middle coronal sections).
Tissue block was cut just anterior to the anterior commisure to eliminate the ventral
cortex. Next, a cut was made along the medial border of the lateral ventricles to remove
basal forebrain tissue. This cut also served to separate injected and contralateral striata.
Then, striatum was carefully pulled away from the corpus collosum at the lateral and
anterior border of the striatum. A single 2mm thick tissue block containing midbrain
tissue was collected (bottom coronal section). A large artery on the ventral surface of the
midbrain was removed, and the section was cut in half through the midline to separate
injected and contralateral midbrain. Ventral midbrain was cut just anterior to the anterior
gray/white border separating the substantia nigra from the medial lemniscus.
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were washed 4 x 5 minutes in TBST. Membranes were incubated in goat anti-mouse
IgG-HRP or bovine anti-goat IgG-HRP secondary antibody for 90 minutes at room
temperature and then were washed an additional 6 times in TBST. MMP
immunoreactivity was visualized with SuperSignal West Dura substrate followed by
exposure to film. Membranes were stripped and reprobed with cyclophilin-A primary
antibody followed by goat anti-rabbit IgG-HRP. For detection of cyclophilin-A and TH
immunoreactivity, visualization was accomplished with Enhanced Chemiluminescence
substrate followed by exposure to film. To quantify protein expression, digital images of
developed film were obtained using GeneSnap image acquisition software (version 6.07)
connected to the G-Box CCD camera (Synoptics, Cambridge, England). Backgroundcorrected immunoreactive band densities were measured using GeneTools software
(version 3.06, Synoptics, Cambridge, England). MMP and TH immunoreactivity was
normalized to cyclophilin-A, which served as the loading control.
Statistical Analysis. All statistical tests were performed using JMP software
(version 7.0). Cell viability dose response and time-dependent experiments were
analyzed with one-way ANOVA (α=0.05), followed by the Tukey-Kramer post-hoc test,
which was used to determine where significant differences in the data resided. Similarly,
temporal changes in MMP mRNA expression in 6-OHDA-treated SH-SY5Y cells were
analyzed by one-way ANOVA (α=0.05), followed by the post-hoc Tukey-Kramer test.
MMP-2 and TH protein densitometry data was analyzed by ANOVA using a two-way
design, where treatment (ascorbic acid or 6-OHDA) and time points (1, 5, and 10 days)
were the independent variables. The post-hoc Tukey-Kramer test was performed when a
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significant overall model and independent variable interaction effect was detected. Data
is presented as the mean ± standard error of the mean.

3.3 Results
SH-SY5Y Experiments. The sensitivity to 6-OHDA, a selective
catecholaminergic neurotoxin was measured in SH-SY5Y cells. To establish the dosereponse relationship, cells were treated with 0, 15, 30, 45, 60, 75, or 90µM 6-OHDA.
Cell viability was assayed by the trypan blue exclusion method 24 hours after treatment
(Figure 3.3). As expected, 6-OHDA treatment induced a dose-dependent decrease in cell
viability (F=53.8, p<0.001) with an LD50 dose of 37.6 ± 6.82µM. Based on the dose
response experiments, 45µM 6-OHDA treatments were used for all subsequent 6-OHDA
experiments with the expectation that this dose would drop the number of viable cells to
35.5 ± 10.3% of ascorbic acid-treated cells. This loss is comparable in magnitude to DA
degeneration associated with the intrastriatal 6-OHDA model (109). The time course for
6-OHDA-induced reduction in cell viability was measured to determine the optimum
time points for subsequent real-time PCR experiments. SH-SY5Y cell viability was
measured following treatment with 45µM 6-OHDA for 0, 3, 6, 12, 24, 48, and 96 hours
after 6-OHDA treatment (Figure 3.4). 6-OHDA treatment induced a significant timedependent decline in cell viability (F=52.7, p<0.001). The decline in cell viability
occurred entirely between 6 and 24 hours, dropping from 102 ± 7.23% at 6 hours to 30.1
± 0.16% at 24 hours. The total number of viable cells remained fairly stable at later time
points (27.0 ± 1.15% at 96 hours).
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FIGURE 3.3: 6-OHDA Dose Response Curve
Cells were treated with 0-90µM 6-OHDA for 24 hours prior to cell viability
measurements using the trypan blue exclusion assay. 6-OHDA treatment caused a dosedependent decline in SH-SY5Y cell viability (p<0.001; LD50=37.6 ± 6.82µM). Asterisks
denote significance compared to untreated control as determined by post-hoc TukeyKramer test. Data presented as the mean ± standard error of the mean from 4
independent experiments.
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Time Dependent Effect
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FIGURE 3.4: Time-dependent 6-OHDA Toxicity in SH-SY5Y Cells
SH-SY5Y cells were treated with 45µM 6-OHDA for 0-96 hours prior to measuring cell
viability with the trypan blue exclusion assay. 6-OHDA induced a time-dependent loss
of cell viability (p<0.001). Viability remained stable over the first 6 hours following
treatment and then sharply declined between 6-24 hours. No significant decline in cell
viability occurred between 24 and 96 hours. Asterisks denote significance compared to 0
hour time point as determined by post-hoc Tukey-Kramer test. Data presented as the
mean ± standard error of the mean from 2 independent experiments.
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Following establishment of the dose-response and time line for 6-OHDA toxicity
in SH-SY5Y cells, the effect of 6-OHDA on MMP mRNA expression was measured.
Cells were treated with 45µM 6-OHDA for 0, 2, 4, 6, and 8 hours. RNA was extracted at
each time point, samples were Dnase-treated, and then MMP-2, -3, -7, -9, -13, -14, -15,
and -24 mRNA was measured by quantitative real-time PCR using TaqMan primers.
Cyclophilin-A mRNA expression served as the internal control and all MMP mRNA
quantities were normalized to this gene. These time points were chosen based on the
hypothesis that MMPs contribute to SH-SY5Y cell death induced by 6-OHDA. It was
reasoned that if MMPs were involved in this process, then mRNA expression would
increase just prior to the steep decrease in cell viability. The 8 hour time point was
chosen as the final time point because cell detachment, indicative of cell death, had
started by this time. MMP-3, -7, -9, and -24 were not detected at any time point
examined. These transcripts were detected in control human reference RNA standards,
indicating that the primer and probes were functional. SH-SY5Y cells displayed basal
mRNA expression levels of MMP-2, -13, -14, and -15. MMP-2 was the most abundant
MMP detected, but 6-OHDA treatment did not result in changes in expression at any time
point (Figure 3.5A; F=1.3, p=0.30). Similarly, MMP-14 and MMP-15 mRNA did not
change in response to 6-OHDA (Figure 3.5C and D; F=2.96, p=0.055 and F=0.19,
p=0.94, respectively). In contrast, 6-OHDA induced a significant increase in MMP-13
mRNA expression (Figure 3.5B; F=6.2, p=0.003). MMP-13 mRNA increased 2.7 fold at
8 hours compared to basal expression levels. The correlation between the start of SHSY5Y cell viability decline and the temporal increase in MMP-13 mRNA expression
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FIGURE 3.5: Effect of 6-OHDA on MMP mRNA Expression in SH-SY5Y Cells
Cells were treated with 45µM 6-OHDA for 0-8 hours, covering the time points leading
up to the sharp drop in cell viability. RNA was extracted at each time point and samples
were sent to the real-time PCR core facility at Virginia Commonwealth University for
measurement of MMP-2, -3, -7, -9, -13, -14, -15, and -24. MMP-3, -7, -9, and -24 were
not detected at any time point. A) MMP-2 displayed the greatest level of endogenous
MMP mRNA expression, but was not significantly affected by 6-OHDA treatment
(p=0.30). B) Compared to 0 hours, MMP-13 mRNA increased 2.7-fold 8 hours
following 6-OHDA treatment (p=0.0034). The 2-6 hour time points were not
significantly different from expression at the start of the experiment. C, D) 6-OHDA
treatment had no effect on MMP-14 (p=0.055) or MMP-15 (p=0.94) expression.
Asterisks denote significance compared to 0 hour time point as determined by post-hoc
Tukey-Kramer test. Data presented as the mean ± standard error of the mean from 3-5
independent experiments.
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suggests that MMP-13 may be an important mediator of 6-OHDA neurotoxicity. MMP
protein was not measured due to the requirement that FBS be present in the treatment
media. FBS drastically interferes with gel-based methods of protein detection. To get
around this issue, future experiments aimed at measuring changes in extracellular protein
expression in SH-SY5Y cells should use ELISA-based methods.
Intrastriatal 6-OHDA Hemi-parkinsonian Rat Experiments. The previous set
of experiments used an isolated system, testing the direct effect of 6-OHDA on MMP
expression in neuronal cells. The MMP response to 6-OHDA in vivo may differ greatly
from that seen with the SH-SY5Y model. For instance, the SH-SY5Y model ignores
potential important contributions of other cell types, such as microglia and astrocytes.
Altered expression of various MMPs, including MMP-2, -3, and -9, have been attributed
to both cell types (27, 183). The intrastriatal 6-OHDA hemi-parkinsonian rat model was
studied in an attempt to confirm the 6-OHDA effect on MMP-13 and to determine if
MMP-2, -3, or -9 expression or activation changed in response to 6-OHDA in vivo.
TH is routinely measured to examine the extent of nigrostriatal injury due to its
selective expression within DA neurons. In order to verify that the 6-OHDA injection
protocol used in these experiments produced a nigrostriatal lesion and to elucidate the
time course of neurodegeneration, TH protein expression was measured by western blot
1, 5, and 10 days post-surgery. TH was normalized to cyclophilin-A immunoreactivity to
correct minor differences in protein loading. To determine the extent of TH depletion,
normalized lesioned tissue TH values were expressed as a percentage of the normalized
contralateral, intact tissue TH values. As expected, there was a significant overall model
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effect on TH expression in both the striatum (F=16.6, p<0.001) and SNc (F= 4.94,
p=0.009). In the striatum, there was a significant interaction effect detected between
treatment groups (6-OHDA and vehicle) and time points examined (F=5.6, p=0.017).
Compared to the contralateral side, ipsilateral striatal TH expression decreased to 31.9 ±
4.08% at day 5, which progressed to 7.46 ± 3.09% at day 10 in the 6-OHDA group
(Figure 3.6). In contrast, TH expression remained unchanged in the ascorbic acid group
(119.5 ± 6.85% at day 5 and 111.8 ± 6.77% at day 10).
In contrast to the striatum, considerable nigral TH depletion was not observed
until 10 days post-surgery (Figure 3.7). Compared to the contralateral side, nigral TH
expression decreased to 57.0 ± 10.1% in the 6-OHDA group, demonstrating that
intrastriatal injection of 6-OHDA resulted in significant nigral neurodegeneration.
Ascorbic acid had no effect on TH expression at this time point (95.6 ± 10.8%). This
pattern of degeneration is consistent with the expected retrograde neurodegeneration
response caused by an intrastriatal DA injury (Figure 3.1).
The reduction in nigral TH falls short of the expected 66% decrease in the number
of TH positive nigral neurons reported in the original description of this 6-OHDA model
(109); however, the 66% measurement was made 3 weeks post-surgery. To determine if
nigral TH decline continued to worsen at later time points, a small pilot experiment was
completed measuring TH protein expression by western blot 21 days post-surgery (Figure
3.8). Compared to the contralateral side, TH expression declined to 36% in animals
injected with 6-OHDA. This 64% overall reduction in TH closely matches the 66%
decline published previously (109).
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FIGURE 3.6: Effect of 6-OHDA on Striatal TH Protein Expression
TH measurements after intrastriatal 6-OHDA (n=3) or ascorbic acid (vehicle, n=3-4)
injection. Cyclophilin-A expression was measured to ensure equal protein loading. A)
Representative western blots demonstrating temporal changes in TH expression
(I=ipsilateral, C=contralateral). B) TH densitometric analysis in striatal tissue samples.
Vehicle had no effect on striatal TH expression, whereas, 6-OHDA treatment resulted in
massive, time-dependent TH depletion. Asterisks denote significance determined by
Tukey-Kramer test. Bars represent mean ± standard error of the mean.
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FIGURE 3.7: Effect of 6-OHDA on Nigral TH Protein Expression
TH measurements after intrastriatal 6-OHDA (n=3) or ascorbic acid (vehicle, n=3-4)
injection. Cyclophilin-A expression was measured to ensure equal protein loading. A)
Representative western blots demonstrating temporal changes in TH expression
(I=ipsilateral, C=contralateral). B) TH densitometric analysis in nigral tissue samples.
Vehicle had no effect on nigral TH expression; however, 6-OHDA treatment resulted in
time-dependent TH depletion that was evident 10 days post-surgery. Asterisks denote
significance determined by Tukey-Kramer test. Bars represent mean ± standard error of
the mean.
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FIGURE 3.8: 6-OHDA-induced Nigral TH Depletion 3 Weeks Post-surgery
TH measurements 3 weeks after intrastriatal 6-OHDA (n=2) or ascorbic acid (vehicle,
n=2) injection. Cyclophilin-A expression was measured to ensure equal protein loading.
A) Representative western blots demonstrating decreased nigral TH expression at day 21
(I=ipsilateral, C=contralateral). B) TH densitometric analysis in nigral tissue samples. In
the 6-OHDA treatment group, TH depletion reached 64%. Bars represent mean ±
standard deviation.
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After examination of TH, temporal MMP-2, -3, -9, and -13 protein expression
was measured in striatal and nigral tissue samples in order to correlate changes in MMP
expression with DA neurodegeneration. ProMMP-2 was detected in all striatal and nigral
tissue samples, and data was analyzed as described above in the TH experiment. Overall,
there was a significant experimental model effect on striatal proMMP-2 expression
(Figure 3.9; F=4.16, p=0.023); however, there was no time point and treatment group
interaction effect (F=0.21; p=0.81). Considering these variables independently, there was
a significantly time dependent effect on proMMP-2 expression (F=9.89, p=0.004), while
there was no treatment group effect (F=0.78, p=0.40). This relationship is readily
apparent in the representative western blots, which show modest increases in proMMP-2
expression 5 and 10 days post-surgery in both treatment groups (Figure 3.9A). These
results indicate that the time dependent increase in striatal MMP-2 expression was likely
due to the tissue injury response, rather than any specific toxic effect of 6-OHDA.
Similar to the striatum, there was a significant overall model effect on proMMP-2
expression in SNc tissue samples (Figure 3.10; F=4.9, p=0.013). There was no
significant interaction between the time and treatment group variables (F=3.3, p=0.075).
Despite the apparent lack of an interaction effect, there was both a significant timedependent (F=6.01, p=0.017) and treatment-dependent effect (F=5.19, p=0.044) on
proMMP-2 expression when these variables were considered independently. When
examining the densitometry graph (Figure 3.10B), there is an apparent trend towards a
treatment effect on proMMP-2 expression 5 days post-surgery. Compared to the
contralateral side, proMMP-2 expression increased to 199.3 ± 24.6% in the 6-OHDA
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FIGURE 3.9: Effect of 6-OHDA on Striatal MMP-2 Protein Expression
MMP-2 measurements after intrastriatal 6-OHDA (n=2-3) or ascorbic acid (vehicle, n=34) injection. Cyclophilin-A expression was measured to ensure equal protein loading. A)
Representative western blots demonstrating temporal changes in proMMP-2 expression
(I=ipsilateral, C=contralateral). B) ProMMP-2 densitometric analysis in striatal tissue
samples. Both 6-OHDA and ascorbic acid induced a time-dependent increase in
proMMP-2 expression. There was no difference in the magnitude of this effect between
the two treatment groups. Bars represent mean ± standard error of the mean.
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FIGURE 3.10: Effect of 6-OHDA on Nigral MMP-2 Protein Expression
MMP-2 measurements after intrastriatal 6-OHDA (n=2-3) or ascorbic acid (vehicle, n=34) injection. Cyclophilin-A expression was measured to ensure equal protein loading. A)
Representative western blots demonstrating temporal changes in proMMP-2 expression
(I=ipsilateral, C=contralateral). B) ProMMP-2 densitometric analysis in nigral tissue
samples. ProMMP-2 expression significantly increased in response to 6-OHDA, but the
effect was not time-dependent, despite the apparent increase at day 5. This is likely due
to small sample size (n=3). Bars represent mean ± standard error of the mean.
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group. In contrast, proMMP-2 expression did not appear different from 100% (121.6 ±
14.82%). When the post-hoc Tukey-Kramer test is applied to this data, a significant
difference is detected between the treatment groups 5-days post-surgery; however, since
no treatment/time interaction effect was detected with the two-way ANOVA (p=0.07), it
cannot be said with certainty that these groups are different. An increased sample size is
needed in order to determine for sure if there is a 6-OHDA effect on nigral proMMP-2
expression 5 days post-surgery. Regardless if there is an increase in proMMP-2 or not,
no activated MMP-2 protein was detected on nigral western blots, suggesting that MMP2 is not involved in nigral neurodegeneration.
Pro and active MMP-3 was undetectable in both striatal and nigral tissue samples
from the 6-OHDA treatment group (Figure 3.11A). In chapter 4, proMMP-3 expression
is described at 60kDa. One sample from the chapter 4 experiments was included here as
a positive control to demonstrate where proMMP-3 should appear on the western blot.
The 60kDa proMMP-3 band was not present in any sample; however, a slightly lower
molecular weight band was detected in most striatal and nigral tissue samples. Curiously,
several intense immunoreactive bands were detected specifically in day 10 striatal and
nigral samples, but the molecular weights were all 62kDa or greater. In addition to
MMP-3, striatal and nigral tissue samples lacked proMMP-9 (Figure 3.11B). In all
samples, a faint 100kDa immunoreactive band was detected which was higher than the
molecular weight of mouse recombinant proMMP-9, which appears at 92kDa. This band
was not affected by injection of 6-OHDA. In contrast to MMP-3 and MMP-9, proMMP13 protein was detected at all time points in both striatal and nigral tissue samples;
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FIGURE 3.11: Effect of 6-OHDA on Striatal and Nigral MMP-3, -9, and -13 Protein
Expression. MMP protein measurements after intrastriatal 6-OHDA injection.
Cyclophilin-A expression was measured to ensure equal protein loading (I=ipsilateral,
C=contralateral). A) ProMMP-3 expression was not detected at any time point in striatal
or nigral tissue samples. LPS=nigral sample from intranigral LPS experiments (chapter
4), which was used as a positive control for proMMP-3 expression. The intense
immunoreactivity detected in the day 10 samples was greater than 62kDa. A faint band
just below 60kDa was detected in all striatal samples and most nigral samples. B)
ProMMP-9 was not detected in any sample from 6-OHDA or vehicle group. Faint
immunoreactivity was typically present around 100kDa, which is larger than proMMP-9.
The rMMP-9 lane consisted of 12.5ng recombinant mouse MMP-9, which was used as
the positive control. C) ProMMP-13 was detected in all samples at all time points;
however, 6-OHDA appeared to have no affect on protein expression.
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however, within the 6-OHDA group ipsilateral proMMP-13 expression did not appear to
change compared to contralateral samples within each time point (Figure 3.11C).

3.4 Discussion
Based on emerging data identifying potentially important functions for MMP-3 in
DA neurodegeneration in vitro in response to MPTP and BH4 (37, 106), it was
hypothesized that the degenerative response to 6-OHDA also involved upregulation and
activation of MMPs. Significant time-dependent DA neurotoxicity was confirmed in
each 6-OHDA model by cell viability measurements for the SH-SY5Y studies and by TH
western blot measurements for the in vivo experiments. Several key MMPs were
examined in both models following 6-OHDA treatment. In SH-SY5Y cells, MMP-13
mRNA expression increased 8 hours after 6-OHDA treatment, suggesting that MMP-13
could serve an important function in 6-OHDA-mediated neurotoxicity. However, in an
attempt to confirm this effect in vivo, striatal and nigral MMP-13 protein expression
failed to change 1, 5, or 10 days post-6-OHDA injection. In contrast to MMP-13, MMP2 mRNA expression did not change in 6-OHDA treated SH-SY5Y cells, while striatal
proMMP-2 protein expression increased in a time-dependent fashion due to tissue injury
caused by multiple needle insertions into the brain. In addition, nigral proMMP-2
expression trended towards an increase in the 6-OHDA group 5 days post-surgery, but no
active MMP-2 was detected at any of the three time points. Interesting, MMP-3 and
MMP-9 were not detected in response to 6-OHDA in either model. Contrary to MPTP
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and BH4 PD models, these studies suggest MMPs are likely not involved in 6-OHDA
mediated DA neurotoxicity.
6-OHDA Neurotoxicity. The first goal of these studies was to define the
neurodegeneration time course following 6-OHDA treatment in SH-SY5Y cells and
hemi-parkinsonian rats. In SH-SY5Y experiments, cell viability remained stable over the
first 6 hours after treatment and then dropped significantly, reaching a maximum of
64.5% depletion by 24 hours. This data agrees with previous experiments examining the
6-OHDA-induced decline in SH-SY5Y cell viability (213). Based on this time course,
MMP mRNA expression was measured 0-8 hours after 6-OHDA treatment to assess
expression at time points leading up to cell death.
The 6-OHDA lesion protocol employed in these studies was first described by
Kirik et al., (109); however, detailed analysis of the neurodegeneration time course in this
specific model was lacking. In a similar model which distributed 6-OHDA over 4 sites
within the striatum, significant loss of striatal TH expression was evident 3 days postsurgery, with almost complete TH depletion present at day 10 (41). Significant loss of
TH+ neurons in the SNc progressed from 20% at day 3, to 50% at day 10, and then to
80% by day 21 (41). The time course described in that study closely matches the
temporal TH decline observed with the triple intrastriatal 6-OHDA injection used in the
current study. With this protocol, over 90% of striatal TH and 47% of nigral TH
expression was eliminated 10 days post-surgery. The maximum extent of nigral injury
reached 3 weeks post-surgery was 16% less with the triple striatal injection than the
quadruple injection protocol (41); however, the 64% loss in nigral TH observed in the
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current study, agrees with the initial description of the triple intrastriatal injection, which
found that 66% of nigral DA neurons were lost by this time point (109). Based on these
results, it is clear that active DA neurodegeneration is occurring at the time points
examined, making them appropriate times to examine temporal changes in MMP
expression in response to 6-OHDA-mediated neurotoxicity.
Effect of 6-OHDA on MMP-3 Expression. Previous studies have shown that
MPTP increases MMP-3 expression in DA neurons present in neuronal cultures derived
from mouse mesencephalic tissue (106). Based on this, it was expected that 6-OHDA
would induce MMP-3 expression in SH-SY5Y cells; however, this did not occur. No
MMP-3 was detected in either untreated or 6-OHDA-treated SH-SY5Y cells. MMP-3
mRNA was detected in both total human reference RNA and U251 cells (data not shown)
confirming that the primer and TaqMan probe set was appropriately designed.
Examination of the SH-SY5Y cell karyotype reveals that no chromosome abnormalities
are associated with the location of the MMP-3 gene (209), eliminating the possibility that
deletions, insertions, or rearrangements of chromosome 11 as the cause for the lack of
MMP-3 expression in these cells. In addition, MMP-13, which is also located on
chromosome 11, was detected in these studies. Species differences may explain the
results obtained. This study is the first to examine MMP-3 expression in response to a
DA-specific neurotoxin in a human model of PD. The investigations mentioned earlier
were carried out in various rodent models (37, 106, 108).
Similar to the SH-SY5Y model, in vivo administration of 6-OHDA failed to
induce MMP-3 expression or activation, suggesting that species differences do not
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account for the different MMP-3 responses between 6-OHDA and MPTP models. The
inability of 6-OHDA to induce MMP-3 in two separate PD model systems strongly
indicates that elevated MMP-3 is not a general response to DA neurotoxicity, but rather is
neurotoxin-specific. Differences between the direct neurotoxic mechanisms initiated by
MPTP and 6-OHDA most likely account for this discrepancy. Both models typically are
used such that the lesion produced develops acutely, which appears to rely on generation
of high levels of oxidative stress (10). A key difference may involve the mechanisms
responsible for elevating oxidative stress within DA neurons. In MPTP-mediated
neurotoxicity, its metabolite MPP+ is selectively taken up by DA neurons, which then
specifically targets complex I of the mitochondrial electron transport chain, resulting in
increased superoxide production and fatal disruption of mitochondrial energetics (117,
175, 213). In comparison, 6-OHDA gains entry into DA neurons via identical transport
mechanisms and has also been shown to inhibit complex I in isolated mitochondria;
however, 6-OHDA autooxidation rapidly occurs in the presence of molecular oxygen
resulting in the formation of quinones, which do not inhibit mitochondrial respiration (10,
72, 73, 192), suggesting that 6-OHDA may be metabolized before it is presented with the
opportunity to bind to complex I (213). Rather than generating oxidative stress by direct
interaction with mitochondria, superoxide and hydrogen peroxide released upon 6-OHDA
autooxidation are likely the major contributors to enhanced oxidative stress (213). The
ability for MPP+ to induce MMP-3 in DA neurons may depend on its direct interaction
with mitochondria and consequent activation of mitochondrial related signaling
pathways. Although differences between the neurotoxic mechanisms involved in the 684

OHDA and MPTP models may explain the different MMP-3 response, it is important to
note that MMP-3 induction by MPTP has only been conclusively demonstrated in
primary cell cultures. Although MMP-3-/- mice exhibit essentially complete resistance to
MPTP neurotoxicity, expression or activation of MMP-3 in response to MPTP in wild
type mice has yet to be demonstrated (106).
Effect of 6-OHDA on MMP-13 Expression. Despite the lack of MMP-3
expression in SH-SY5Y cells, there was a significant increase in MMP-13 expression in
response to 6-OHDA, at least at the transcript level. Expression peaked 8 hours
following 6-OHDA treatment, suggesting that MMP-13 could play a role in 6-OHDAmediated neurotoxicity. However, in contrast to the SH-SY5Y experiments, 6-OHDA
had no effect on MMP-13 protein expression at the time points examined. Several
factors could explain the difference in MMP-13 expression between these two model
systems. First, the assays used to measure MMP-13 were different. MMP-13 mRNA
expression was measured in SH-SY5Y experiments, while MMP-13 protein was
examined in the in vivo experiments. It may be possible that the increase in MMP-13
mRNA expression failed to result in a corresponding elevation of MMP-13 protein due to
translational or post-translational regulatory mechanisms. Second, SH-SY5Y cells are an
immortalized cell line derived from a neuroblastoma tumor. Although these cells retain
important DA qualities, they clearly are not nigrostriatal DA neurons; therefore, the
molecular events ultimately leading to cell death likely differ between these two cell
types. It would be interesting to examine MMP-13 expression in response to 6-OHDA in
a primary cell culture system derived from the rat ventral midbrain. Third, species
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differences could explain the apparent disconnect in MMP-13 results described for these
two models although the effects on MMP-3 and MMP-9 were identical in the both
models.
Effect of 6-OHDA on MMP-2 Expression. No change in MMP-2 mRNA
expression was observed in response to 6-OHDA in SH-SY5Y cells. In contrast, 6OHDA and ascorbic acid treatment groups both exhibited a 2-3 fold increase in
proMMP-2 expression 5 and 10 days post surgery, suggesting that trauma caused by
insertion of the needle may be responsible for the changed expression. Alterations in
MMP-2 expression following needle stick injury have been reported previously in other
neurosurgical models. For example, proMMP-2 mRNA expression increased transiently
2 hours after a single intrastriatal saline injection in Sprague-Dawley rats (148). In a
similar study, MMP-9 gelatinolytic activity increased 24 hours following saline injection,
but no change in MMP-2 activity was observed (79). No published data exists on the
long-term effect of needle stick injury on MMP-2 expression. To my knowledge, the data
presented in this chapter is the first to describe delayed, but prolonged induction of
proMMP-2 expression in response to needle stick injury; although, similar sustained
increases in MMP-2 expression have been reported in other models of mechanical brain
trauma. For instance, proMMP-2 expression increased 3-10 days in the olfactory bulb
following olfactory nerve transection (44). The effect on MMP-2 peaked 7 days postsurgery and was marked by the appearance of active MMP-2. Peak MMP-2 expression
and activation correlated with recovery, suggesting that MMP-2 plays an important role
in controlling the regeneration of olfactory neurons (44). In another example, MMP-2
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expression and activity peaked 7-14 days after spinal cord injury (76). At these time
points, MMP-2 was associated with reactive astrocytes surrounding the lesion border
separating damaged tissue from intact cord (90). In addition, MMP-2-/- mice displayed
more severe glial scar formation, increased chondroitin sulfate proteoglycan expression,
decreased axonal plasticity, and significantly impaired motor recovery (90). As with the
olfactory nerve transection model, data from this spinal cord injury model strongly
suggests that delayed MMP-2 expression promotes neuronal recovery following
traumatic injury, likely involving degradation of axonal growth inhibiting chondroitin
sulfate proteoglycans. Perhaps the sustained increase in striatal proMMP-2 following
needle stick injury observed in the intrastriatal 6-OHDA model serves an analogous
purpose.
In contrast to the striatum, 6-OHDA significantly increased nigral proMMP-2
expression compared to ascorbic acid; however, this did not turn out to be a timedependent effect although it would appear that there is an increase at day 5. This increase
precedes measurable loss of nigral TH expression, which was evident 10 days postsurgery, indicating that the increase in nigral MMP-2 expression was not in response to
tissue repair as suggested above for changes in MMP-2 expression detected in the
striatum. Instead, nigral MMP-2 may play an important role in focal BBB disruption
associated with neurodegeneration reported to occur in response to intrastriatal 6-OHDA
injection (31). In models of cerebral ischemia, transient increases in MMP-2 activity are
responsible for an early phase of BBB disruption (186). It is important to note that no
active MMP-2 was detected in nigral protein samples in either treatment group; however,
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it cannot be ruled out that active MMP-2 was present at levels below the detection limit
of the antibody used. To address this, gelatin or in situ zymography could be performed
to directly measure nigral gelatinase activity following intrastriatal 6-OHDA injection. In
addition, immunolocalization of MMP-2 could determine if its expression is associated
with the vasculature.
Conclusions. The results in the present study suggest that 6-OHDA neurotoxicity
fails to induce significant MMP expression or activation in correlation with DA
neurodegeneration; however, the potential effect of 6-OHDA on nigral proMMP-2
expression hinted at in this study warrants further scrutiny. In contrast, MPTP-mediated
neurodegeneration depends on induction of MMP-3 in DA neurons, which serves as a
microglial activating factor (106). The difference in the MMP requirement between 6OHDA and MPTP-mediated neurodegeneration, suggests that neurodegeneration induced
by these neurotoxins occurs by different mechanisms. This difference has potential
important implications for PD. It has been hypothesized that idiopathic PD could be
initiated by exposure to a variety of neurotoxins present in the environment (34, 141). If
the mechanisms of neurodegeneration associated with each neurotoxin differ
significantly, then effective neuroprotective treatments for PD may require the
development therapeutic strategies that are tailored to specific neurotoxins.
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CHAPTER 4
Matrix Metalloproteinase Expression and Activation during
Lipopolysaccharide-induced Dopaminergic Neurodegeneration

4.1 Introduction
In the previous chapter, 6-OHDA induced a time-dependent loss of TH expression
in both the striatum and SNc that was accompanied by a modest increase in nigral
proMMP-2 expression, but not activation. Neurodegeneration was not associated with
changes in MMP-13 expression or activation, while MMP-3 and MMP-9 were
undetectable at the three time points examined. These experiments indicate that a direct
neurotoxic insult to DA neurons does not trigger a major MMP response. In addition to a
direct neurotoxic insult, neuroinflammatory stimuli can trigger DA neurodegeneration.
Intranigral injection of LPS has been used extensively to examine neuroinflammatory
mechanisms that contribute to DA cell death. LPS induces a robust neuroinflammatory
response characterized by microgliosis, proinflammatory cytokine production, release of
ROS, and secretion of nitric oxide, which results in selective degeneration of DA neurons
(4, 32, 56, 84, 95). The neurodegenerative response to LPS appears to be specific for the
SNc, since direct injection of identical quantities into the cortex or hippocampus fails to
induce neuronal loss (104). In addition, intranigral LPS injection has no effect on 5-HT
or its metabolite, 5-HIAA, in either the SNc or striatum
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(84). GABAergic neurons also appear to be resistant to neuroinflammation induced by
LPS since expression of the GABAergic marker, GAD67, in the substantia nigra pars
reticulata does not change (84). Thus, DA neurons are selectively destroyed by
neuroinflammation triggered by LPS.
The events associated with neuroinflammation are initiated when LPS interacts
with TLR4 expressed on the plasma membrane of microglia and astrocytes (56). LPS is
not capable of acting directly on DA neurons, due to their lack of TRL4 expression;
therefore, neurodegeneration resulting from LPS occurs purely through glia-mediated
mechanisms, making it an ideal model to examine the role of MMPs in
neuroinflammation-mediated DA neurodegeneration.
The purpose of the current study was two-fold. First, the temporal pattern of
MMP-2, -3, -9, and -13 expression and activation was examined in relationship to LPSinduced DA neurotoxicity. Intracerebral injection of LPS results in upregulation and
activation of MMP-2, MMP-3, and MMP-9 (26, 27, 79, 148, 149); however, the MMP
response to injection of LPS into the SNc has not been characterized. In addition, these
studies will provide important information regarding the expression of these MMPs in
relationship to DA neurodegeneration. Second, a potential downstream MMP-3 target
that may be involved in the neurodegenerative process was measured. Recent evidence
indicates that CTGF/CCN2 is a target of MMP-3 activity. MMP-3 controls CTGF/CCN2
function in 2 ways. First, MMP-3 cleaves CTGF/CCN2 protein into two fragments of
~20kDa that are thought to have distinct functions (83). Second, MMP-3 acts
intracellularly to enhance CTGF/CCN2 transcription by directly binding to the
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CTGF/CCN2 promoter (57). The function of CTGF/CCN2 in the brain is poorly
understood; however, it has been localized to amyloid-β plaques in Alzheimer’s disease
brain and degenerating spinal cord regions in amyotrophic lateral sclerosis patients, areas
known to be affected by neuroinflammation (212, 225).

4.2 Materials and Methods
Materials. Ketamine (100mg/mL), xylazine (100mg/mL), and buprenorphine
(0.3mg/mL) were obtained from the central pharmacy at Main Hospital, Medical College
of Virginia campus. Pentobarbital was supplied in a Euthasol formulation (390mg/mL)
by the Department of Animal Resources, Virginia Commonwealth University. PBS,
100mM ethylenediaminetetraacetic acid (EDTA), 4-12% polyacrylamide 15-well bis-tris
gels, 0.45µm nitrocellulose membranes, sample reducing agent, LDS sample buffer, MES
running buffer, antioxidant solution, and western blot transfer buffer were acquired from
Invitrogen Corp. (Carlsbad, CA). Mouse anti-rat TH (Cat# MAB318), goat anti-mouse
MMP-13 (Cat# AB8120), and rabbit anti-human cyclophilin-A (Cat# 07-313), were
procured from Millipore (Billerica, MA). Sterile drapes, No. 3 scalpel blades, bone wax,
4-0 chromic gut sutures, 10% povidone/iodine solution, alcohol prep pads, coronal small
rodent brain matrix, cutting mat, brain matrix razor blades, citrisolve, Permount mounting
media, absolute ethanol, SDS, CaCl2·2H2O, NaCl, Tween-20, deoxycholic acid, TrisHCl, and bovine serum albumin (fraction V) were purchased from Fisher Scientific
(Pittsburgh, PA). LPS (serotype 0127:B8), paraformaldehyde, 3,3”-diaminobenzidine
tetrahydrochloride (DAB), imidazole, 30% Brij-35, Triton X-100, NaOH, 4-491

aminophenylmercuric acetate (APMA), NP-40, and mouse anti-human β-actin (Cat#
A2228) were obtained from Sigma-Aldrich (St. Louis, MO). Goat anti-mouse IgG-HRP
and goat anti-rabbit IgG-HRP were obtained from Rockland Immunochemicals, Inc.
(Gilbertsville, PA). MMP FRET peptide XIII was purchased from Anaspec (San Jose,
CA). SuperSignal West Dura extended duration HRP substrate solution was obtained
from Pierce (Rockford, IL). Enhanced Chemiluminescence HRP substrate solution was
purchased from GE Healthcare (United Kingdom). Protease inhibitor cocktail was
purchased from Calbiochem (San Diego, CA). Full length recombinant human MMP-3
and goat anti-human MMP-3 (Cat# ab18898) were procured from Abcam, Inc.
(Cambridge, MA). Goat anti-human CTGF/CCN2 (Cat# sc-14939) and bovine anti-goat
IgG-HRP (Cat# sc-2350) were purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Goat anti-mouse MMP-2 (Cat# AF1488) and goat anti-mouse MMP-9 (Cat#
AF909) were obtained from R&D Systems, Inc. (Minneapolis, MN). Anti-mouse
Vectastain ABC Elite kit was purchased from Vector Laboratories (Burlingame, CA).
Non-fat dry milk was bought from The Kroger Co. (Cincinnati, OH). Methanol was
purchased from Colonial Scientific, Inc. (Richmond, VA).
Surgical Procedures. Forty-four adult male Sprague-Dawley rats (250-350g)
were housed individually in an AAALAC accredited (#00036), USDA registered (#52-R007, and PHS approved (#A-3281-01) animal facility. Room temperature and humidity
were kept constant, a 12-hour light/dark cycle was maintained, and food and water were
available ad libitum. Rats were monitored by qualified animal technicians throughout the
studies and were examined daily after surgery to check for weight loss, lethargy,
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periorbital crusting or bleeding, and gait. If deficits were observed, appropriate measures
were taken to alleviate pain and suffering. All experiments were carried out in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University.
Immediately prior to intranigral injection of LPS, rats were anesthetized with
ketamine/xylazine (100mg/kg/10mg/kg, i.p.). Hair was removed from the scalp and the
surgical area was cleaned with alternating povidone/iodine antiseptic and alcohol washes.
After the rat was draped and mounted onto the rodent stereotaxic frame (Kopf
Instruments, Tujunga, CA), a single incision was made through the skin along the
rostrocaudal length of the scalp using a No.10 scalpel blade attached to a No. 3 handle. A
single burr hole was drilled 4.8mm caudal and 1.7mm to the right of bregma. LPS (2µl
of 5µg/µl) or PBS was injected 8.0mm below the dura with a 10µl Hamilton syringe
fitted with a 26-guage needle. The needle was held in place for 5 minutes prior to
injection. Flow rate (1µl/min) was kept constant with a motorized syringe pump (BASi,
West Lafayette, IN). Five minutes after the conclusion of the injection, the needle was
slowly removed to prevent fluid backflow through the needle track (quarter turn per 10
seconds). Burr hole was filled with bone wax and wound was sutured closed. Body
temperature was maintained at 37°C throughout the duration of the surgery with a
homeothermic blanket (Harvard Apparatus, Holliston, MA) and post-operative pain was
managed with buprenorphine (0.02mg/kg) injected in 12 hour intervals. Rats were kept
under a heat lamp until recovered from anesthesia.
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It is imperative that the following procedure be followed for LPS use in future
studies. LPS was dissolved in ice cold sterile PBS to make 5µg/µl stock solution. The
stock solution was divided into 20µl aliquots and was stored at -20°C. Aliquots were
thawed immediately prior to use and were never re-frozen. Each aliquot was used on
only 1 rat. Optimization studies revealed that once thawed, LPS losses its potency 30-60
minutes after initial thaw and is not stable enough to undergo multiple freeze-thaw
cycles. In addition, LPS has the tendency to bind to the wall of the Eppendorf tube and
should be vigorously vortexed prior to administration.
Immunohistochemistry. Forty-eight hours (n=3) or 7 days (n=1) post-surgery,
rats were euthanized with pentobarbital (150mg/kg, i.p.) and were transcardially perfused
with ice-cold saline (300-400mL) followed by 4% paraformaldehyde (400-500mL).
Whole brain was removed, post-fixed overnight in 4% paraformaldehyde, and then stored
in PBS until sectioning. The non-lesioned side of the brain was notched in order to
maintain ipsilateral/contralateral orientation throughout the staining procedure. Notched
brain was sectioned with a vibratome (Leica Microsystems, Wetzlar, Germany). Floating
40µm thick midbrain and striatal tissue sections were blocked in 10% normal horse
serum containing 0.2% Triton X-100 for 1 hour and then were incubated overnight at 4°C
in mouse anti-rat TH diluted in 1% normal horse serum. Sections were washed 3 x 10
minutes in 1% normal horse serum and then were incubated for 1 hour in biotinylated
anti-mouse secondary antibody. After 3 PBS washes, sections were incubated in avidinbiotin complex for 1 hour and then were washed 3 x 10 minutes in PBS followed by 2 x
10 minutes in phosphate buffer. Immunoreactivity was visualized with 0.5% DAB
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containing 0.3% imidazole. Sections were mounted, dried overnight, dehydrated in
ethanol, cleared in citrisolve, and coverslipped in Permount mounting media. Sections
were analyzed on a Nikon Optiphot microscope and images were captured with a Coolpix
990 3.34 megapixel digital camera (Nikon, Tokyo, Japan).
Protein Extraction. Rats were euthanized with pentobarbital (150mg/kg, i.p.)
followed by rapid decapitation 12, 24, 48 hours, or 30 days post-surgery. Brains were
rapidly removed and placed ventral-side up in a rat brain matrix (Figure 4.1). For the 12,
24, and 48 hour time points, a single 2mm coronal tissue block containing the midbrain
was cut using brain matrix razor blades. For the 30 day time point, 2 2mm coronal tissue
blocks containing striatum were collected. Tissue blocks were transferred to the cutting
mat, which was kept cold with an ice pack. Ventral midbrain or striatum was dissected,
cut through the midline to separate ipsilateral and contralateral tissue, and immediately
placed in 1.5mL microcentrifuges tube containing 100µl (300µl for striatum) ice-cold
protein extraction buffer (50mM Tris-HCl pH 7.2, 150mM NaCl, 1% sodium
deoxycholate, 1% NP-40, and 0.5% SDS) with an added protease inhibitor cocktail.
Tissue chunks were homogenized and then centrifuged at 14,000 x g for 30 minutes at
4°C. Supernatants were saved and stored at -80°C until use.
Western Blot. Sample protein concentration was determined with the DC protein
assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin solutions to
construct the standard curve. LDS sample buffer and sample reducing agent were added
to samples (40µg). Samples were heated to 70°C for 10 minutes, loaded on 4-12%
polyacrylamide bis-tris gels, separated by SDS-PAGE (50 minutes at 200V), and
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FIGURE 4.1: LPS Model of Parkinson’s Disease
Stereotaxic injection of LPS directly into the SNc induces neuroinflammation, which
directly leads to selective anterograde neurodegeneration of nigrostriatal DA neurons.
The lesion is confined to the side ipsilateral to the injection site, resulting in a unilateral
loss of striatal dopamine. The contralateral side remains intact and serves as the control
in all experiments.
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transferred to nitrocellulose membranes (2 hours at 30V). All western blots used for
MMP-13 detection were run under non-reducing conditions (all procedures are identical
to reducing conditions except that reducing agent was omitted from the sample
preparation and antioxidant was not added to the running buffer). Membranes were
blocked for 1 hour in 5% non-fat dry milk prepared in tris-buffered saline containing
0.05% Tween-20 (TBST). Membranes were incubated in TH, MMP-3, MMP-9, or
MMP-13 primary antibody overnight at 4°C. Membranes were washed 4 x 5 minutes in
TBST. Membranes were incubated in bovine anti-goat IgG-HRP secondary antibody for
90 minutes at room temperature and then were washed an additional 6 times in TBST.
Immunoreactivity was visualized with SuperSignal West Dura substrate followed by
exposure to film. All MMP-3 blots were reprobed with CTGF/CCN2, while MMP-9
blots were reprobed with MMP-2 primary antibodies. Membranes were stripped once
more and were reprobed with cyclophilin-A (MMP-3 and MMP-9 blots) or β-actin
(MMP-13 blots) primary antibody followed by goat anti-rabbit or anti-mouse IgG-HRP.
For these loading controls, immunoreactivity was visualized with Enhanced
Chemiluminescence Substrate followed by exposure to film. To quantify protein
expression, film was scanned with the Personal Densitometer (Molecular Dynamics) and
background-corrected band densities were measured using ImageQuant software (version
5.1, Molecular Dynamics). MMP and CTGF/CCN2 immunoreactivity was normalized to
cyclophilin-A or β-actin, which served as the loading control.
TNF-α ELISA. TNF-α was quantified in nigral protein lysates following the
manufacturer’s instructions (eBioscience, San Diego, CA). Briefly, wells were incubated
97

in capture antibody overnight at 4°C. After 5 washes, wells were blocked for 1 hour at
room temperature, washed, and then incubated with samples overnight at 4°C. Wells
were washed, incubated in detection antibody for 1 hour, washed again, incubated in
avidin-HRP for 30 minutes, washed, and incubated in substrate solution for 15 minutes.
Stop solution was added to each well prior to measuring A450nm. Sample TNF-α
concentration was calculated from a TNF-α standard curve. TNF-α ELISA was
performed by Steve Bakos in Dr. Richard Costanzo’s lab.
Activation of Recombinant Human MMP-3. APMA stock solution (10mM)
was prepared in 50mM NaOH. 1mL APMA stock solution was diluted to 2mM APMA
with 4mL assay buffer (50mM Tris-HCl pH 7.5, 5mM CaCl2·2H20, 0.05% Triton X-100).
Recombinant human MMP-3 stock solution was diluted to 5ng/µl with assay buffer.
Equal volumes (15µl) of 5ng/µl MMP-3 and 2mM APMA were combined in 0.6mL
microcentrifuge tubes and were incubated for 4 hours at 37°C. Reaction mixtures were
immediately used for MMP-3 activity assays.
MMP-3 Activity Assay. Rats were euthanized with pentobarbital (150mg/kg,
i.p.) followed by rapid decapitation 24 hours post-surgery. Nigral protein was extracted
as described above with one exception. The protein extraction buffer used contained
50mM Tris-HCl (pH 7.5), 150mM NaCl, 10mM CaCl2·2H20, 0.05% Brij-35, and 1%
Triton X-100. The protease inhibitor cocktail was omitted from this preparation in order
to maintain MMPs in their active state. Protein concentration was determined using the
DC protein assay prior to measuring MMP-3 activity. MMP-3 proteolytic activity was
measured using the fluorogenic MMP FRET substrate XIII. The manufacturer claims
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that MMP-3 shows stronger proteolytic activity towards this FRET peptide than other
MMPs. Protein (100µg) was mixed with an equal volume of 2µM substrate (1µM final
substrate concentration). Positive control consisted of 75ng APMA-activated
recombinant human MMP-3. Three negative controls were made: (1) 200µl of assay
buffer; (2) 100µl substrate and 100µl assay buffer; and (3) 75ng APMA-activated
recombinant human MMP-3 with 2µl EDTA, 100µl substrate, and 68µl assay buffer.
Reaction components were combined in a 96-black well plate. As soon as possible,
fluorescence measurements at 485ex/520em were read using the Fluostar Optima plate
reader (BMG Labtech, Durham, NC). Measurements were made in 5-minute intervals
for 60 minutes.
Statistical Analysis. Statistical tests were performed using JMP software
(version 7.0). For quantitative densitometric analysis, treatment group (LPS or PBS) and
time-dependent differences were computed using two-way ANOVA (α=0.05). If a
significant model effect was detected, then the Tukey-Kramer test was conducted to
reveal which experimental groups were significantly different. Bonferroni corrected pvalues were calculated for all comparisons made by the Tukey-Kramer test. Quantitative
data is presented as mean ± standard error of the mean.

4.3 Results
TH immunohistochemistry was performed on midbrain tissue sections 48 hours
post-surgery and on striatal tissue sections 7 days post-surgery to confirm that intranigral
injection of LPS resulted in DA neurodegeneration. Ipsilateral and contralateral TH
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staining was compared qualitatively. At 48 hours, contralateral midbrain displayed
numerous intensely stained TH+ neuronal cell bodies, indicative of an intact SNc (Figure
4.2). In contrast, few TH+ neurons were detected in the LPS-injected SNc. Most TH+
neurons resided in the ventral tegmental area, while the few remaining in the SNc stained
faintly (Figure 4.2 inset). Striatal tissue sections collected 7 days post surgery showed a
similar relationship between ipsilateral and contralateral TH staining intensity; however,
the decreased staining intensity associated with the LPS injection was not as dramatic as
that observed for the SNc (Figure 4.3A).
Western blot performed on samples collected 30 days post-surgery confirmed that
intranigral administered LPS resulted in prolonged striatal TH depletion, consistent with
permanent DA neurodegeneration (Figure 4.3B). To measure the extent of TH depletion,
TH immunoreactivity was normalized to cyclophilin-A expression. The ratio of
normalized ipsilateral TH expression to normalized contralateral TH expression was
calculated to obtain the percent of contralateral TH expression. This comparison
demonstrated that ipsilateral TH depletion reached 60% (Figure 4.3C). In contrast, the
PBS-injected rat showed no loss of ipsilateral striatal TH expression, indicating that
neither PBS nor injury caused by the surgery resulted in permanent damage to the
nigrostriatal tract.
LPS-mediated DA neurodegeneration has been shown to be dependent on
microglial-derived proinflammatory cytokines, nitric oxide, and ROS. To verify that an
active neuroinflammatory reaction was present during active DA neurodegeneration,
TNF-α expression was measured in nigral protein samples collected 24 hours following
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Ipsilateral

Contralateral

FIGURE 4.2: LPS-induced Nigral DA Neurodegeneration
Representative TH stained midbrain section 48 hours post-LPS injection (n=3).
Intranigral LPS injection resulted in substantial loss of TH+ DA neurons in the SNc. The
side contralateral to the injection remains intact. Remaining DA neurons on the
ipsilateral side have decreased TH expression compared to the contralateral side. Arrows
indicate areas of enlargement shown in the inset. Scale bar = 100µm for large images
and 20µm for insets.
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FIGURE 4.3: LPS-induced Degeneration of DA Projections to the Striatum. A)
Representative TH-stained striatal tissue section from LPS lesioned animal 7 days postsurgery. TH immunoreactivity was decreased on the side ipsilateral to the LPS injection.
Scale Bar equals 250µm. B) Western blot demonstrating depletion of striatal TH 30 days
post-LPS injection (I=ipsilateral, C=contralateral). C) Densitometric analysis of TH
western blot (n=1). TH:cyclophilin-A density ratio was calculated for each lane.
Ipsilateral density ratio was divided by the contralateral density ratio to obtain percent of
contralateral TH expression. LPS injection resulted in 60% loss of striatal TH, while no
decrease in TH was detected following PBS injection.
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LPS or PBS injection. Protein samples were sent to Steve Bakos in Dr. Costanzo’s lab
for the TNF-α ELISA measurement. TNF-α was detected only in the ipsilateral sample
from the LPS-lesioned rat, indicating that LPS induced a localized neuroinflammatory
response (Figure 4.4).
MMP-2, MMP-3, MMP-9, and MMP-13 protein expression and activation were
measured by western blot 12, 24, and 48 hours post-surgery. These time points were
chosen based on the known time course of DA neurodegeneration in which maximum
nigral neuronal loss is reached in 48 hours (94, 96). Time points preceding this loss were
assayed in an attempt to correlate changes in MMP expression and activation with
neuroinflammation-induced DA neurodegeneration. Cyclophilin-A or β-actin expression
was measured and served as the loading control for each lane.
First, the effect of intranigral LPS on MMP-3 expression and activation was
examined. ProMMP-3 was detected in all samples from the LPS group but was only
observed 12 hours post-surgery in the PBS group, indicating that a transient change in
proMMP-3 expression was associated with tissue injury (Figure 4.5A). Mean
densitometry values for all groups were compared using two-way ANOVA. Overall,
there was a significant experimental effect on proMMP-3 protein expression (F=24.5,
p<0.001). In addition, a significant interaction effect was detected between the time
points measured and treatment groups (F=16.2, p<0.001). Within the LPS group, the
effect on proMMP-3 expression was time-dependent, peaking 24 hours post-surgery
(Figure 4.5B, p<0.001). At this time point, proMMP-3 expression was 4-fold and 3.4fold greater than expression at 12 and 48 hours, respectively. In contrast, PBS had no
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FIGURE 4.4: LPS Increases Nigral TNF-α Production
TNF-α ELISA was performed on ventral midbrain tissue samples collected 24 hours
post-LPS or PBS injection (n=1, assay performed by Steve Bakos). TNF-α was detected
in the ipsilateral sample from the LPS injected rat. No TNF-α was detected on the
contralateral side or in either sample from the PBS injected rat. This assay confirms that
LPS triggers neuroinflammation when introduced into the SNc.
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FIGURE 4.5: Effect of LPS on Nigral MMP-3 Expression and Activation
MMP-3 measurements after intranigral LPS (n=6) or PBS (n=6) injection. Cyclophilin-A
expression was measured to ensure equal protein loading. A) Representative western blot
demonstrating temporal changes in pro and active MMP-3 expression (I=ipsilateral,
C=contralateral). B) Densitometric analysis of proMMP-3 in ipsilateral nigral tissue
samples. ProMMP-3 was significantly elevated 24 hours post-surgery in the LPS group
compared to the PBS group. Within the LPS group, proMMP-3 expression peaked at 24
hours. C) Densitometric analysis of MMP-3 in ipsilateral tissue samples. MMP-3
activation increased 24 and 48 hours post-surgery in the LPS group compared to the PBS
group. Data presented as mean ± standard error of the mean. Asterisks indicate
significance compared to PBS group, while # denotes significance compared to 12 hour
LPS time point.
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time-dependent effect on proMMP-3 expression despite being detected only 12 hours
post-surgery. It should be noted that expression of proMMP-3 in this group was only
detectable in 3 of the 6 animals. Compared to the PBS group, proMMP-3 expression in
the LPS group was significantly increased at 24 hours (p<0.001), but not at 48 hours
post-surgery (p=0.17). Although a significant difference was not detected at 48 hours, it
should be emphasized that proMMP-3 was detected in all 6 LPS-injected rats, but was
completely absent in all 6 PBS-injected rats.
MMP-3 activation requires prodomain removal, the ~10kDa N-terminal portion of
the protein that maintains enzyme latency (150). Prodomain removal causes a molecular
weight shift that allows pro and active MMP-3 to be distinguished on western blots.
Activated MMP-3 was detected at all time points in ipsilateral samples collected from
LPS-injected rats (Figure 4.5A). Mean densitometry values for all groups were compared
using two-way ANOVA. Overall, there was a significant experimental effect on the
amount of active MMP-3 protein (F=18.7, p<0.001). In addition, a significant interaction
effect between the time points measured and treatment groups was detected (F=14.4,
p<0.001). MMP-3 activation was more prominent at 24 hours than at 12 hours in the
LPS group, a change that was maintained through the 48 hour time point (Figure 4.5C,
p=0.007). In one LPS animal, low MMP-3 expression was noted on the contralateral side
at 48 hours. In addition, a slight injury-induced effect on MMP-3 activation was
observed in the PBS group 12 hours post-surgery; however, active MMP-3 was never
detected beyond this point. These results indicate that LPS-mediated neuroinflammation
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induces proMMP-3 expression and activation that is temporally related to DA
neurodegeneration, suggesting that MMP-3 may be involved in the degenerative process.
In addition to MMP-3, the temporal relationship between gelatinase expression
(MMP-2 and MMP-9) and DA neurodegeneration was examined. Consistent with results
from previous 6-OHDA in vivo experiments, proMMP-2 (72kDa) was detected in all
tissue samples, indicating that proMMP-2 is normally expressed in the ventral midbrain
(Figure 4.6A). Mean normalized densitometry values for ipsilateral and contralateral
samples were analyzed separately by two-way ANOVA (Figure 4.6B). For ipsilateral
samples, there was a significant overall experimental effect on proMMP-2 expression
(F=5.12, p=0.003). In addition, a significant interaction effect between the time point
measured and treatment groups was detected (F=6.25, p=0.007). There was a significant
time-dependent effect on ipsilateral proMMP-2 expression in the LPS group, with
expression peaking 24 hours post-surgery (p=0.0495). In contrast, there was no timedependent effect on ipsilateral proMMP-2 expression in the PBS group. Compared to the
PBS group, proMMP-2 expression was significantly increased at the 24 hour time point
(p=0.004). There was no difference in proMMP-2 between the LPS and PBS group at 12
and 48 hours post-surgery.
In addition to ipsilateral proMMP-2 expression, there was a significant
experimental effect on contralateral proMMP-2 expression (F=4.39, p=0.004), although
there was no significant interaction between the chosen time points and treatment groups
(F=2.66, p=0.091). There was no difference between the LPS and PBS animals (F=2.25,
p=0.1463); however, there was a significant time-dependent effect on contralateral
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proMMP-2 expression (F=7.7, p=0.0026). When the effect of time is considered
independently of treatment group, contralateral proMMP-2 expression increased 4.5 fold
48 hours post-surgery compared to the 12 hour time point (Figure 4.6B, p=0.002). The
absence of a treatment-induced effect suggests that the increase in contralateral proMMP2 is likely caused by needle injury; however, if this was the case, then proMMP-2
expression would have been expected to also increase in the ipsilateral SNc of the PBS
group. Although there was a significant effect on contralateral proMMP-2 expression,
the magnitude of this effect was not nearly as great as was present in ipsilateral samples:
the contralateral proMMP-2:cyclophilin ratio was 0.52 at 48 hours, while the peak
proMMP-2:cyclophilin-A ratio 24 hours post-LPS in ipsilateral samples was 3.1.
Similar to the results for MMP-3, substantial MMP-2 activation was detected in
association with intranigral LPS injection, particularly 24 hours post-surgery (Figure
4.6A). Ipsilateral tissue samples from PBS and LPS groups were compared by two-way
ANOVA. Overall, there was a significant experimental effect on MMP-2 activation
(F=8.25, p<0.001). In addition, a significant interaction effect was detected between the
time points studied and treatment groups (F=7.59, p= 0.003). Intranigral PBS injection
resulted in MMP-2 activation 12 hours post-surgery; however, no activated MMP-2
immunoreactivity was detected at later time points. In contrast, intranigral LPS injection
caused long lasting time-dependent MMP-2 activation that peaked 24 hours post-surgery
(Figure 4.6C, p=0.02). Activation at 24 hours was 3.6 and 2.6 fold greater than the
amount of activated MMP-2 detected at 12 and 48 hours, respectively. Compared to the
PBS group, LPS-induced MMP-2 activation was significantly greater only at the 24 hour
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FIGURE 4.6: The Effect of LPS on Nigral MMP-2 Expression and Activation
MMP-2 measurements after intranigral LPS (n=5) or PBS (n=5) injection. Cyclophilin-A
expression was measured to ensure equal protein loading. A) Representative western blot
demonstrating temporal changes in pro and active MMP-2 expression (I=Ipsilateral,
C=contralateral). B) Densitometric analysis of proMMP-2 expression. LPS caused a
time-dependent increase in proMMP-2 expression in ipsilateral ventral midbrain tissue
samples with peak expression levels reached 24 hours post-surgery. When comparing
LPS and PBS ipsilateral samples, proMMP-2 was significantly elevated at the 24 hour
time point in LPS samples. In addition, there was a time-dependent increase in proMMP2 expression in contralateral tissue samples that was not dependent on treatment group.
Contralateral proMMP-2 expression peaked 48 hours post-surgery. C) Densitometric
analysis of active MMP-2 in ipsilateral tissue samples. At 12 hours, active MMP-2 was
identical in both groups; however, increased active MMP-2 persisted 24 and 48 hours
post-surgery only in the LPS group. Data presented as mean ± standard error of the
mean. Asterisks indicate significance compared to PBS group, while # denotes
significance compared to 12 hour LPS time point.
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time point (p<0.001). Although a significant difference was not detected 48 hours postsurgery (p=0.65), it should be emphasized that active MMP-2 was detected in all LPSinjected rats, but was completely absent in all PBS-injected rats. Importantly, these
results demonstrate that along with MMP-3, active MMP-2 is present during the
neurodegenerative phase of this model, suggesting that MMP-2 could be involved in
events leading to DA neuronal loss.
In addition to proMMP-2 and proMMP-3, both LPS and PBS induced an increase
in proMMP-9 protein expression that was associated with the ipsilateral SNc only (Figure
4.7). However, analysis of normalized proMMP-9 densitometry values revealed that
there was no significant overall model effect (F=1.66, p=0.182). This means that neither
treatment nor measured time point had an effect on proMMP-9 expression. This was
surprising, particular when comparing LPS and PBS proMMP-9 expression 24 hours
post-surgery. At this time point, the average proMMP-9:cyclophilin-A ratio was 1.06 ±
0.21 in LPS-injected samples, compared to just 0.13 ± 0.08 in PBS-injected samples, an
8-fold difference. This difference is masked by the extreme variability present in the 48
hour LPS group in which the standard deviation (1.32) was greater than the group’s mean
(0.79). When the 48 hour time point was omitted from the two-way analysis, a
significant overall model effect was revealed (F=3.69, p=0.034). Importantly, the 8-fold
increase due to LPS at the 24 hour time point becomes significant (p=0.029). No
difference between the 2 groups was detected 12 hours post-surgery, indicating that tissue
injury induced a transient increase in proMMP-9.
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FIGURE 4.7: The Effect of LPS on Nigral MMP-9 Expression
MMP-9 measurements after intranigral LPS (n=5) or PBS (n=5) injection. Cyclophilin-A
expression was measured to ensure equal protein loading. A) Representative western blot
demonstrating temporal changes in pro and active MMP-9 expression (I=Ipsilateral,
C=contralateral). B) Densitometric analysis of proMMP-9 expression. Both LPS and
PBS induce proMMP-9 expression 12 hours post-surgery; however, proMMP-9 remains
elevated through at least the 24 hour time point only in the LPS group. Unlike MMP-2
and MMP-3, no active MMP-9 was detected at any time point. Data presented as mean ±
standard error of the mean. Asterisks indicate significance compared to PBS group.
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The response of proMMP-9 to LPS differed from those described for MMP-2 and
MMP-3 in two ways. First, proMMP-9 expression was consistently elevated at the same
magnitude 12 and 24 hours post-surgery. This suggests that proMMP-9 expression peaks
before proMMP-2 or proMMP-3. Events resulting in increased MMP-9 must be in full
swing by the 12 hour time point. Second, no MMP-9 activation was detected in any
samples from the LPS group. The lack of active MMP-9 was surprising given the well
described ability of MMP-3 to remove the MMP-9 prodomain (161). The lack of active
MMP-9 may indicate that the expression of these two MMPs differs spatially. The high
variability in the 48 hour LPS group could be caused by the nature of the temporal
proMMP-9 expression pattern. In some animals upregulation may last slightly longer
than 48 hours, while in others it may end just prior to this time point. In future
experiments, this time point should not be used to assay proMMP-9 expression in
response to LPS.
Two-way analysis of proMMP-13 densitometry data revealed that there was no
overall experimental effect (F=2.02, p=0.124), meaning that LPS had no effect on MMP13 expression. In addition to this lack of an effect, there were some peculiarities with the
MMP-13 western blots that were not observed in the 6-OHDA studies (Figure 4.8).
Upon examination of the western blots, there was a clear decrease in proMMP-13 in each
24 hour LPS sample. In addition to this apparent MMP-13 effect, there was an obvious
LPS-induced decrease in detection of the loading control, which was also particularly
evident in the 24 hour samples (Figure 4.8A). This was the case for both β-actin and
cyclophilin-A (data not shown). The effect of LPS on loading control was not noticeable
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FIGURE 4.8: Effect of LPS on Nigral MMP-13 Expression
MMP-13 measurements after intranigral LPS (n=4) or PBS (n=4) injection. CyclophilinA expression was measured to ensure equal protein loading. A) Representative MMP-13
western blot (I=Ipsilateral, C=contralateral). B) Densitometric analysis of proMMP-13
expression. No experimental effect on proMMP-13 was detected. Data presented as
mean ± standard error of the mean.
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in experiments examining MMP-2, MMP-3, or MMP-9. The only methodological
difference between these western blots was that samples for MMP-13 were assayed under
non-reducing conditions, due to antibody detection requirements. This suggests that
something present in non-reduced samples from the 24 hour LPS group interfered with
protein detection. In the future, other MMP-13 detection methods should be considered.
Preliminary attempts were made with two additional MMP-13 antibodies, but proMMP13 detection was unsuccessful (data not shown).
Detection of the activated form of MMP-2 and MMP-3 does not necessarily mean
that these proteases are active in vivo. For instance, TIMPs inhibit activated MMPs.
Upon sample reduction with dithiothreitol coupled with heat denaturation, TIMP-MMP
interactions should be broken, resulting in the detection of the activated form of MMP at
its proper molecular weight. In an attempt to address this, non-denatured samples from
LPS and PBS injected rats collected 24 hours post-surgery were incubated with a FRET
peptide substrate that is reportedly preferentially recognized by MMP-3. When this was
done, substrate degradation was detected in equally high amounts in both LPS and PBS
samples, regardless if they were from the ipsilateral or contralateral SNc (Figure 4.9).
Since western blots only show active MMP-3 in ipsilateral samples from the LPS group
at this time point, equal detection of substrate degradation in all nigral samples indicates
that additional proteases recognize the substrate. The appropriate controls were done to
eliminate the presence of degraded substrate in the substrate preparation and the presence
of proteases in the assay buffer. Purified APMA-activated recombinant MMP-3 was
capable of cleaving the FRET substrate.
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FIGURE 4.9: MMP-3 Fluorogenic Substrate Assay
Recombinant human MMP-3 activated with APMA treatment displayed a steady increase
in fluorescent activity over the course of the experiment (n=1). This increase was not
present in untreated MMP-3 samples and EDTA was capable of blocking the APMA
effect. These observations confirm the ability of the assay to detect active MMP-3.
Fluorescence in tissue samples was much greater than the fluorescence detected in the
recombinant human MMP-3 preparations. In addition, there was no apparent difference
between lesioned vs. unlesioned tissue or between LPS vs. PBS. This does not match the
western blot data and suggests that other proteins present in the protein samples are
capable of cleaving the FRET substrate. (Ipsi = ipsilateral, Contra = contralateral)
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In an effort to identify potential MMP targets, CTGF/CCN2 protein expression
was measured. The hinge region of CTGF/CCN2 that connects the insulin-like growth
factor binding protein and von Willebrand factor motifs to the thrombospondin-1 and Cterminal motifs is vulnerable to both MMP-2 and MMP-3-mediated proteolysis (Chapter
2, Figure 2.3), although MMP-3 is much more efficient than MMP-2 (83). Furthermore,
active MMP-3, recently localized to the nucleus, was shown to activate CTGF/CCN2
gene transcription by directly binding to the CTGF/CCN2 promoter (57). In the current
study, CTGF/CCN2 was detected at all time points in both ipsilateral and contralateral
protein samples collected from each rat (Figure 4.10A). Mean densitometry values were
compared using two-way ANOVA (Figure 4.10B). In ipsilateral samples, there was a
significant experimental effect on CTGF/CCN2 protein expression (F=3.7, p=0.01). No
significant interaction effect between the treatment groups and time points was found
(F=3.1, p=0.06); however, there was a significant effect due to treatment (F=11.7,
p=0.002), with the principle difference detected 24 hours post-surgery. At this time
point, intranigral injection of LPS induced a 5-fold increase in CTGF/CCN2 expression
compared to PBS (p=0.008). In contrast, no contralateral treatment effect was observed
(F=0.5, p=0.47). In addition to increased CTGF/CCN2 protein expression, preliminary
data shows that a limited amount of CTGF/CCN2 proteolysis may occur at the 24 hour
time point (Figure 4.10A). Upon longer film exposure, a faint band at ~20kDa, the
predicted molecular weight for MMP-cleaved CTGF/CCN2, was detectable only in the
LPS group at the 24 hour time point. Additional studies are required to further
characterize the identity of this low molecular weigh immunoreactivity, but the
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FIGURE 4.10: Effect of LPS on Nigral CTGF/CCN2 Expression
CTGF/CCN2 measurements after intranigral LPS (n=6) or PBS (n=6) injection.
Cyclophilin-A expression was measured to ensure equal protein loading. A)
Representative western blot demonstrating temporal changes in CTGF/CCN2 expression
(I=ipsilateral, C=contralateral). Densitometric analysis of CTGF/CCN2 expression in
nigral tissue samples. At 24 hours, LPS induced a 5-fold increase in CTGF/CCN2
expression compared to PBS in ipsilateral tissue samples. In addition, a faint band at
20kDa was associated with the LPS group at 24 hours, which could represent MMPcleaved CTGF/CCN2 (circle). Data presented as mean ± standard error of the mean.
Asterisks indicate significance compared to PBS group.
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correlation of its appearance with the presence of both active MMP-2 and MMP-3 is
intriguing.

4.4 Discussion
Neuroinflammation in PD contributes to progressive, chronic loss of DA neurons
(14, 16, 232). Intranigral injection of LPS causes selective degeneration of nigrostriatal
DA neurons purely through neuroinflammation, making it an ideal model to study the
neuroinflammatory mechanisms involved in neurodegeneration (32, 84). Changes in the
extracellular environment invariably accompany neuroinflammatory reactions, including
increased proteolytic activity. The results from the above studies indicate that the
response to LPS includes dramatic alterations in the expression and activation of several
MMPs; changes which occur at time points that are consistent with the neurodegenerative
phase of the model used. In addition, this is the first study to report an increase in
CTGF/CCN2 expression in association with DA neurodegeneration. CTGF/CCN2 is
potentially involved in neurodegenerative diseases and has been identified as a target for
MMP-3-mediated proteolysis and transcriptional control (57, 83, 212, 225).
Direct injection of LPS into the SNc triggers a localized neuroinflammatory
response that results in massive anterograde DA neurodegeneration (32, 84). Due to the
anterograde nature of this lesion, cell body degeneration is obvious days before striatal
depletion of DA axon terminals. Within 48 hours of LPS exposure, 70-80% of TH+
nigral neurons are lost (94, 96). Importantly, by the 30th day, no further degeneration
can be detected, indicating that neurodegeneration is permanent and complete at the level
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of the SNc 48 hours after LPS infusion (95, 96). In contrast to the SNc, striatal TH
expression remains at control levels 48 hours post-surgery (96). Significant striatal TH
depletion has been reported as early as 9 days post-surgery, progressing to completion by
the 15th day (5, 84). These observations were confirmed qualitatively with the LPS
injection protocol used in the current studies. Immense loss of TH+ DA neurons was
revealed by immunohistochemistry performed on midbrain sections collected 48 hours
post-surgery. In addition, marginal loss of TH in the striatum was evident 7 days postsurgery and had reached 60% by day 30. Based on these results and previous reports, it
would appear that most striatal TH depletion takes place 7-9 days following intranigral
administration of LPS (5).
There were several reasons for the selection of the intranigral mode of LPS
administration. First, the time course for neurodegeneration is well established compared
to the other LPS models available. This was an important characteristic, since the
principal goal of these studies was to measure MMP and CTGF/CCN2 expression at time
points relevant to neurodegeneration. Second, intranigral injection of LPS produces a
lesion that is comparable to the extent of neurodegeneration present in human PD.
Intrastriatal LPS injection has been attempted, though injection of comparable quantities
needed to produce neurodegeneration when delivered directly to the SNc results in injury
that is largely confined to the striatum, while the cell bodies in the SNc are spared (84).
An alternative intrastriatal LPS injection model has been developed; however, generation
of this model requires at least 60µg of LPS injected in 8 different locations spread over
the entire striatum (91). Third, the short neurodegenerative time course associated with
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intranigral LPS injection allowed for easy selection of a small number of time points in
which to quickly determine if MMPs and CTGF/CCN2 were potentially involved in DA
death. Unfortunately, the acute time course is also the model’s biggest fault, since
neurodegeneration associated with PD is thought of as a chronic process. Chronic DA
neurodegenerative models have been developed in which LPS is delivered systemically
or directly to the SNc via osmotic mini-pumps. Osmotic mini-pumps release tiny
amounts of LPS over a long period of time resulting in slower, delayed
neurodegeneration that begins after 2 weeks (68). The start of neurodegeneration in this
model corresponds to the initiation of microglial activation. Systemic LPS administration
results in nigral degeneration that progresses from 23% at 7 months to 47% at 10 months
post-treatment, suggesting that the model more closely resembles PD (173). Altered
MMP and CTGF/CCN2 expression detected in the current study provide a rational basis
to explore these proteins further in these chronic neurodegenerative LPS models.
Detection of increased MMP-2 and MMP-3 expression and activation indicate
that MMP regulation in response to intranigral LPS injection is a complex process.
Multiple mechanisms must be involved that lead to both upregulation of the proform and
removal of the prodomain. The large increase in proMMP-2 and proMMP-3 observed
following LPS injection hints at upregulation of proMMP at the transcriptional level;
still, post-transcriptional or post-translational mechanisms cannot be ruled out as the
cause for increased proMMP protein expression. Several components of the microglial
response to LPS are strong candidates for regulation of proMMP expression, including
TNF-α, IL-1β, ROS, and nitric oxide. Transcriptional upregulation of MMP-3 often
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requires the binding of phosphorylated c-Jun to the AP-1 DNA binding site located in the
MMP-3 gene promoter (51, 239). Phosphorylation of c-Jun is controlled by activation of
the c-Jun N-terminal kinase pathway, which can be activated by TNF-α, IL-1β, ROS, and
nitric oxide (82, 139, 203). In addition, both IL-1β and ROS have been shown to
increase MMP-2 transcription and protein expression (207, 229).
The activation of MMP-2 and MMP-3 detected by western blot following LPS
injection indicates that mechanisms that control the cysteine switch are involved in the
response generated by LPS exposure. MMP-2 activation requires the binding of its
hemopexin-like domain by TIMP-2, which then forms a complex with MT-MMP. The
MT-MMP cleaves the MMP-2 prodomain, resulting in MMP-2 activation and TIMP-2
dissociation (150). MT1-MMP and MT5-MMP are expressed constitutively within the
brain and represent strong candidates that activate MMP-2 in response to LPS (27, 200).
Constitutive MT1-MMP and MT5-MMP in the brain suggests that the activation of
MMP-2 seen after intranigral LPS injection may depend on regulation of MT-MMP
activation. In addition, microglia-derived neuroinflammatory constituents, including
TNF-α, appear to regulate proMMP-2 activation through regulation of MT1-MMP
expression (199). Activation of proMMP-3 requires proteolytic removal of the
prodomain, an action carried out by serine proteases or other activated MMPs (150). The
serine protease plasmin is an efficient activator of proMMP-3 (151); however, its
distribution in the SNc has not been explored. In addition, the inactive zymogen form of
plasmin, plasminogen, requires the action of urokinase or tissue plasminogen activator
for activation (29), neither of which have been explored in models of PD.
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An attempt was made to measure MMP-3 activity in protein samples collected 24
hours post-surgery using a FRET-based substrate assay; however, the results suggested
that the substrate used could be detected by additional proteins present in both LPStreated and control samples. It is suspected that this may be a common problem
associated with these substrate assays; therefore, their use may be more appropriate for
more isolated systems, such as cell culture or in vitro enzyme kinetic assays. In the
future, alternative methods to measure MMP activity should be employed. These include
gelatin and casein zymography for the detection of activated MMP-2 and MMP-3,
respectively. The FRET-based assay was chosen based on its lower activity detection
threshold compared to zymographic methods. The lack of sensitivity inherent with a gelbased assay could be overcome by immunoprecipitation to pull down all of the MMP-2
or MMP-3 present in a sample prior to running the zymogram assay.
Increased MMP-2 and MMP-3 activity could contribute to DA neurodegeneration
in a variety of ways. First, increased MMP-2 and MMP-3 activity mediates BBB
disruption in stroke and other models of neuroinflammation (26, 27, 79, 240). Although
BBB disruption has not been conclusively demonstrated in PD patients, BBB leakage
occurs in response to 6-OHDA and MPTP, and emerging evidence points to the
peripheral immune system as an important component in PD (31, 146, 248). Second,
MMP-3 is required for maximal microglial activation by LPS and can induce certain
aspects of an activated microglial response by itself (106, 108). This suggests that MMP3 could contribute to neurodegeneration by supporting microglia-mediated DA
neurotoxicity. Third, MMP-3 could act intracellularly to promote DA neurodegeneration,
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as was recently shown to occur in BH4-treated DA cells (37). Fourth, α-synuclein is a
target for MMP-2 and MMP-3 proteolysis (217). In particular, the α-synuclein fragments
generated by MMP-3-mediated proteolysis promote α-synuclein fibril formation and
consequent aggregation, which increases its toxicity towards DA neurons (121, 217).
Furthermore, aggregated α-synuclein directly activates resting microglia (246), although
it is not clear if aggregates formed following degradation by MMP-3 duplicate this effect.
Whether CTGF/CCN2 is involved in any of these processes remains to be seen, but the
increased CTGF/CCN2 expression at the same time points as increased MMP-2 and
MMP-3 expression and activation indicates that CTGF/CCN2 could mediate some of
these effects.
Upon discovery that active MMP-3 was induced by intranigral LPS injection, it
was expected that MMP-9, if present, would also be activated. Activated MMP-3 is
capable of activating MMP-9 in a process that involves two MMP-3-dependent
proteolytic events within the MMP-9 prodomain (161, 201). Despite the ability of MMP3 to activate MMP-9, only the 92kDa band corresponding to proMMP-9 was detected by
western blot following intranigral LPS injection. The following scenario may explain the
lack of active MMP-9. TIMP-1 regulates proMMP-9 activation by binding to its Cterminal hemopexin-like domain (150). Even when bound to MMP-9, TIMP-1 retains its
ability to inhibit active MMPs, including MMP-3; however, interaction with an active
MMP results in dissociation of the proMMP-9:TIMP-1 complex, freeing proMMP-9 for
activation by TIMP-free active MMP-3 (150). Therefore, the total amount of active
MMP must exceed the amount of TIMP-1 present in the tissue to permit MMP-3123

mediated activation of proMMP-9. The presence of TIMP-1 in the ventral midbrain may
explain the lack of proMMP-9 activation. TIMP-1 has been detected in the human SNc
(127); therefore, it would not be surprising if the rat SNc also expressed TIMP-1.
Another possible explanation involves the spatial distribution pattern of MMP-3 and
MMP-9. They could be expressed in different locations within the SNc in such as way
that they are unable to interact. Immunohistochemical experiments are needed to address
potential differences in spatial distribution and to identify the cell types associated with
MMP upregulation. Also, it cannot be ruled out that the antibody used was not
sufficiently sensitive to detect low levels of active MMP-9. Gelatin zymography could
be done in order to completely rule out the presence of active 84kDa MMP-9.
Unlike MMP-2, -3, and -9, proMMP-13 expression did not change in response to
LPS, despite the fact that transcriptional regulation of MMP-13 is very similar to that
described above for MMP-3 and MMP-9. In fact, the promoters for MMP-3, MMP-9,
and MMP-13 each contain AP-1 and Ets-1 recognition sites just upstream from the
TATA box that are involved in TNF-α and IL-1β-mediated regulation of these genes (51,
122, 239). These results suggest that MMP-13 is not involved in LPS-mediated
neuroinflammation. The function of MMP-13 in the brain is poorly understood;
however, recent data from cerebral ischemia models support the idea that MMP-13 is not
involved in neuroinflammation. Cerebral ischemia causes a prolonged increase in MMP13 expression within and surrounding cortical neurons beginning 3 days after reperfusion.
Expression remains elevated during the injury recovery phase, implicating MMP-13 in
post-injury neuronal remodeling (154). In addition, MMP-13 is expressed in normal
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brain, suggesting that it serves an important physiological role and that its expression is
regulated by mechanisms different from those involved in upregulation of the other
MMPs in response to neuroinflammation. In the current study, proMMP-13 was
expressed in contralateral and ipsilateral nigral tissue in all animals. Similar results were
reported in the previous chapter which also examined striatal tissue samples from the
intrastriatal 6-OHDA model. Others have also detected proMMP-13 expression within
neurons of non-injured cortex (154).
The increase in CTGF/CCN2 expression in response to neuroinflammationinduced nigrostriatal damage is a novel finding. MMP-3 is capable of regulating
CTGF/CCN2 function through proteolytic cleavage of CTGF/CCN2 protein and by
directly binding to the CTGF/CCN2 promoter to trigger transcription (57, 83). Full
length CTGF/CCN2 expression increased 5-fold following intranigral LPS injection and
preliminary data hints that a limited amount of CTGF/CCN2 degradation occurs in
correlation with increased MMP-2 and MMP-3 activation. This suggests that if MMPs
are involved in the regulation of CTGF/CCN2 function, it could occur though
transcriptional and/or post-translational regulation.
Increased MMP-2 and MMP-3 protein expression and activity is associated with
neuroinflammation-induced DA neurodegeneration. In addition, this is the first report to
demonstrate that CTGF/CCN2 could be involved in PD pathology. Furthermore, the
results further extend support for a significant role for MMP-3 in DA neurodegeneration.
Studies that interrupt MMP and/or CTGF/CCN2 function are needed to further
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characterize the role of these proteins in neurodegeneration and to assess their potential
as a target for the development of novel neuroprotective therapies for PD.
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CHAPTER 5
Matrix Metalloproteinase and Connective Tissue Growth Factor
Expression in Lipopolysaccharide-treated BV-2 Microglia

5.1 Introduction
In the preceding chapter, nigral MMP and CTGF/CCN2 protein expression was
measured following intranigral LPS injection. Increased expression and activation of
MMP-2 and MMP-3 was temporally associated with neuroinflammation-induced DA
neurodegeneration. ProMMP-9 protein expression also increased in response to LPS, but
it was not activated, while proMMP-13 was unaffected. In association with activated
MMP-2 and MMP-3, there was a significant increase in CTGF/CCN2 protein expression
along with potentially low levels of MMP-cleaved CTGF/CCN2. The strong temporal
relationship between MMP-2 and MMP-3 activation, CTGF/CCN2 upregulation, and
LPS-induced DA injury suggests that these proteins may participate in events leading to
microglial activation or DA cell death.
Identification of the cell types responsible for altered MMP and CTGF/CCN2
expression will provide valuable information regarding the potential role of these proteins
in DA neurodegeneration. Microglia are likely candidates for MMP-3 and MMP-9. In
primary rat microglia cultures, LPS treatment induces MMP-3 and MMP-9 expression in
a dose-dependent fashion (237). In addition, MMP-3 upregulation in microglia occurs
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during reperfusion injury following ischemic stroke (79, 187, 208). Expression of MMP2 in microglia has not been described; however, astrocytes express MMP-2, which is kept
localized to the plasma membrane of astrocytic end feet, placing MMP-2 in prime
position to regulate the opening of the BBB during neuroinflammation (27).
Characterization of CTGF/CCN2 expression in the brain is limited. It has been detected
in specific populations of pyramidal neurons in normal brain and in reactive astrocytes
following brain injury or in response to neurodegeneration (87, 111, 197, 198, 212), but
expression in microglia has not been described.
In response to LPS, microglia transform from a resting state to an activated state
which is characterized by enhanced proliferation, morphological transformation,
proinflammatory cytokine production, nitric oxide release, and ROS generation (14, 16).
This dramatic response occurs through receptor-mediated mechanisms, many of which
involve the binding of LPS to TLR4, which requires the presence of LPS binding protein
and CD14 (56). Since microgliosis is a prominent consequence of nigral LPS exposure
and microglial-derived proinflammatory factors promote DA neurodegeneration, it was
hypothesized that changes in MMP and CTGF/CCN2 expression directly involved
microglia.
The following chapter describes a preliminary attempt to address this hypothesis
in vitro using BV-2 cells, an immortalized murine microglial cell line commonly used to
study the microglial response to LPS (13, 18). The goal of this study was to measure
MMP-2, -3, -9, and CTGF/CCN2 protein expression in response to LPS in order to
determine the suitability of this model for further study of MMP-CTGF/CCN2
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interactions. In addition, this data would provide a first look at microglia as the potential
source for alterations in MMP and CTGF/CCN2 protein expression in LPS-induced DA
neurodegeneration.

5.2 Materials and Methods
Materials. DMEM, L-glutamine, penicillin/streptomycin, PBS, 4-12%
polyacrylamide 10-well bis-tris gels, 0.25% trypsin-EDTA, 0.45µm nitrocellulose
membranes, sample reducing agent, LDS sample buffer, MES running buffer, antioxidant
solution, western blot transfer buffer, and MMP-3 ELISA kit were acquired from
Invitrogen Corp. (Carlsbad, CA). Amicon Ultra-15 centrifugal filter devices with a 3kDa
molecular weight cutoff were procured from Millipore (Billerica, MA). Culture flasks
and plates, SDS, CaCl2·2H2O, NaCl, sodium deoxycholate, tris-HCl, Tween-20 and
bovine serum albumin (fraction V) were purchased from Fisher Scientific (Pittsburgh,
PA). NP-40, NaOH, APMA, and Triton X-100 were obtained from Sigma-Aldrich (St.
Louis, MO). FBS was secured from Gemini Bio-products (West Sacramento, CA).
Protease inhibitor cocktail was purchased from Calbiochem (San Diego, CA). Full length
recombinant human MMP-3 was procured from Abcam, Inc. (Cambridge, MA). Goat
anti-human CTGF/CCN2 (Cat# sc-14939) and bovine anti-goat IgG-HRP (Cat# sc-2350)
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). SuperSignal
West Dura extended duration HRP substrate solution was obtained from Pierce
(Rockford, IL). Goat anti-mouse MMP-2 (Cat# AF1488), goat anti-mouse MMP-3
(Cat#AF548), and goat anti-mouse MMP-9 (Cat# AF909) were obtained from R&D
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Systems, Inc. (Minneapolis, MN). Non-fat dry milk was bought from The Kroger Co.
(Cincinnati, OH). Methanol was purchased from Colonial Scientific, Inc. (Richmond,
VA).
BV-2 Cell Culture. Passage 3 murine BV-2 microglial cells were kindly
provided by Dr. Michele Block. Cells were maintained in DMEM supplemented with
10% FBS, 2mM L-glutamine, 100U/mL penicillin, and 100µg/mL streptomycin. Cells
were passed regularly as needed and culture media was replaced every 3rd day. For
experiments, cells were plated in 6-well plates or T25 flasks at a density of 3x104 to
4x104 cells/cm2 in 2% FBS media. For ELISA and nitrite assays, cells were treated with
0, 10, or 100ng/mL LPS in media containing 2% FBS. For western blot experiments,
cells were activated with 100ng/mL LPS in media containing 2% FBS for 16 hours.
Then cells were placed in serum-free, LPS-free media and conditioned media was
collected 24 hours later for MMP and CTGF/CCN2 protein detection.
Protein Extraction. Media was saved and cells were rinsed three times with
2mL PBS. Saved media was kept on ice and concentrated as described below. PBS
washes were saved and centrifuged at 1000rpm for 6 minutes to collect cells that had
detached. The supernatant was discarded and the cell pellet was homogenized in 50µl
ice-cold protein extraction buffer (50mM Tris-HCl pH 7.2, 150mM NaCl, 1% sodium
deoxycholate, 1% NP-40, 0.5% SDS) containing a protease inhibitor cocktail. Cells
remaining in T25 flasks or 6-well plates were homogenized in 250µl or 150 µL ice-cold
extraction buffer, respectively. Homogenates were collected into 1.5mL microcentrifuge
tubes, repeatedly passed through a 26-guage needle connected to a 1mL syringe, and
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centrifuged at 14,000 x g for 30 minutes at 4°C. Supernatants were saved and stored at
-80°C until use. Protein concentration was determined with the DC protein assay (BioRad Laboratories, Hercules, CA) using bovine serum albumin solutions prepared in
protein extraction buffer to construct the standard curve.
Concentration of Conditioned Media. Conditioned media (10mL) was
centrifuged for 6 minutes at 1000rpm at 4°C to remove cellular debris. Supernatants
were transferred to sample reservoirs of Amicon Ultra 15mL filter units with a 3kDa
molecular weight cut-off. Filter units were centrifuged at 2500rpm in a refrigerated
centrifuge set at 4°C. Centrifugation was continued until media volume had been
reduced to approximately 250µl (20:1). Concentrated conditioned media was transferred
from sample reservoir to a 1.5mL microcentrifuge tube, and protease inhibitor cocktail
was added to each media sample (5µl per sample). Concentrated conditioned media was
stored at -80°C until use. Protein concentration was determined with the DC protein
assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin solutions
prepared in DMEM to construct the standard curve. Filtered media collected from
centrifugation was used to measure nitrite as described below. Nitric oxide is small
enough to pass through the filter membrane.
Griess Assay. The Griess assay (Promega, Madison, WI) was employed to
measure nitrite in cell culture conditioned media to provide an indirect measure of nitric
oxide production by BV-2 microglia. The nitrite standard curve was prepared by diluting
1µL 100mM nitrite in 999µL DMEM containing 2% FBS. Serial dilutions were
performed in 96-well plates to generate 100, 50, 25, 12.5, 6.25, 3.13, and 1.56µM nitrite.
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Sulfanilamide solution was added to each standard and sample. Plate was incubated at
room temperature for 10 minutes, protected from light. Then, N-1napthylethylenediamine dihydrochloride solution was added to each standard and sample,
and then the plate was incubated at room temperature for an additional 10 minutes,
protected from light. Absorbance was measured at 450nm using a Fluostar Optima plate
reader (BMG Labtech, Durham, NC).
TNF-α ELISA. TNF-α was quantified in conditioned media (not concentrated)
collected 24 hours after LPS treatment following the manufacturer’s instructions
(eBioscience, San Diego, CA). Briefly, wells were incubated with capture antibody
overnight at 4°C. After 5 washes, wells were blocked for 1 hour at room temperature,
washed, and then incubated with 50µL of conditioned media overnight at 4°C. Wells
were washed, incubated in detection antibody for 1 hour, washed again, incubated in
avidin-HRP for 30 minutes, washed, and incubated in substrate solution for 15 minutes.
Stop solution was added to each well prior to measuring A450nm. Sample TNF-α
concentration was calculated from a TNF-α standard curve. TNF-α ELISA was
performed by Steve Bakos in Dr. Richard Costanzo’s lab.
MMP-3 ELISA. Protein lysates and conditioned media (not concentrated)
samples were collected 24 hours after treatment with 100ng/mL LPS in 2% FBS media.
MMP-3 ELISA was performed following manufacturer’s instructions. Briefly, 50µl of
each sample or MMP-3 standard was combined with 50µl incubation buffer in 8-well
strips precoated with MMP-3 capture antibody. Biotinylated anti-MMP-3 was added to
each well and the plate was incubated for 2 hours at room temperature. After 4 washes,
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wells were incubated in streptavidin-HRP solution for 30 minutes at room temperature.
Wells were washed 4 times and then were incubated in 100µL chromogen solution for 35
minutes. An equal volume of stop solution was added to each well and then A450 was
measured using a Fluostar Optima plate reader. Sample MMP-3 content was calculated
from a standard curve constructed from human recombinant MMP-3 formulated at the
following concentrations in ng/mL: 0, 0.625, 1.25, 2.5, 5, and 10.
Western Blot. LDS Sample buffer and sample reducing agent were added to
concentrated conditioned media (20µg) and protein lysates (30µg). Samples were heated
to 70°C for 10 minutes, loaded on 4-12% polyacrylamide bis-bris gels, separated by
SDS-PAGE (50 minutes at 200V), and transferred to nitrocellulose membranes (2 hours
at 30V). Membranes were blocked for 1 hour in 5% non-fat dry milk prepared in TBST.
Membranes were incubated in MMP-2, MMP-3, MMP-9, or CTGF/CCN2 primary
antibody overnight at 4°C. Membranes were washed 4 x 5 minutes in TBST and were
incubated in peroxidase conjugated bovine anti-goat IgG or goat anti-rabbit IgG
secondary antibodies for 90 minutes at room temperature. Membranes were washed 6 x
5 minutes in TBST. Immunoreactivity was visualized with SuperSignal West Dura
substrate followed by exposure to film.
Activation of Human Recombinant MMP-3. APMA stock solution (10mM)
was prepared in 50mM NaOH. 1mL APMA stock solution was diluted to 2mM APMA
with 4mL assay buffer (50mM Tris-HCl pH 7.5, 5mM CaCl2·2H20, 0.05% Triton X-100).
Recombinant human MMP-3 stock solution was diluted to 5ng/µl with assay buffer.
Equal volumes (25µl) of 5ng/µl MMP-3 and 2mM APMA were combined in 0.6mL
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microcentrifuge tubes and were incubated for 4 hours at 37°C. Reaction mixtures were
immediately combined with concentrated conditioned media samples used to determine
the ability of activated MMP-3 to degrade 52kDa CTGF/CCN2 immunoreactivity.
Statistical Analysis. Statistical tests were performed using JMP software
(version 7.0). MMP-3 ELISA and Griess Assay nitrite data were compared with one-way
ANOVA (α=0.05) followed by the post-hoc Tukey-Kramer test to determine where
significant differences resided. Quantitative data is presented as mean ± standard
deviation.

5.3 Results
Since LPS directly activates microglia through receptor mediated mechanisms, it
was hypothesized that changes in MMP and CTGF/CCN2 expression detected following
intranigral LPS injection occurred in microglia. Initial experiments aimed at addressing
this hypothesis studied the effect of LPS on MMP and CTGF/CCN2 expression in the
immortalized murine BV-2 microglia cell line. To demonstrate LPS activation of this
cell line, BV-2 cells were treated with 0, 10, or 100 ng/mL LPS in 2% FBS media for 24
hours. TNF-α protein and nitrite were measured in the collected conditioned media by
ELISA and Griess assay, respectively. TNF-α production increased in response to LPS
treatment (Figure 5.1A). The magnitude of this increase was similar for both the 10 and
100ng/mL treated cells. Similar to TNF-α, LPS treatment induced a significant increase
in nitric oxide production (Figure 5.1B, p=0.002). Nitric oxide and TNF-α were barely
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FIGURE 5.1: Activation of BV-2 Microglial Cells with LPS
BV-2 microglia were treated with LPS (0-100 ng/mL) for 24 hours. Conditioned media
was collected for TNF-α and nitrite measurements. A) TNF-α ELISA (n=1). LPS
treatment increased TNF-α secretion by BV-2 microglia. Little TNF-α was present in
conditioned media harvested from untreated control cells. B) Griess Assay (n=2). LPS
treatment caused a concentration dependent increase in nitric oxide production.
Untreated cells generated very low levels of nitric oxide. Data presented as mean ±
standard deviation. Asterisks denote significance compared to untreated controls.
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detectable in untreated control cultures. These results demonstrate that LPS induces
activation of BV-2 microglia, consistent with the literature on this cell line (108).
Next, the effect of LPS on MMP-3 expression was measured by ELISA. BV-2
microglia were cultured and treated with LPS for 24 hours as described. At the end of
treatment, conditioned media and protein lysates were collected and ELISA was
performed (Figure 5.2). MMP-3 was detected in BV-2 lysates, but LPS had no
measurable effect on its expression (p=0.08). MMP-3 was not detected in conditioned
media samples, indicating that the MMP-3 concentration was below the detection limit of
the ELISA. As an alternative method for MMP-3 detection, western blot was performed
on concentrated conditioned media samples.
Conditioned media must be collected under serum free conditions for
measurement of secreted MMPs by western blot. This requirement presented a challenge
since full activation of microglia is TRL4 receptor dependent. The binding of LPS to this
receptor requires LPS-binding protein, which is only present in serum (56); therefore,
serum is essential for LPS to maximally activate microglia. It was decided to compare
nitric oxide production by microglia during LPS treatment in 2% FBS media to nitric
oxide production after LPS and serum are removed. Conditioned media samples were
collected after cells were treated with 100ng/mL LPS for 16 hours in 2% FBS media.
After media collection, cells were cultured in serum free media. After 24 hours, serumfree conditioned media was collected and concentrated. As before, 100ng/mL LPS
treatment induced a significant increase in nitric oxide production compared to untreated
controls (Figure 5.3). Importantly, BV-2 microglia sustained this nitric oxide production
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FIGURE 5.2: Effect of LPS on MMP-3 Expression in BV-2 Microglia
BV-2 microglial cells were treated with 0-100ng/mL LPS for 24 hours. Conditioned
media and protein lysates were collected and MMP-3 was measured by ELISA.
Treatment with LPS had no effect on MMP-3 present in protein lysates (p=0.08). MMP3 in conditioned media was below the detection limit of the assay. Data presented as
mean ± standard deviation (n=2).
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FIGURE 5.3: Effect of Serum Withdrawal on LPS-induced Nitric Oxide Production
in BV-2 Microglia. BV-2 microglia were treated with 100 ng/mL LPS for 16 hours in
the presence of 2% FBS. After 16 hours, serum was removed and activated cells were
incubated in serum free media for 24 hours. Conditioned media was collected and nitric
oxide production was compared in samples collected just before serum was removed
(during) to samples collected 24 hours after serum removal (after). LPS induced nitric
oxide production in BV-2 microglia (p<0.001). Nitric oxide production was sustained
after removal of LPS and serum from the culture (p<0.001), indicating that BV-2
microglia remained in an activated state. Data presented as mean ± standard deviation
(n=3). Asterisks denote significance compared to vehicle-treated controls.
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once the cells were switched to serum free media, indicating that the activated state was
maintained. Once this was established, MMP expression was measured in concentrated
conditioned media and BV-2 protein lysates (Figure 5.4). ProMMP-3 was detected in
cell lysates, while mainly the active form of MMP-3 was detected in concentrated
conditioned media; however, 100ng/mL LPS treatment had no apparent effect on MMP-3
expression or activation compared to controls.
The effect of LPS on gelatinase expression was also examined by western blot.
Pro and active MMP-2 was detected in BV-2 lysates, while little was present in
conditioned media. Similar to the results for MMP-3, LPS had no effect on MMP-2
expression or activation. In contrast, proMMP-9 was detected at low levels in
conditioned media collected from untreated control cells. Treatment with LPS
dramatically increased proMMP-9 expression, but no active MMP-9 was detected.
MMP-9 was not present in protein lysates.
The presence of CTGF/CCN2 in concentrated conditioned media and cell lysates
was also measured by western blot using samples treated with or without 100ng/mL LPS.
CTGF/CCN2, a 38kDa protein, was not detected in any samples at this molecular weight.
Instead, immunoreactivity in concentrated conditioned media samples was focused at
~52kDa (Figure 5.4). This band was barely detectable in cell lysates and 100ng/mL LPS
treatment did not alter its expression in media samples. CTGF/CCN2 is capable of
binding to many proteins through its four structural motifs, including TGF-β which binds
to the von Willebrand type C motif, IGF-1 which binds to the IGF binding protein motif,
and VEGF which binds to both the cysteine knot and thrombospondin-1 motifs (49).
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FIGURE 5.4: Effect of LPS on MMP-2, MMP-3, MMP-9, and CTGF/CCN2 Protein
Expression in BV-2 Microglia. BV-2 microglia were treated with 100ng/mL LPS for 16
hours in the presence of 2% FBS. Serum and LPS were removed and cultures were
incubated in serum free media for 24 hours. Conditioned media and protein lysates were
collected and protein expression was measured by western blot. LPS had no effect on
MMP-2, MMP-3, or CTGF/CCN2 protein expression. Immunoreactivity for
CTGF/CCN2 was concentrated at 52kDa. No 38kDa CTGF/CCN2 was detected. LPS
treatment strongly induced proMMP-9 expression, which was found only in conditioned
media. No active MMP-9 was detected.
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This ability of CTGF/CCN2 to interact with many other proteins brought up the
possibility that the 52kDa immunoreactive CTGF/CCN2 band consisted of CTGF/CCN2
and a tightly bound binding partner. It was hypothesized that if this was CTGF/CCN2
bound to another protein, then the addition of activated MMP-3 to concentrated
conditioned media samples would result in digestion of this band. It was predicted that
the 52kDa band would be reduced to ~20kDa, similar to what has been reported for
MMP-3-mediated cleavage of CTGF/CCN2 (83). To test this, recombinant human
MMP-3 was incubated in APMA for 4 hours at 37°C to activate MMP-3 (57). Activated
MMP-3 was then incubated for 12 hours at 37°C in concentrated conditioned media from
cells that had been treated with 100ng/mL LPS. At the conclusion of the incubation,
EDTA (20mM) was added to terminate MMP-3-mediated proteolysis. Samples were
then analyzed by western blot. APMA treatment resulted in significant activation of
MMP-3; however, activated MMP-3 had no effect on the 52kDa immunoreactive band
(Figure 5.5). The data suggests that this band is not a MMP-3 target; however, it does not
rule out the possibility that this band contains CTGF/CCN2 protein. It is possible that the
interaction between CTGF/CCN2 and the interacting protein block access to the
CTGF/CCN2 hinge region, which could prevent MMP-mediated proteolysis. However,
it is clear that LPS has no effect on the 52kDa band intensity, which does not match the
in vivo effect observed for CTGF/CCN2. Based on this, combined with the lack of
microglial CTGF/CCN2 expression described in other central nervous system injury
models, it seems possible that the 52kDa band is not CTGF/CCN2; however, further
studies are needed to confirm this.
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FIGURE 5.5: Effect of Activated MMP-3 on 52kDa CTGF/CCN2
Immunoreactivity. CTGF/CCN2 can be degraded by MMP-3 into two 20kDa bioactive
fragments. Recombinant proMMP-3 was activated with APMA treatment (4hrs).
Activated MMP-3 was incubated with conditioned media samples obtained from LPSstimulated BV-2 microglia for 16 hours at 37°C. A) CTGF/CCN2 western blot.
Incubation of conditioned media samples with activated MMP-3 did not result in
degradation of the 52kDa immunoreactive band. B) MMP-3 western blot confirming that
APMA treatment caused MMP-3 activation.
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5.4 Discussion
When injected into the SNc, LPS triggers MMP-3 and MMP-9 expression and
upregulates basal expression of CTGF/CCN2 and MMP-2 at time points that match the
neurodegenerative response, suggesting that these proteins may be involved in
neuroinflammation-induced DA neurodegeneration. Lesion formation in response to LPS
is driven by neurotoxic factors derived from activated microglia. BV-2 microglia are
commonly used to study the characteristics of microglial activation in response to LPS
and were used in the above experiments to examine the effect of LPS on MMP and
CTGF/CCN2 protein expression. LPS treatment resulted in robust activation of BV-2
microglia that was characterized by significant upregulation of TNF-α and increased
release of nitric oxide. In addition, proMMP-9 expression was induced by LPS
treatment; however, MMP-2 and MMP-3 expression and activation did not change in
response to LPS, while 38kDa CTGF/CCN2 was not detected. These experiments
identify microglia as the potential source for MMP-9 expression observed in the in vivo
response to intranigral LPS.
MMP-9 expression was induced by LPS treatment, a response that could be
detected with as little as 1ng/mL LPS (data not shown). This strong response may have
important implications regarding the temporal expression pattern of MMP-9 described in
the in vivo LPS model of PD. In vivo, proMMP-9 expression peaked prior to the 12 hour
time point, well before maximum MMP-2 and MMP-3 expression were detected. Since
microglia activate within hours of LPS exposure, the early peak of proMMP-9 may be
due to increased expression in microglia. It is difficult to predict the functional
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significance of the increase in proMMP-9 expression exhibited by microglia, since no
active MMP-9 was present in either the BV-2 or rat model, suggesting a lack of MMP-9mediated proteolysis. It is interesting to note that the C-terminal hemopexin-like domain
of MMP-9 can be bound by TIMP-1 when in its proform (150). If an excess of proMMP9 were present, MMP-9 could potentially act as a TIMP-1 sink. By binding to TIMP-1,
proMMP-9 may make it more likely that other MMPs present could become and remain
proteolytically active. Such a role for MMP-9 has never been described and several
studies have shown that the TIMP-1 bound to proMMP-9 is still capable of binding to
and inhibiting active MMPs, including MMP-3 (150). The ability of TIMP-1 to continue
to bind other MMPs even when bound to proMMP-9 indicates that proMMP-9 cannot
sequester TIMP-1 away from other MMPs.
The lack of an MMP-3 response to LPS in BV-2 microglia was not completely
unexpected, even though microglia have been identified as a source for MMP-3 in
various models of neuroinflammation and neurological diseases (26, 79, 208). In
cultured cells, expression of MMP-3 mRNA was shown to not be affected by LPS
treatment in BV-2 microglia; however, a strong induction of MMP-3 was noted in LPStreated primary rat microglia (237). MMP-3 expression has also been described in
neurons and astrocytes. Stressed DA neurons express MMP-3 following treatment with
MPTP or BH4, and primary astrocyte cultures express MMP-3 following LPS treatment
(37, 102, 106). In addition, MMP-3 has been localized to reactive astrocytes in models of
traumatic brain injury (63, 101).
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MMP-2 was expressed by BV-2 microglia, but LPS had no effect on this
expression or on MMP-2 activation. MMP-2 expression has never been co-localized
with microglia in vivo; however, in agreement with the studies described in this chapter,
primary microglia cultures constitutively express MMP-2 (45, 124, 125). Several studies
have demonstrated that LPS has no effect on constitutive MMP-2 expression in primary
microglia, but LPS does cause a significant increase in MMP-2 expression in astrocytes
(124-126). In addition, data from cerebral ischemia/reperfusion models suggest that
astrocytes are likely sources of MMP-2 in vivo. In these models, MMP-2 expression is
localized to astrocytic end feet processes surrounding capillary epithelial cells (27, 47).
Little is known about CTGF/CCN2 function in the central nervous system and its
expression has never been described in microglia. In the uninjured brain, CTGF/CCN2 is
expressed by subpopulations of pyramidal neurons and neurons present in the olfactory
bulb (87, 111). In response to injury and neurodegeneration, CTGF/CCN2 expression
has been described in reactive astrocytes (86, 197, 198, 212, 225). In BV-2 microglia, a
52kDa band of immunoreactivity was detected by the CTGF/CCN2 antibody, which is
12-14kDa larger than the molecular weight of full length CTGF/CCN2. Given the ability
of CTGF/CCN2 to bind to growth factors, cytokines, and other proteins within the ECM,
it was possible that this high molecular weight CTGF/CCN2 immunoreactivity
represented CTGF/CCN2 bound to a binding partner. Since CTGF/CCN2 is susceptible
to MMP-3-mediated cleavage, it was reasoned that treatment of concentrated conditioned
media with APMA-activated MMP-3 would result in degradation of the 52kDa band and
the appearance of the 20kDa CTGF/CCN2 fragments characteristic of MMP-mediated
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CTGF/CCN2 cleavage (83). Degradation did not occur when concentrated conditioned
media was incubated with activated MMP-3 for 16 hours, suggesting that the 52kDa band
recognized by the CTGF/CCN2 antibody cannot be degraded by MMP-3. Interference
with MMP-3 access to the CTGF/CCN2 cleavage site located between the von
Willebrand factor and thrombospondin-1 motifs caused by the presence of a
CTGF/CCN2 binding partner cannot be ruled out. In addition, MMP-3 western blot of
activated MMP-3 revealed that most of the activated MMP-3 present in reaction mixtures
lacked the C-terminal hemopexin-like domain. It may be possible that MMP-3-mediated
cleavage of CTGF/CCN2 requires recognition of the cleavage site by the hemopexin-like
domain. The presence of TIMPs in concentrated conditioned media could have also
interfered with MMP-3 proteolytic activity, preventing it from degrading the 52kDa
band. An alternative explanation is that the 52kDa band does not represent CTGF/CCN2
immunoreactivity.
These experiments indicate that BV-2 microglia are not the ideal model to study
interactions between MMPs and CTGF/CCN2. Strong induction of proMMP-9 was
observed following LPS treatment; however, MMP-2, MMP-3, and CTGF/CCN2
expression was unaltered. The lack of an effect on these three proteins also supports the
idea that the MMP response to LPS-mediated neurodegeneration is complex, likely
involving microglia and other cell types, such as astrocytes and neurons. Mixed
mesencephalic cultures established from embryonic mice or rats represents an alternative
model to study these proteins in vitro. In addition, immunohistochemical studies are
needed to determine which cell types participate in the dramatic changes in MMP and
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CTGF/CCN2 expression that accompany neuroinflammation-mediated DA
neurodegeneration. Spatial characterization of these proteins will greatly assist in
determining the functional consequences of their overexpression in PD models.
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CHAPTER 6
General Discussion

6.1 Summary of Important Findings
This project has successfully measured the temporal expression pattern of four
MMPs in three different models of PD: 1) 6-OHDA treated DA SH-SY5Y neuroblastoma
cells, 2) unilateral intrastriatal 6-OHDA injection in rats, and 3) unilateral intranigral LPS
injection in rats. In SH-SY5Y cells, 6-OHDA treatment caused a time-dependent
increase in MMP-13 mRNA expression, but did not alter constitutive MMP-2 expression
nor did it induce MMP-3 or MMP-9. MMP-13 upregulation coincided with the start of
cell viability decline, suggesting that MMP-13 could be involved in the neurotoxic
response to 6-OHDA. To confirm the temporal relationship between MMPs and 6OHDA-mediated neurotoxicity, DA neurodegeneration and MMP expression was
measured in the unilateral 6-OHDA PD rat model. In contrast to the SH-SY5Y model,
MMP-13 expression did not change at the time points examined, which corresponded to
the known time course of striatal and nigral DA neurodegeneration. In addition, 6OHDA caused an overall increase in nigral proMMP-2 expression, but did not induce
activation. In the striatum, a delayed increase in proMMP-2 expression was observed in
both 6-OHDA and ascorbic acid injected rats, suggesting that this was due to mechanical
injury. Similar to the SH-SY5Y model, 6-OHDA did not induce MMP-3 or MMP-9
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expression. Given the role of MMPs in neuroinflammation and their presence in other
models of neurodegeneration, I was surprised to find that 6-OHDA was not associated
with significant changes in MMP activation in vivo. At this point, it was decided to
characterize the MMP response in neuroinflammation-induced DA neurodegeneration to
provide a detailed comparison of temporal MMP expression in an inflammatory and
neurotoxin model. LPS was used to lesion the nigrostriatal system through
neuroinflammatory mechanisms. In this model, MMP-2, MMP-3, and MMP-9
expression increased at time points associated with nigral DA neurodegeneration. In
addition, increased MMP-2 and MMP-3 expression was accompanied by activation of
these two MMPs. No change in proMMP-13 expression was detected in response to
LPS.
In the LPS study, measurement of CTGF/CCN2 was included. CTGF/CCN2 is a
target of MMP-2 and MMP-3 proteolytic activity, and MMP-3 was recently shown to
directly regulate trans-activation of the CTGF/CCN2 gene in a novel transcription factor
mechanism (57, 83). In parallel with increased MMP-3 expression and activation,
upregulation of CTGF/CCN2 was detected along with degraded products that potentially
represent cleaved CTGF/CCN2, a result that will require further examination. This is the
first study to describe alterations in CTGF/CCN2 expression in PD, and the temporal
relationship between CTGF/CCN2, MMP-3, and DA neurodegeneration suggests that
CTGF/CCN2 may serve an important function in neuroinflammation-induced DA
neurodegeneration.
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The subsequent sections below describe the potential significance of the MMP
and CTGF/CCN2 response as it relates to PD. Particular emphasis is placed on MMP-2
and MMP-3, since the active form of these MMPs was prominent in the LPS model. The
potential functions of MMP-2, MMP-3, and CTGF/CCN2 in neuroinflammation and DA
neurodegeneration are discussed in detail. An effort is made to compare 6-OHDA and
LPS-mediated neurodegeneration with known PD pathology. Finally, future experiments
aimed at further characterization of the functional role of MMP-2, MMP-3, and
CTGF/CCN2 in models of PD are outlined.

6.2 Comparing 6-OHDA and LPS Animal Models to Human Parkinson’s Disease: Is
there an Argument for MMP involvement in PD?
Factors that drive progressive neurodegeneration in PD remain to be elucidated;
however, strong evidence supports that chronically activated microglia contribute to
degeneration of DA neurons (14, 16). The leading mechanism proposed to explain how
microglia function in neurodegeneration involves the self-sustaining neurotoxic cycle
(14, 16). In this cycle, damaged DA neurons release signaling proteins and other factors
that initiate an activated microglial response. In return, microglia-derived
proinflammatory cytokines, ROS, and nitric oxide exert neurotoxic effects on remaining
DA neurons. This cycle is self-sustaining due to microglia-activating factors released by
DA neurons and to neurotoxic factors elaborated by activated microglia.
Initiation of the self-sustaining neurotoxic cycle could potentially be neurotoxinor inflammogen-mediated (14, 16). To address whether MMPs are involved in either
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case, MMP expression was measured in response to 6-OHDA or LPS. 6-OHDA had no
effect on MMP activation, while LPS induced MMP-2, MMP-3, and MMP-9 expression
that was accompanied by activation of MMP-2 and MMP-3. MMP-13 was not affected
by either 6-OHDA or LPS in vivo. One major difference that might explain the
significantly different MMP responses concerns the microglial reaction and level of
nigral neuroinflammation associated with each model.
Neurotoxicity associated with the LPS model occurs purely through
neuroinflammation-mediated mechanisms (32, 56, 84). In contrast, 6-OHDA causes
significant neuronal death through its direct interaction with the DA neuron; however, a
microglial reaction does accompany neurodegeneration, which is believed to be involved
in slow loss of DA neurons at later time points (41, 193, 215). Studies that examine these
models refer to the microglial reaction in general terms as an activated microglia
response; however, there are different stages of the activation response that could have
potentially significant consequences towards whether or not significant changes in MMPs
are observed. A full microglial activation response is characterized by rapid population
expansion involving both proliferation of resident microglia and migration of microglia
to the injured site from surrounding regions; release of proinflammatory cytokines, ROS,
and nitric oxide; and morphological transformation from a highly ramified resting state to
an amoeboid phagocyte (14, 16, 113). Importantly, intermediate activation states are
known to exist. Microglia can be induced to proliferation and migrate without generating
a neurotoxic proinflammatory environment or they can trigger neuroinflammation
without becoming fully activated phagocytes (Nixon 2008; Tambuyzer, 2009).
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Microglial markers commonly used to examine microglial reactions are not
specific for particular activation states or even capable of specifically labeling only an
activated phenotype (70, 113, 218). These markers include the peripheral benzodiazepine
receptor, CD11b, Iba1, MHC Class II, and GSA-lectin. The only exception appears to be
CD68 (ED1 in rats), which specifically labels phagocytic cells, including fully activated
microglia (46, 158). When examining the ED1 response, a crucial difference between the
LPS and 6-OHDA models is brought to the surface. Intrastriatal or intranigral injection
of 6-OHDA fails to increase the number of ED1+ microglia over that associated with
needle-stick injury caused by the surgery (50, 93). This strongly indicates that
neuroinflammation occurring secondarily to 6-OHDA neurotoxicity does not involve a
maximal microglia response. When CD11b is used, a clear microglial reaction is
detected in both the striatum and SNc after intrastriatal 6-OHDA injection (41). More
CD11b+ microglia are present, suggesting that population expansion has occurred.
Morphologically, they are not as highly ramified as resting microglia, but they have not
achieved a phagocyte-like appearance, indicating that they are at an intermediate
activated state (41). In contrast, intranigral injection of LPS is associated with a 3-fold
increase in the number of ED1+ microglia compared to control, and they are present
throughout the damaged nigra (94), supporting that neuroinflammation in the presence of
LPS involves a fully activated microglial response.
In addition to the stark contrast in ED1 staining, other components of
neuroinflammation are different between these two models (Table 6.1). For example, in
mixed mesencephalic cultures, more than 500pg/mL of TNF-α accumulated in
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ED1+ (Iczkiewicz et al. 2005)
*TNF-α: 3-fold (Kim et al. 2009)

ED1- (Iczkiewicz et al. 2007; Depino et al. 2003)
*TNF-α: 1.5 fold (Mladenovic et al. 2004)

Parkinson's Disease

**CD68+ (Croisier et al.2005)
TNF-α: 3.7-fold (Mogi et al. 1994a)

CD11b ?

MHC-II+ (McGeer et al.1988)

60-80% (Kirik et al. 1998)

No change in MMP-3, MMP-9 or MMP-13; nigral

expression, no change in proMMP-13

2004)
active MMP-2 and MMP-3; proMMP-9

et al. 2002)

MMP-1 and MMP-9 in subset of patients (Lorenzl

Not yet shown directly (Monahan et al. 2008)

(Savitt et al. 2006)

Focal Disruption (Carvey et al. 2005)

phosphorylation, nitration, and aggregation

Fischer et al. 2008)

nitration, and aggregation (Choi et al. 2008)
Disrupted (Ji et al. 2008; Tomas-Camardiel et al.

Syn-/- mice are not resistant to 6-OHDA (Alvarez- (Gao et al. 2008); α-syn phosphorylation,

IL-1β: 2-fold (Depino et al. 2003)
IL-1β: 3.5-fold (Mogi et al. 1994b)
No Lewy Bodies; syn-/- mice are resistant to LPS α-syn+ Lewy Bodies; α-syn degradation,

CD11b+ (Iczkiewicz et al. 2005)

IL-1β: none (Depino et al. 2003)
No Lewy Bodies;

MHC-II+ (Arimoto et al. 2007)

CD11b+ (Cicchetti et al. 2002)

proMMP-2 but not activation
*mRNA levels
**CD68 is the human orthologue to rat ED1

MMP Response

BBB Involvement

α-Synuclein

Proinflammatory Cytokines

Microglial Reactivity

Lipopolysaccharide
80% (Iravani et al, 2005)

MHC-II+ (Carvey et al. 2005)

Table 6.1 Comparision of 6-OHDA and LPS models with PD
Characteristic
6-Hydroxydopamine
Nigral DA Degeneration 60-70% (Kirik et al. 1998)

conditioned media 6 hours after LPS treatment, while only 45pg/mL accumulated 24
hours after an equally neurotoxic application of 6-OHDA (137). In vivo, intranigral LPS
injection resulted in a 3-fold increase in TNF-α mRNA expression (105), compared to a
~1.5-fold increase following intrastriatal 6-OHDA injection (143). In another example,
no change in IL-1β protein expression was detected following intrastriatal 6-OHDA
injection, while a 200% increase was observed after intranigral LPS injection (50).
These results support that the neuroinflammation resulting from 6-OHDA is not
as severe as neuroinflammation associated with LPS. This could explain why dramatic
changes in MMP expression and activation accompany DA neurodegeneration in the LPS
model and not in the 6-OHDA model. TNF-α and IL-1β are classic inducers of MMP-3
and MMP-9 expression (51, 177, 207). The modest increase in these cytokines that
accompany neuroinflammation in the 6-OHDA model may not be sufficient to induce
MMP expression. In contrast, the sizeable upregulation of TNF-α and IL-1β following
LPS injection could provide a strong enough signal to induce MMP expression.
Major differences exist between the microglial reactions associated 6-OHDA and
LPS. The changes in MMP expression and activation associated with the LPS model
suggest that MMPs participate in neuroinflammatory reactions characterized by the
presence of fully activated microglia. Given these clear differences between the models
in regards to neuroinflammation and MMP expression, an important question is which
model more closely matches the ongoing microglial response in human PD? The initial
study that examined microglial activation in PD patients demonstrated that there were
numerous activated microglia present in the SNc, with many closely associated with
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remaining TH+ DA neurons (138). The authors suggested that the activated microglia
were in the process of phagocytizing damaged DA neurons; however, they labeled
microglia with MHC class II, which is upregulated in microglia from multiple activation
states. A more recent study measured activated microglia in postmortem nigral tissue
samples using CD68, which specifically labels maximally activated phagocytic
microglia. Samples from PD patients displayed numerous CD68+ microglia, which had
macrophage-like morphology and cytoplasm that contained neuromelanin granules,
indicating that they were active phagocytes (46). Examination of TNF-α and IL-1β levels
in human striatal tissue samples revealed that these proinflammatory cytokines are
elevated 366% and 350%, respectively, in PD patients compared to neurologically
normal controls (144, 145). These studies, which directly examine human PD tissue,
strongly suggest that the chronic neuroinflammatory reaction ongoing in PD more closely
resembles neuroinflammation associated with LPS (Table 6.1). Further experiments are
required, but this supports the idea that changes in MMP expression detected in the LPS
model may also be a part of the ongoing neuroinflammatory reaction present in PD
patients.
Clearly, the neurotoxic response to neuroinflammation is greater in the LPS
model than is present in PD, since DA degeneration was completed 48 hours post-LPS
administration, whereas loss of DA neurons in PD is a slow, chronic process that occurs
over years. Recently, a chronic LPS model has been developed in which LPS is
delivered in a single intraperitoneal bolus. This model results in gradual DA
neurodegeneration that occurs over a 10 month period. It would be interesting to
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determine the role of MMPs in a chronic LPS model, which more closely models the
progressive nature of PD.

6.3 Dual-role for Matrix Metalloproteinases in Inflammation-induced Dopaminergic
Neurodegeneration
Recent studies employing MPTP and BH4 suggest that activation of MMP-3 is
detrimental to DA neurons by contributing to microglia activation and promoting
neurotoxicity through some unknown intracellular mechanism (37, 106). In the current
project, neuroinflammation-mediated degeneration was associated with increased MMP-2
and MMP-3 expression and activation. Although evidence implicates MMP-2 and MMP3 as important components of neurodegeneration, additional experimental work is
required to elucidate the precise mechanisms by which they contribute. In the following
section, two distinct mechanisms are proposed that address potential functional
consequences of increased nigral MMP activity in PD: BBB dysfunction and promotion
of microglial activation.
Contribution to BBB Dysfunction. MMPs play a major role in BBB breakdown
associated with ischemia/reperfusion injury and models of neuroinflammation. MMPs
target the basal lamina surrounding capillaries, which is rich in laminin, fibronectin, and
type IV collagen. In addition, strong evidence indicates that MMPs can degrade occludin
and claudin which are major structural components of tight junctions that tightly adjoin
adjacent capillary endothelial cells (188, 240). The mechanism by which MMPs interfere
with BBB function has been studied extensively in stroke models. In these models,
156

MMPs mediate the breakdown of the BBB in two phases. First, within hours of
ischemia, a transient increase in MMP-2 activity derived from astrocytic end feet causes
mild BBB disruption, which does not contribute directly to neuronal injury caused by
reperfusion (26). Second, a prolonged increase in MMP-3 and MMP-9 activity mediates
longer-lasting, more severe disruption that directly contributes to reperfusion-induced
neuronal injury (26). Importantly, pericyte-derived MMP-3 activity may be required for
activation of proMMP-9 (187).
In the PD models used in the current project, MMP-2 and MMP-3 activity
increased following intranigral injection of LPS, but not intrastriatal injection of 6OHDA. In both models, others have demonstrated that BBB disruption occurs at time
points consistent with active neurodegeneration. In the LPS model, entry of IgG into the
brain parenchyma, an index of BBB function, begins 6 hours post-surgery, peaks at 24
hours, and lasts at least through 6 days, although, BBB restoration is complete by day 14
(222, 223). In another study, Evan’s Blue dye extravasation was significantly more
pronounced when LPS was delivered to the SNc compared to the cortex (100). With the
temporal expression profile of MMPs described in this project, it is reasonable to predict
that MMPs are involved in BBB breakdown in the LPS model by a mechanism that is
similar to stroke models; however, MMP-9 activity is crucial in BBB pathology in stroke
models, which was determined to be absent by western blot in nigral tissue samples.
Perhaps the antibody used in the current project was not sufficiently sensitive to detect
low levels of active MMP-9, if present. Further investigation into MMP-9 is warranted.
Other MMP-9 antibodies could be employed or gelatin zymography could be attempted
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to detect active MMP-9 in nigral tissue samples. In addition, double-labeled
immunohistochemistry experiments could provide support for BBB involvement if
MMPs are localized around blood vessels.
Similar to the LPS model, medial forebrain bundle and intrastriatal 6-OHDA
models exhibited significant albumin leakage into both the SNc and striatum 10 days
post-surgery (31). Leakage was closely associated with areas of DA loss in the SNc.
Given that MMP-2, MMP-3, and MMP-9 are critical for BBB disruption in stroke
models, it is interesting that leakage occurs in 6-OHDA models, which lack a measurable
MMP response. Other mechanisms must be responsible for BBB damage following
administration of 6-OHDA. In the intrastriatal 6-OHDA model, increased expression of
β3 integrin, a marker for proliferating capillary endothelial cells, was noted around focal
areas of BBB leakage, suggesting that angiogenesis occurs in response to 6-OHDA, a
process that has been associated with leakage in other experimental models (31, 146).
Additional studies are needed to determine the mechanism of BBB disruption in 6OHDA and other neurotoxin-specific models.
Direct disruption of the BBB has never been demonstrated in PD patients. They
lack noticeable brain edema, suggesting that widespread BBB disruption is not associated
with the disease (146). Despite this, there is evidence that the BBB is compromised to
some extent in PD. For example, there is a significant increase in endothelial cell number
in PD patients, suggestive of enhanced angiogenesis, which has been associated with
BBB leakage (64, 146). In addition, there are increased numbers of cytotoxic and
memory T cells within the SNc, indicating that they have attained greater access to the
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brain parenchyma (146). Although, widespread BBB disruption is not present in PD
patients, localized disruption of BBB function could still play a significant role in disease
progression (146).
Supporting Microglial Activation. Recent work has demonstrated that MMP-3
is required for microglial activation in a mixed mesencephalic culture model following
MPTP treatment (106); however, the specific mechanisms by which MMP-3 triggers
microglial activation remain to be elucidated. Similar to this in vitro model, intranigral
injection of LPS caused a significant time-dependent increase in MMP-3 expression and
activation (chapter 4), raising the possibility that MMP-3 may contribute to the robust
microglial reaction induced by LPS. In support of this, MMP-3 inhibition with NNGH (a
hydroxamate-based MMP inhibitor with reported preference towards MMP-3) treatment
partially attenuates nitric oxide, ROS, and TNF-α production by LPS-treated microglia
(237). These experiments not only identify microglia as cells that potentially express
MMP-3, they also suggest that MMP-3 mediates maximum activation of LPS-exposed
microglia.
There are several potential mechanisms by which MMP-3 could contribute to
microglial activation (Figure 6.1). Of particular interest to PD, is the apparent interaction
of MMP-3 with α-synuclein. In addition to activated microglia and loss of pigmented
nigral DA neurons, accumulation of α-synuclein within intracellular Lewy Bodies
represents one of the major pathological characteristic of PD (99, 120); however, recent
evidence points towards secreted α-synuclein as playing an important role in DA
neurodegeneration associated with neuroinflammation. α-Synuclein is found in CSF
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FIGURE 6.1: Proposed Roles for MMP-2, MMP-3, and CTGF/CCN2 in the Support
of Microglial Activation. MMP inhibition prevents maximum microglial activation by
LPS, indicating that MMPs perform critical functions that promote microglial activation.
In PD, this could be accomplished in three ways: 1) stressed DA neurons release αsynuclein and activated MMP-3. MMP-3 generates α-synuclein fragments, which shifts
α-synuclein conformation equilibrium towards oligomerization and aggregation.
Aggregated α-synuclein directly interacts with microglia to cause activation. 2) MMP-3
and astrocyte-derived MMP-2 target laminin, resulting in reorganization of extracellular
laminin that promotes its interaction with the 67kDa non-integrin laminin receptor
expressed by microglia. Binding of laminin to this receptor contributes to activation. 3)
Intracellular MMP-3 can contribute to increased CTGF/CCN2 expression by reactive
astrocytes through its transcription factor-like activity. CTGF/CCN2 can promote
microglial activation by stimulating microglial migration towards sites of
neurodegeneration and by serving as a microglial proliferation signal to increase the
overall microglial population. The effects of CTGF/CCN2 on microglia could be
mediated by interaction of CTGF/CCN2 with integrin receptors.
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from both PD patients and age matched controls, and cell culture experiments have
demonstrated that DA cells are capable of constitutively secreting this protein (20, 59, 60,
119, 216). Although α-synuclein CSF concentrations do not differ between those with PD
and age-matched controls, the conformational state of α-synuclein is predominantly in the
oligomer/aggregated state in PD patients, while monomeric α-synuclein is the major form
present in controls (20, 60).
Consistent with the theory that aggregated α-synuclein is toxic towards DA
neurons, addition of aggregated α-synuclein to mixed mesencephalic cultures specifically
induces DA neurodegeneration (246). The degenerative response was not observed in
neuronal enriched cultures or microglia-depleted cultures; however, introduction of
microglia to neuronal enriched cultures recapitulated the neurodegenerative response
observed in mixed mesencephalic cultures, demonstrating the importance of microglia in
α-synuclein-mediated DA neurodegeneration (246). In addition, two transgenic mouse
models that specifically overexpress α-synuclein in nigral DA neurons have an associated
neuroinflammatory response, supporting that α-synuclein can activate microglia in vivo
(216, 220). Similar to MMP-3, direct application of α-synuclein to primary microglia
cultures triggers activation characterized by increased ROS, but, unlike MMP-3, TNF-α or
nitric oxide release was not induced (106, 108, 246). Activation of microglia by MMP-3
in mixed mesencephalic cultures may involve its ability to cleave α-synuclein. Two
independent studies have confirmed that MMP-3 can cleave α-synuclein and that αsynuclein partially digested by MMP-3 readily aggregates (121, 217).
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Modification and aggregation of α-synuclein may play an important role in
neuroinflammation-induced DA neurodegeneration mediated by LPS. Mice genetically
deficient in α-synuclein exhibit remarkable resistance to DA neurodegeneration when LPS
is injected into the SNc, despite a seemingly unaltered neuroinflammatory response (69).
When human α-synuclein is overexpressed in these genetically deficient mice, LPS
triggers α-synuclein nitration, phosphorylation, and aggregate formation, indicating that
intranigral LPS can alter the conformational state of α-synuclein (69). Other studies
provide support for modification of α-synuclein in LPS PD models. For example,
intrapalladial injection of LPS in Fisher 344 rats induced α-synuclein nitration and
oligomerization (38). Given the ability of MMP-3 to cleave and promote α-synuclein
aggregation (121, 217), coupled with the observation that MMP-3 expression and
activation peak at time points consistent with DA neurodegeneration, the reported
alteration in α-synuclein aggregation in various LPS models could vary well depend on
MMP-3. Additional experiments should be done to address this possible scenario. In
contrast to the LPS models, α-synuclein does not appear to play a major role in 6-OHDAinduced neurotoxicity. Injection of 6-OHDA into the medial forebrain bundle does not
alter α-synuclein expression (231). In addition, the extent of striatal dopamine depletion
induced by 6-OHDA was identical in wild-type and α-synuclein-/- mice, indicating that αsynuclein is not a major component of 6-OHDA neurotoxicity (2).
In addition to promoting α-synuclein aggregation, MMP-2 and MMP-3 activity
could promote microglial activation through modification of the local ECM present in the
SNc. The brain ECM differs substantially from the ECM present elsewhere in that it lacks
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fibrous collagen and only low amounts of laminin, fibronectin, vitronectin, and perlecan
are present (191). Instead, brain ECM is rich in tenascins and chondroitin sulfate
proteoglycans, including aggrecan, neurocan, brevican, and versican (238). Of these ECM
molecules, MMP-2 and MMP-3 have been shown to degrade aggrecan (238). Little is
known regarding the organization of the nigral ECM. DA neurons lack chondroitin sulfate
proteoglycan-rich perineuronal nets characteristic of many other brain regions (25, 88);
however, the DA cell bodies are in close proximity to aggrecan-rich axonal coats and are
said to be “embedded in a matrix-associated fiber plexus (25).” In addition to aggrecan,
the SNc expresses testican mRNA and laminin (134, 202). MMP-mediated ECM
reorganization could potentially promote damaging microgliosis in PD. In support of this,
activation of the 67kDa non-integrin laminin receptor occurs in response to MPTP in
primary mesencephalic cultures (230). Blockade of the receptor with laminin receptor
antibodies attenuated MPTP-induced neurodegeneration and microglial superoxide
production. Furthermore, exogenous addition of laminin to these cultures was sufficient to
induce DA neurodegeneration (230). Additional studies are needed, but re-organization of
laminin mediated by MMP-2 or MMP-3 proteolytic activity such that it promotes
interaction between laminin and the 67kDa non-integrin receptor could represent a
potential mechanism through which MMPs promote microglial activation.

6.4 Potential Role for Connective Tissue Growth Factor in Parkinson’s Disease
The increase in CTGF/CCN2 expression in response to neuroinflammation-induced
nigrostriatal damage is a novel finding. The role of CTGF/CCN2 in the central nervous
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system is poorly understood; however, it is upregulated in numerous fibrotic diseases, as
well as peripheral inflammatory diseases including atherosclerosis and rheumatoid arthritis
(42, 181). In fact, increased CTGF/CCN2 expression in these two diseases occurs in the
same locations that overexpress MMPs (132). In normal brain, CTGF/CCN2 expression is
found in the olfactory bulb and subsets of pyramidal neurons, suggesting that CTGF/CCN2
serves important physiological functions for these neuronal populations (87, 111). In
neurodegenerative diseases, CTGF/CCN2 expression is increased in amyloid-β plaques
associated with Alzheimer’s disease and spinal cord lesions associated with amyotrophic
lateral sclerosis (212, 225). In these cases, CTGF/CCN2 expression is mainly confined to
reactive astrocytes.
The function of CTGF/CCN2 in neurodegeneration is not known; however,
CTGF/CCN2 can induce proliferation and migration in a wide variety of cell types through
interaction with integrin receptors (35). In PD and other neurodegenerative diseases, the
activated microglial response is characterized by microglial population expansion,
production of proinflammatory cytokines, and release of reactive oxygen and nitrogen
species (14, 113). Intense focus has been placed on the role of microglial-derived
cytokines and radicals, but the mechanisms that regulate the number of microglia present
during neuroinflammation are poorly understood. Microglial population expansion can be
caused by multiple factors, including proliferation of resident microglial cells and
migration of microglia from neighboring brain regions (113). Regulation of microglial
migration and proliferation appears to be at least partly mediated by β1 and β2-containing
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integrins (142, 155), both of which are capable of interacting with CTGF/CCN2 (35).
CTGF/CCN2 could potentially act on microglia through interaction with these integrins.
The functional consequences of increased CTGF/CCN2 expression warrant further
scrutiny. The temporal relationship between increased CTGF/CCN2 expression, the
appearance of fragments that could represent cleaved CTGF/CCN2, and the increase in
MMP-3 expression and activity raises the intriguing possibility that CTGF/CCN2 may be
involved in MMP-3-mediated functions, including support of microglial activation. This
project only provides correlative evidence that these two proteins are involved in PD and
future experiments must directly address whether there is a functional connection between
MMP-3 and CTGF/CCN2 and determine the significance of this for PD.

6.5 Future Directions
Unanswered questions abound with this project and several paths could be taken to
further elucidate the role of MMPs and CTGF/CCN2 in neuroinflammation-mediated DA
neurodegeneration. As mentioned previously, the studies presented in the preceding
chapters provide only correlative data in support of the involvement of MMPs, specifically
MMP-2 and MMP-3, in nigral degeneration in response to LPS. Likewise, western blot
data showing that CTGF/CCN2 protein expression increases in parallel with the MMPs is
correlative. Data demonstrating direct involvement of MMP-2, MMP-3, or CTGF/CCN2
in DA neurodegeneration is lacking. In addition, identification of the cell types
responsible for the observed changes in MMP expression would provide valuable
information regarding their potential role in the nigral neuroinflammatory response. This
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information could be used to design future functional studies aimed at elucidated the
precise mechanisms by which MMPs and CTGF/CCN2 contribute to PD. It is also
important to determine if MMP-2, MMP-3, and CTGF/CCN2 expression changes in
human PD.
Neuroprotection Studies. The next experiments must address the neuroprotective
potential of perturbing the MMP or CTGF/CCN2 response in the LPS model. If
experiments were to be continued using the rat, a pharmacological approach could be taken
to inhibit MMP activity, although this approach has significant limitations. First, the
currently available MMP inhibitors are broad spectrum in nature. For example, GM6001,
a MMP inhibitor commonly used in vivo, potently blocks the activity of MMP-1, MMP-2,
MMP-3, MMP-8, and MMP-9 with Ki values in the low nanomolar range (67). Several
inhibitors have been reported to exhibit strong inhibition towards one or two MMP
members; however, these inhibitors have not been tested on other MMPs. For instance,
NNGH is marketed by several suppliers as a specific MMP-3 inhibitor, but if one examines
the literature, MMP-3 is the only MMP that has been tested with this inhibitor (129). If
tested, it is probable that NNGH would be found to inhibit other MMPs. A second
limitation is that MMP inhibitors cannot cross an intact BBB (71). The BBB could be
bypassed through direct infusion of the inhibitor to the SNc. Alternatively, infusion into
the lateral ventricle could minimize tissue damage to the SNc and would allow for the drug
to be delivered multiple times if a cannula was pre-implanted allowing easy access.
Alternatively, breakdown of the BBB following intranigral administration of LPS could
allow passage of inhibitor injected systemically. Given the challenges and limitations
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involved with pharmacological inhibition of MMP-2 and MMP-3, a better strategy might
be to employ genetic knockout mice. MMP-2 and MMP-3 knockout mice have been
developed (61, 106). Intranigral injection of LPS in wild type, MMP-2-/-, and MMP-3-/mice would be a simple way to determine whether either MMP contributes significantly to
neuroinflammation-induced DA neurodegeneration. In addition, this approach would
allow for the development of MMP-2/3 double knock out mice. If MMP-2 or MMP-3 is
important in neuroinflammation-induced DA neurodegeneration, then genetic knockout of
either or both should result in significant neuroprotection against LPS-mediated injury.
Disrupting the function of CTGF/CCN2 may prove more problematic due to the
current lack of pharmacological inhibitors and knockout models. CTGF/CCN2-/- mice die
immediately after birth due to respiratory failure caused by catastrophic skeletal
developmental defects (97), making it difficult to examine the effect of genetic ablation of
CTGF/CCN2 on LPS-induced neurodegeneration. Although CTGF/CCN2-/- mice do not
survive past birth, there may be methods to circumvent this limitation. For example,
mixed mesencephalic cultures used in various PD studies must be established from E14
mice; therefore, it should still be possible to measure DA neurodegeneration following
LPS exposure in cultures established from E14 CTGF/CCN2-/- mice. Alternatively, siRNA
techniques could be used to knockdown CTGF/CCN2 expression in cell culture and animal
models.
Stereological assessment of the number of DA neurons remaining in the SNc has
traditionally been the method used to assay neuroprotection in most in vivo PD models;
however, several end points could be used to determine how ablation of MMP-2 and/or
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MMP-3 protects DA neurons from LPS. First, the microglial reaction induced by LPS
could be studied to determine if loss of MMP-2 or MMP-3 ameliorates neuroinflammation.
Microglia immunohistochemistry could be done to assess the proliferative and
morphological effect of loss of MMP-2 or MMP-3 in response to LPS. In addition,
production of neuroinflammatory cytokines, expression of iNOS, and ROS generation
could be measured to determine specific aspects of the microglial response that are
affected by ablation of MMP-2 or MMP-3. Second, BBB integrity could be measured in
wild type and knock out mice to assess the role of MMPs in LPS-induced BBB
dysfunction. These experiments could involve measurement of dye extravasation and
examination of MMP-mediated tight junction protein degradation. Third, the effect on αsynuclein physiology and neurotoxicity after LPS injection could be examined.
Aggregation of α-synuclein in the SNc has been demonstrated in the rat following
intrapalladial LPS injection and the mouse following intranigral LPS injection (38, 69). It
would be interesting to determine if loss of MMP-2 or MMP-3 prevents the aggregation of
α-synuclein in the LPS model.
Confocal Microscopy Experiments. The second important set of experiments
requires the identification of cell types that express MMPs and CTGF/CCN2 in response to
LPS-induced DA neurodegeneration. This could most easily be addressed with doublelabeling immunofluorescence experiments which may be done in primary mesencephalic
cultures or on midbrain tissue sections following LPS treatment in mice or rats. Glial
fibrillary acidic protein, TH, and CD11b or ED1 can be used to specifically label
astrocytes, DA neurons, and activated microglia, respectively. Detection of each of these
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cell types could be combined with simultaneous detection of MMP-2, MMP-3, or
CTGF/CCN2 to determine which cells express which proteins. These experiments should
assist in elucidating the function of these proteins in vivo. For instance, concentration of
MMP or CTGF/CCN2 immunoreactivity in astrocytes and microglia associated with the
vasculature would suggest important involvement in BBB disruption, while expression in
cells in areas of active neurodegeneration would indicate a direct role in
neuroinflammation-induced DA injury.

6.6 Concluding Remarks
Currently approved therapies for PD provide symptomatic relief in the early years
following diagnosis; however, these treatments fail to arrest the underlying cause of
chronic neurodegeneration and eventually loss their therapeutic benefit. These
shortcomings underscore the importance for developing novel neuroprotective therapies,
which requires a more complete understanding of the causes of PD and the mechanisms
that drive neurodegeneration. Only 5-10% of PD cases can be attributed directly to
functional mutations in a select number of proteins (221). The cause for remaining PD
cases is unknown, but likely results from a combination of genetic and environmental
factors. Among environmental factors, exposure to both neurotoxins (6-OHDA, MPTP,
rotenone, paraquat, maneb) and inflammogens (diesel exhaust particles, LPS) are
hypothesized to contribute to increased PD risk, although, direct evidence in humans is
lacking (34, 141). In this dissertation, the 6-OHDA and LPS models of PD were examined
and it was found that these two models involve completely different MMP responses,
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suggesting that MMPs may be involved in PD predominantly triggered by certain
environmental factors, but not others. If this is the case, then changes in MMP expression
would be expected to be observed in only a subset of PD patients. In support of this, a
small histopathology study has reported drastically increased MMP-1 in 2 out 5 patients
examined and elevated MMP-9 expression in 1 patient (127).
Accumulating evidence points towards important processes ongoing outside of the
DA neuron that contribute significantly to disease pathology, including chronic
neuroinflammation and alterations in extracellular proteins (14). Along these lines,
induction of active MMP-2 and MMP-3 along with increased CTGF/CCN2 protein
expression was correlated with LPS-induced neurodegeneration. Additional experiments
are needed aimed at identifying the cell types associated with these changes and at testing
the neuroprotective potential of blocking MMP or CTGF/CCN2 function in inflammationinduced degeneration. Depending on the results of these crucial studies, methods that
interfere with MMP or CTGF/CCN2 function could represent novel neuroprotective
therapeutic strategies for PD.
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APPENDIX I

A.

B.

*

Undifferentiated SH-SY5Y Cells
C.

Vehicle-treated SH-SY5Y Cells
D.

Differentiated SH-SY5Y Cells (high density) Differentiated SH-SY5Y Cells (low density)

FIGURE A1-1: SH-SY5Y Differentiation
SH-SY5Y cells exhibit a neuroblast-like appearance, lacking important morphological
features characteristic of mature neurons. Therefore, SH-SY5Y differentiation prior to 6OHDA treatment was considered. To induce differentiation (Encinas et al. 2000), SHSY5Y cells were cultured in DMEM/F-12 containing 10% FBS, 1% Pen/Strep, and
10µM retinoic acid (RA) for 5 days (media was changed on day 3). This was followed
by a 5 day treatment with serum-free DMEM/F-12 supplemented with 50ng/mL brainderived neurotrophic factor (BDNF, media was changed on the third day). A) Untreated
SH-SY5Y cells. B) SH-SY5Y cells treated 5 days with DMSO and 5 days with PBS, the
vehicles for retinoic acid and BDNF, respectively, show no morphological change
compared to untreated cells. Cells not found in clusters had a characteristic unipolar
appearance with a short neurite (*). C) RA + BDNF differentiation resulted in extensive
neurite growth. D) Low density area of differentiated cells showing that cell clusters
extend multiple long neurites that make contact with several neighboring clusters. Some
neurites branch to contact more than one neighboring cell or neurite (arrow heads). Panel
C scale bar=50µm and is applicable to the other three panels.
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FIGURE A1-2: Neuronal Marker Expression in Undifferentiated and Differentiated
SH-SY5Y Cells. Western blots comparing neuronal marker expression in
undifferentiated and differentiated SH-SY5Y cells (n=1). Differentiation of SH-SY5Y
cells with retinoic acid and BDNF had no effect on β-tubulin III or TH protein
expression, suggesting that differentiation does not result in loss of DA characteristics.
Differentiation resulted in a slight increase in MAP2 protein expression and low levels of
neurofilament-L (NF-L) expression was detected only in differentiated cells. hNT cell
lysates were included as a positive control for NF-L and MAP2 expression.
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FIGURE A1-3: Dose-dependent 6-OHDA Toxicity in Undifferentiated and
Differentiated SH-SY5Y Cells. Vulnerability to 6-OHDA-mediated neurotoxicity was
compared between undifferentiated and differentiated SH-SY5Y cells. Cells were treated
with 6-OHDA concentrations ranging from 0-90µM for 24 hours. Cell viability was
measured using the trypan blue exclusion method (results for undifferentiated SH-SY5Y
cells appear alone in figure 3.3). Statistical comparisons were made with two-way
ANOVA. Overall there was a significant model effect (p<0.001); however, there was no
interaction between culture conditions (undifferentiated vs. differentiation) and 6-OHDA
concentration (p=0.09). When considering culture conditions independently from 6OHDA concentration, differentiated SH-SY5Y cell viability was significantly greater
compared to undifferentiated cells (p<0.001). When considering 6-OHDA concentration
independently from culture conditions, 6-OHDA induced a significant dose-dependent
decline in cell viability (p<0.001). The lack of an interaction effect is likely due to low
sample size, particularly in the differentiated group. The data hints that differentiated
SH-SY5Y cells are less vulnerable to 6-OHDA-mediated neurotoxicity than their
undifferentiated counterparts. In support of this, the LD50 for undifferentiated cells was
37.6 ± 6.82µM, while the LD50 for differentiated cells was right-shifted to 55.3 ±
10.7µM. Data presented as mean ± standard deviation.
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FIGURE A1-4: Time-dependent 6-OHDA-mediated Neurotoxicity in
Undifferentiated and Differentiated SH-SY5Y Cells. The difference in the 6-OHDA
dose-dependent relationship between undifferentiated and differentiated SH-SY5Y cells
could have resulted from differences in the time-dependent 6-OHDA effect. In this
experiment (n=1), undifferentiated and differentiated SH-SY5Y cells were treated with
45µM 6-OHDA for 0-96 hours. Cell viability was measured at each time point using the
trypan blue exclusion method. In undifferentiated SH-SY5Y cells, the decrease in cell
viability occurred some time after 6 hours and was complete by 24 hours. In contrast, the
start of cell viability decline in differentiated SH-SY5Y cells was evident 6 hours after
treatment and was complete by 24 hours. In agreement with the dose-dependent
relationship, maximum cell viability loss was greater in undifferentiated cells at the 24
hour time point, remaining this way through the 96 hours. Data in figures A3 and A4
suggested that differentiation results in a decrease in vulnerability to 6-OHDA-mediated
neurotoxicity. For this reason, differentiation was discontinued and MMP mRNA
measurements were made in undifferentiated SH-SY5Y cells.
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FIGURE A2-1: Temporal CTGF/CCN2 Expression following Intrastriatal 6-OHDA
Injection. CTGF/CCN2 expression increased significantly 24 hours after intranigral LPS
injection and fragments were detected that could represent cleaved CTGF/CCN2 (Figure
4.10). CTGF/CCN2 expression was measured in the 6-OHDA rat model to provide a
comparison between neurotoxin and inflammation-induced DA neurodegeneration.
CTGF/CCN2 expression was measured in striatal and nigral protein samples collected 1,
5, and 10 days post-6-OHDA injection. Measurements were made in 2 rats per group.
A) Ipsilateral nigral CTGF/CCN2 expression did not change compared to contralateral
expression in the vehicle or 6-OHDA groups. This was to be expected if MMP-3
regulates CTGF/CCN2 expression in PD models, since no nigral proMMP-3 or active
MMP-3 was detected in 6-OHDA injected rats (Figure 3.11). B) Striatal CTGF/CCN2
expression was more variable with no discernable expression pattern emerging within
these sample sets.
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FIGURE A3-1: Amphetamine Challenge in LPS-lesioned Rat
Several methods have been developed to measure functional deficits in unilateral rodent
models of PD. When amphetamine is injected i.p., it triggers massive dopamine release
from nigral DA neurons. If one side of the nigrostriatal tract is significantly damaged, then
dopamine release is asymmetric, causing the rat to rotate in the direction ipsilateral to the
nigrostriatal tract lesion. This test was performed on one intranigral LPS-injected rat to
determine if nigrostriatal damage associated with this model is sufficient to induce
ipsilateral rotational behavior. Amphetamine sulfate was injected i.p. and rat was placed in
a circular enclosure. Ipsilateral and contralateral full body rotations were counted
manually for 90 minutes. A) Net ipsilateral rotations were condensed into 5-minute time
intervals. The maximum rotational rate over a 5-minute interval reached 1.6 rpm 80-85
minutes after injection; however, a rotation rate of ~1 rpm was maintained over most of the
test. B) Total ipsilateral and contralateral rotations were compared. There was a clear
tendency for the rat to rotate in the ipsilateral direction (75 ipsilateral rotations vs. 4
contralateral rotations). Recent reports with the LPS model suggest that amphetamine
should induce rotational rates near 6 rpm (96). The reason for the discrepancy is unknown.
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